UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2016
or
☐
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________.to _______________.
Commission file number 1-11388
VIVEVE MEDICAL, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
04-3153858
(I.R.S. Employer Identification No.)
150 Commercial Street
Sunnyvale, California 94086
(Address of principal executive offices - Zip Code)
Registrant's telephone number, including area code: (408) 530-1900
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
The NASDAQ Capital Market
Securities registered pursuant to Section 12(g) of the Act: None.
Indicate by check mark if the Registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12
months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of
the Exchange Act. (Check one):
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting
company)
Smaller reporting company ☒
Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Act). Yes ☐ No ☒
As of June 30, 2016, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the
Registrant, based on the last reported sales price of the Registrant’s common stock, par value $0.0001 per share, on The NASDAQ Capital
Market on such date, was approximately $26,985,811.
Number of shares outstanding of the Registrant’s common stock, as of February 7, 2017: 10,700,606
DOCUMENTS INCORPORATED BY REFERENCE
None.
VIVEVE MEDICAL, INC.
Table of Contents
Part I
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Part II
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosure about Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures
Controls and Procedures
Other Information
Part III
Item 1
Item 1A
Item 1B
Item 2
Item 3
Item 4
Item 5
Item 6
Item 7
Item 7A
Item 8
Item 9
Item 9A
Item 9B
Item 10
Item 11
Item 12
Item 13
Item 14
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accountant Fees and Services
Item 15
Exhibits, Financial Statement Schedules
Signatures
Part IV
i
1
20
36
36
37
37
38
39
40
50
50
50
50
51
52
56
61
63
65
66
70
Unless otherwise noted, the terms “Viveve”, “the Company,” “we,” “us,” “our” and similar designations in this Annual Report on Form
10-K refer to Viveve Medical, Inc. and its wholly-owned subsidiaries, Viveve, Inc. and Viveve BV.
PART I
FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements. Forward-looking statements give our current expectations or forecasts of future
events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but
not all) of these statements by looking for words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,”
“projects,” “intends,” “plans,” “would,” “should,” “could,” “may” or other similar expressions in this report. In particular, forward-looking
statements include statements relating to future actions, prospective products, applications, customers and technologies, and future
performance or future financial results. These forward-looking statements are subject to certain risks and uncertainties that could cause
actual results to differ materially from our historical experience and our present expectations or projections. Factors that could cause actual
results to differ from those discussed in the forward-looking statements include, but are not limited to:
●
●
●
●
●
●
●
●
●
●
●
●
●
●
our limited cash and our history of losses;
our ability to achieve profitability;
our limited operating history;
emerging competition and rapidly advancing technology;
whether we are successful in having our medical device approved or cleared for sale by the U.S. Food and Drug
Administration (“FDA”) for all indications;
whether demand develops for our medical device;
the impact of competitive or alternative products, technologies and pricing;
the adequacy of protection afforded to us by the patents that we own and the cost to us of maintaining, enforcing and
defending those patents;
our ability to obtain, expand and maintain protection in the future, and to protect our non-patented intellectual property;
our exposure to and ability to defend third-party claims and challenges to our patents and other intellectual property
rights;
our ability to obtain adequate financing in the future, as and when we need it;
our ability to continue as a going concern;
our success at managing the risks involved in the foregoing items; and
other factors discussed in this report
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future
results, levels of activity, performance or achievements. The forward-looking statements are based upon management’s beliefs and
assumptions and are made as of the date of this report. We undertake no obligation to publicly update or revise any forward-looking
statements included in this report to conform such statements to actual results or changes in our expectations. You should not place undue
reliance on these forward-looking statements.
Item 1. Business
Viveve designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity,
for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that we refer
to as Geneveve™. Women can develop vaginal laxity for a number of reasons, including aging, genetic predisposition, lifestyle, and/or the
trauma of natural childbirth. Vaginal laxity can often cause decreased sexual function and satisfaction in women, yet most surveyed
physicians who practice obstetrics and gynecology (“OB/GYNs”) and urogynecologists recognize that it is an underreported, yet
bothersome, medical condition that impacts relationship happiness as well as sexual function. Currently, few medical treatments are
available to effectively treat vaginal laxity. The most widely prescribed treatments include Kegel exercises, although, to our knowledge,
there is no validated evidence indicating that Kegel exercises improve vaginal laxity, and surgical procedures, which are not only invasive
and expensive but sometimes lead to worse outcomes as a result of scarring. At this time, Geneveve™ is indicated for use in general
surgical procedures for electrocoagulation and hemostasis in the United States, but the device has not been cleared or approved for use for
the treatment of vaginal laxity, to improve sexual function, or for vaginal rejuvenation in the United States. Accordingly, the Company is
prohibited under current U.S. regulations from promoting it to physicians or consumers for these unapproved uses.
1
Geneveve is a non-invasive solution for vaginal laxity which includes three major components: the Viveve System™ (an RF, or
radio frequency, generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other
consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator
authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is
performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. The tissue tightening effect resulting
from Geneveve has been demonstrated by our pre-clinical and clinical research.
We believe that Geneveve provides a number of benefits for physicians and patients, including:
● a non-invasive, non-ablative alternative to surgery with no identified safety issues to date;
● it requires only a single treatment;
● compelling physician economics; and
● ease of use.
Currently, Geneveve is cleared for marketing in 51 countries throughout the world under the following indications for use:
Indication for Use:
General surgical procedures for electrocoagulation and hemostasis
For treatment of vaginal laxity
For treatment of the vaginal introitus, after vaginal childbirth, to improve sexual
function
For vaginal rejuvenation
No. of Countries:
3 (including the United States)
34
13
1
In the U.S., Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis and we market and
sell through a direct sales force to health care practitioners. Outside the U.S., we market and sell through an extensive network of
distribution partners.
Our goal is to become the leading provider of non-invasive solutions to treat vaginal laxity by:
● Increasing the Number of Installed Base of Viveve Systems. In our existing markets, we plan to (i) expand the number of
Viveve Systems from our initial base of early adopters by leveraging our current and future clinical study results and through
innovative marketing programs directed at both physicians and patients, where permissible by law, and (ii) expand our
efforts and obtain regulatory approvals in additional markets, although there are no assurances that we will ever receive such
approvals.
● Driving Increased Treatment Tip Usage. We work collaboratively with our physician customer base to increase treatment tip
usage by enhancing customer awareness and facilitating the marketing efforts of our physician customers to their patients.
We intend to launch innovative marketing programs with physician customers to develop a profitable Geneveve practice.
● Broadening Our Physician Customer Base. While our initial focus is on marketing our procedure to the OB/GYN specialty,
we intend to selectively expand our sales efforts into other physician specialties, such as plastic surgery, dermatology,
urology, urogynecology, general surgery and family practice. Additionally, we intend to pursue sales from physician-directed
medi-spas with track records of safe and successful aesthetic treatments.
● Developing New Treatment Tips and System Enhancements. We intend to continue to expand our line of treatment tips to
allow for even shorter procedure times to benefit both physicians and patients. We also plan to pursue potential system
modifications and next generation enhancements that will further increase the ease-of-use of Geneveve.
2
● Investing in Intellectual Property and Patent Protection. We will continue to invest in expanding our intellectual property
portfolio, and we intend to file for additional patents to strengthen our intellectual property rights.
As of December 31, 2016, we have sold 217 Viveve Systems and approximately 4,050 single-use treatment tips in countries
outside of the U.S.
On September 23, 2014, Viveve Medical, Inc. (formerly PLC Systems, Inc.), a Delaware corporation (“Viveve Medical”,
“Viveve”, “we”, “us” or “our”) completed a reverse acquisition and recapitalization pursuant to the terms and conditions of an Agreement
and Plan of Merger (the “Merger Agreement”) by and among PLC Systems Acquisition Corp., a wholly owned subsidiary of PLC Systems
Inc., with and into Viveve, Inc., a Delaware corporation (the “Merger”). In conjunction with the Merger, we changed our name from PLC
Systems Inc. to Viveve Medical, Inc. to better reflect our new business. Viveve Medical competes in the women’s health industry by
marketing the Geneveve™ product as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal
laxity, depending on the relevant country-specific clearance or approval. We are currently located at 150 Commercial Street, Sunnyvale,
California and our telephone number is (408) 530-1900. We plan to relocate the corporate headquarters toward the end of the first quarter
of 2017 as discussed in Part II – Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations –
Recent Events. Our website can be accessed at www.viveve.com. The information contained on or that may be obtained from our website
is not a part of this report. Viveve, Inc. operates as a wholly-owned subsidiary of Viveve Medical and was incorporated in 2005.
Market Overview
Overview of Vaginal Laxity
Vaginal laxity and tissue architecture have often been overlooked as contributing etiological factors to female sexual dysfunction.
Vaginal laxity can lead to diminished physical sensation during intercourse. This reduction in sensation is often coupled with a reduction in
sexual satisfaction, all of which can also impact a woman’s sense of sexual self-esteem and her relationship with her sexual partner.
Vaginal laxity is rarely discussed in the clinical situation, yet most surveyed OB/GYNs and urogynecologists recognize that it is
an underreported, yet bothersome, medical condition that impacts relationship happiness and sexual function. Another survey of
OB/GYNs, found that vaginal laxity is the most frequent physical change seen or discussed post-vaginal delivery . Additionally, in a
survey of women ranging from 25-45 years of age, who had experienced at least one vaginal delivery, approximately half expressed some
degree of concern over “looseness” of the vaginal introitus.
3
1
2
Women can develop vaginal laxity for a number of reasons, including aging, genetic predisposition, lifestyle, and/or trauma. As
women age, slower cellular renewal coupled with reduced vascular and glandular networks contributes to loss of underlying supportive
fibrous tissue. Some women may have underlying pathophysiological issues with collagen formation, remodeling and repair; and their
lifestyle choices (e.g., alcohol consumption, tobacco use, and excessive food consumption) also play a role in the integrity of vaginal
tissue. Vaginal trauma (e.g., childbirth, surgery, self-stimulation, or coitus) can also contribute to vaginal laxity.
3
All women who have given birth vaginally undergo stretching of the tissues of the vaginal opening to accommodate the fetal
head. Often the effects are permanent and many women have long-term physical and psychological consequences including sexual
dissatisfaction. One significant issue is the loosening of the introitus ─ the vaginal opening. This happens with the first vaginal delivery
and usually is made worse with subsequent vaginal deliveries. Vaginal laxity can result in decreased sexual pleasure for both women and
their partners during intercourse. We believe that this condition is not frequently discussed because women are embarrassed, fear that their
concerns will be dismissed or fear that their physicians will not understand. Physicians hesitate to discuss the situation with their patients
because historically there has been no safe and effective treatment. Physicians frequently recommend Kegel exercises. However, these
exercises only strengthen the pelvic floor muscles and do not address the underlying cause of vaginal laxity – loss of tissue elasticity.
While surgery can be performed to tighten the vaginal canal, the formation of scar tissue from the surgery may lead to painful intercourse
and permanent side effects.
As a consequence of the physical tissue damage that can result from childbirth, a significant decrease in sexual satisfaction has
been reported in women who underwent vaginal delivery, when assessed two years after delivery, in comparison with those who
underwent elective caesarian section. In the past several years there has been a marked increase in the number of women requesting
delivery by caesarian section with the intention of preventing damage to the pelvic floor and introitus. Caesarian sections are not without
risk to both the baby and mother. Whether or not to agree to a woman’s request for an elective caesarian section has generated considerable
controversy among obstetricians. If a procedure were available to address the concerns of women about vaginal laxity, we believe the
perceived need to have a caesarian section to prevent vaginal tissue damage may decrease significantly.
1
Pauls RN, Fellner AN, Davila GW. Vaginal laxity: a poorly understood quality of life problem; a survey of physician members of the
International Urogynecological Association (IUGA). Int Urogynecol J. 2012 Oct;23(10):1435-48.
2
Lukes A, Kigsberg S. OB/GYNs Attitudes and Perceptions Regarding Sexual Health of Patients After Delivery. Poster at ISSWSH
Annual Meeting. 2010.
3
Millheiser L, Kingsberg S, Pauls R. A cross-sectional survey to assess the prevalence and symptoms associated with laxity of the vaginal
introitus. ICS Annual Meeting 2010. Abstract #206
Market for a Proven Solution to Vaginal Laxity
In 2009, we sponsored several on-line marketing surveys in the U.S. with both OB/GYNs and women, ages 25-55, to assess
attitudes of physicians and women about vaginal laxity and towards a safe, non-invasive solution to treat this condition.
●
●
Physician Survey: An OB/GYN marketing survey was conducted by OB/GYN Alliance with nearly 525 practicing
OB/GYNs from across the U.S. The objectives of the study were to: obtain insights from physicians on physical changes
resulting from childbirth and the corresponding sexual health implications for patients; understand the perceptions and
opinions of OB/GYN physicians on a procedure that could be offered to address vaginal laxity following childbirth; and
gain an understanding of whom the early adopters may be of Geneveve.
Consumer Survey: In a consumer marketing survey conducted by Q&A Research, 421 women were screened for vaginal
delivery, age (25-55), income, education and other factors. The objectives of the survey were to assess the need for
Geneveve and better understand the complexity of emotions and the psychological profile of women who experience, but
do not discuss, vaginal changes post childbirth.
Results from these surveys suggested that vaginal laxity is a significant unmet medical need, and that patients and physicians
would benefit significantly from a safe and effective non-invasive treatment that would also increase physical sensation and sexual
satisfaction following vaginal childbirth. Of the 421 patient respondents, up to 48% felt that vaginal laxity was a concern post-childbirth.
Furthermore, it is evident that patients and their OB/GYNs are not discussing vaginal laxity on a regular basis; in fact, we believe such
conversations occur quite infrequently due to many factors, including patient embarrassment and fear of being ridiculed, lack of time and
lack of solutions for physicians. Of the nearly 525 OB/GYNs surveyed, 84% indicated that vaginal laxity is the number one post-delivery
physical change for women, being more prevalent than weight gain, urinary incontinence and stretch marks, and believe that it is under-
reported by their patients. Additionally, in a separate international survey of urogynecologists, 83% of the 563 respondents described
vaginal laxity as underreported by their patients and the majority considered it a bothersome condition that impacts sexual function and
relationships. Despite the lack of communication regarding this issue, we believe there is a strong interest among patients and doctors for a
treatment that is clinically proven and safe.
4
Applying U.S. census data, CDC Vital Statistics data and our projections as a result of these studies, we estimate there are
approximately 6 million post-partum women who are potential candidates for this procedure in the U.S. alone, approximately 3 million of
whom could be early adopters for Geneveve.
In 2012, we conducted a similar consumer study in Japan and Canada in order to understand cultural differences that may exist
towards vaginal laxity and Geneveve. The results corroborated our U.S. survey conclusions. Applying World Health Organization census
data as well as data from individual countries, we estimate there are 25-30 million women outside the U.S. that could be early adopters of
Geneveve.
Current Treatments and Their Limitations
Currently, few clinically proven medical treatments are available to effectively treat vaginal laxity. The most widely prescribed
treatments include Kegel exercises and invasive surgical procedures, known as laser vaginal rejuvenation (“LVR”) or vaginoplasty.
●
●
Kegel Exercises: Kegels are an exercise that was developed by Dr. Arnold Kegel designed to strengthen the muscles of
the pelvic floor - the pubococcygeal (“PC”) muscles - to increase vaginal muscle tone, improve sexual response, and limit
involuntary urine release due to stress urinary incontinence. These exercises are often prescribed following childbirth or
during and after menopause. However, we are not aware of any validated evidence indicating that Kegels improve vaginal
laxity or sexual function due to laxity.
Surgical Procedures: Of the various alternatives for treating vaginal laxity, invasive surgical procedures, such as LVR, are
the only modalities with any proven efficacy outcomes. Typically, they are performed by plastic surgeons with patients
under general anesthesia. According to The International Society of Aesthetic Plastic Surgeons (“ISAPS”), approximately
114,135 LVR surgeries were performed world-wide in 2013. However, these invasive surgical procedures are expensive,
costing thousands of dollars, and can involve weeks of post-surgical recovery time for the patient. They also carry the risk
of scarring, which can lead to uncomfortable or painful intercourse, long-term or permanent loss of sensation, serious
infection, tissue necrosis, hematomas (fluid collection under the tissue that may require removal), and adverse reactions to
anesthesia.
The Viveve Solution
We believe that Geneveve provides a compelling, clinically proven, safe, non-invasive treatment for vaginal laxity and
improvement of sexual function. Geneveve consists of three major components: the Viveve System™ (an RF, or radio frequency,
generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable
accessories. Geneveve is typically performed in a medical office setting by, or under the supervision of, trained and qualified physicians,
that may include obstetricians and gynecologists, plastic surgeons, dermatologists, general surgeons, urologists, urogynecologists or family
practitioners.
Benefits of the Viveve Solution
Our solution provides a number of benefits for physicians and patients:
●
●
Non-Invasive, Non-Ablative Alternative to Surgery with No Identified Safety Issues. Geneveve has been used to treat
over 200 clinical study patients and physicians have used Geneveve on more than 2,000 patients as of the date of this
report. The procedure is non-invasive and offers an alternative to surgery at a much lower price with little or no
downtime from the patient’s normal routine. It is also not a surgical procedure and does not damage either the mucosal
or sub-mucosal tissue or require any form of anesthesia.
Single Treatment. Geneveve is normally performed in a medical office setting as a single treatment that takes less than
30 minutes to complete. Our studies have shown that the clinical effect from our procedure occurs within one to three
months and patients continue to report improvements over a period of six months following treatment. In addition, our
studies have shown that Geneveve maintains its effect for at least 12 months, based upon currently available data from
our clinical studies.
5
●
●
Our Technology
Compelling Physician Economics. We believe that in an era of declining government and insurance reimbursement,
many physicians are seeking to add effective and safe, self-pay procedures to their practices. Geneveve can be easily
adapted into many physician practices and offers compelling per-procedure economics for the physician, despite
requiring a small capital equipment purchase.
Ease of Use. Geneveve offers an easy-to-use, straightforward user interface that allows a trained physician or nurse to
perform the treatment in less than 30 minutes. Geneveve provides real-time feedback and the patient can be monitored
during the treatment. The handpiece and single-use treatment tip are designed with a small profile for accurate
placement during treatment, comfort and ease of use.
Geneveve uses a patented method of delivering monopolar RF energy for heating tissue.
●
●
Monopolar Radiofrequency Energy. Monopolar RF delivery uses two electrodes, with one active electrode being held in
the device handpiece by the physician or nurse and the second, a passive return electrode, typically attached to the
patient’s upper leg. Monopolar delivery allows for precise administration of energy because the electrical current is
concentrated where the active electrode touches the body and disperses quickly as it travels towards the return electrode.
The monopolar RF process is distinct from bipolar RF-based technology, which is superficial, relying on current passing
through tissue located between two probes placed close together on the surface of the skin. We believe that our
monopolar technology delivers energy more effectively and to a greater tissue depth than bipolar technology.
The Capacitive Coupling Mechanism of Action for Collagen Heating. Our single-use Viveve treatment tip contains
patented technology that uses monopolar RF energy as a controlled tissue heating source through the use of a non-
conducting material, known as a dielectric. Capacitive coupling is the use of the dielectric to create an electric field in the
area where the treatment tip touches the body. The electric field induces a current within the surrounding tissue, resulting
in volumetric heating of the tissue due to the tissue’s natural resistance to electrical current flow. Collagen is an efficient
conductor of electricity and therefore acts as a pathway for the electric current. This process results in heating of the
fibrous septae, the strands of collagen fibers that permeate tissues and connect the outer mucosal layer to the underlying
muscle. Delivery of heat to the fibrous septae located in deeper layers of the tissue shrinks and shortens them, resulting
in tightening of the mucosal tissue. Over time, new collagen strands may grow as part of the body’s natural response to
the activation of fibroblasts that results from the application of low-energy hyperthermic RF energy. These new strands
may add strength and produce additional tissue tightening over the next one to three months. This tightening of the tissue
has the potential to reduce vaginal laxity and increase sexual function.
Geneveve
Geneveve includes three major components: the Viveve System™ (an RF, or radio frequency, generator housed in a table-top
console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians or nurses attach
the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and
programs the system for the desired treatment without further physician intervention.
●
●
●
Radiofrequency Generator. The generator produces a six-megahertz signal and is simple and efficient to operate. Controls
are within easy reach, and important user information is clearly displayed on the console’s built-in display, including
energy delivered, tissue impedance, duration and feedback on procedure technique. Cooling is achieved, in conjunction
with the generator, though the delivery of a coolant that helps to cool and protect the mucosa during a procedure.
Handpiece. The reusable handpiece holds the treatment tip in place and processes information about temperature,
contact, cooling system function and other important data. A precision control valve within the handpiece meters the
delivery of coolant, which protects the mucosal surface.
Treatment Tip. The single-use treatment tip is available in one size and comes pre-sterilized. Each treatment tip contains
a proprietary internal EPROM, or programmable memory chip, which stores treatment parameters and safety limits in
order to optimize performance and safety. To enhance procedural safety, we have programmed the EPROM for single-
use treatments. Using the same treatment tip to perform multiple procedures could result in injury, therefore, the EPROM
disables the treatment tip after a pre-programmed number of pulses to ensure that the treatment tip is not reused.
6
Geneveve also includes other consumable components. The console houses a canister of coolant that can be used for
approximately four to five procedures. Each procedure requires a new return pad, which is typically adhered to the patient’s upper leg to
allow a path of travel for the RF current through the body and back to the generator. We also sell proprietary single-use bottles of coupling
fluid, a viscous liquid that helps ensure electrical and thermal contact with the treatment tip.
Geneveve is conducted on an outpatient basis in a physician’s office. The procedure typically takes less than 30 minutes and does
not require any form of anesthesia. To perform the procedure, a physician or nurse attaches the single-use treatment tip to the handpiece.
As described above, the return pad is then adhered to the patient’s upper leg to allow a path of travel for the RF current back to the
generator. Prior to treatment, the treatment area is bathed in coupling fluid, which is used for conduction and lubrication. The area from the
1:00 o’clock position to the 11:00 o’clock position just inside the hymenal ring is treated using the Viveve treatment tip by delivering a
three-phased pulse: Phase 1 – cooling, Phase 2 – 90 Joules/cm2 of RF energy, and Phase 3 – cooling. Each pulse lasts approximately eight
seconds. The Viveve treatment tip is then repositioned in an overlapping fashion clockwise and the three-phased treatment pulse is
repeated. The entire circumferential treatment area from the 1:00 o’clock position to the 11:00 o’clock position is treated five times with
overlapping pulses. Treatment of the urethral area is avoided. During the treatment procedure patients are expected to feel a sensation of
warmth when the RF phase is delivered and a cooling sensation when the cooling phases are delivered. Based on our current clinical
results, Geneveve is only required once, with efficacy lasting for at least 12 months.
Our Customers
To date, we have focused our initial commercial efforts in markets where we have received regulatory clearances for Geneveve,
or in the case of Japan, where we use a physician import license pathway to sell our product. Within each market, we target thought leaders
in the OB/GYN and plastic surgery specialties in order to increase awareness of vaginal laxity and accelerate patient acceptance of
Geneveve. As our markets mature, we intend to target a broader number of physician specialties, including urogynecologists,
dermatologists, urologists, general surgeons, and family practitioners.
Through our sales employees, and distributors, we currently target physicians who have a demonstrated commitment to building a
high-volume, non-invasive, treatment business within their practice. As distribution of our product continues to expand globally, we intend
to continue to utilize distribution partners in all countries except the U.S. and Canada where we have a direct sales force. To date, we are
heavily reliant on our relationships with distribution partners for the sale of our products outside the U.S.
Business Strategy
Our goal is to become the leading provider of non-invasive solutions to treat vaginal laxity by:
Increasing the Installed Base of Geneveve. In our existing markets, we plan to expand the number of Geneveve users from our
initial base of early adopters by leveraging our current and future clinical study results and through innovative marketing programs
directed at both physicians and patients, where permitted by law. As a condition that has historically had no viable, non-invasive
solutions, we intend to focus much of our marketing effort on physician and patient education. Further, we intend to expand the
number of regulatory approvals both internationally and in the U.S., to further increase the areas in which we can market
Geneveve.
Driving Increased Treatment Tip Usage. Unlike the capital equipment model of other businesses, we maintain an active,
continuous relationship with our physician customer base because of the single-use, disposable nature of the treatment tips. We
work collaboratively with our physician customer base to increase treatment tip usage by enhancing customer awareness and
facilitating the marketing efforts of our physician customers to their patients. We believe that our customers’ interests are closely
aligned with our interests, and we plan to monitor the market to foster continued procedure growth for our customers and treatment
tip sales for us. We intend to launch innovative marketing programs with physician customers to develop a profitable Geneveve
practice.
7
Broadening Our Physician Customer Base. While our initial focus is on marketing our procedure to the OB/GYN specialty, we
intend to selectively expand our sales efforts into other physician specialties, such as plastic surgery, dermatology, urology,
urogynecology, general surgery and family practice. Additionally, we intend to pursue sales from physician-directed medi-spas
with track records of safe and successful aesthetic treatments.
Developing New Treatment Tips and System Enhancements. We intend to continue to expand our line of treatment tips to allow for
even shorter procedure times to benefit both physicians and patients. We also plan to pursue potential system modifications and
next generation enhancements that will further increase the ease-of-use of Geneveve.
Investing in Intellectual Property and Patent Protection. We will continue to invest in expanding our intellectual property
portfolio, and we intend to file for additional patents to strengthen our intellectual property rights. Areas in which we may pursue
additional patent protection include, but are not limited to, redesign of certain system components, disposable components and
software algorithms. We believe that our intellectual property rights protect our position as the exclusive provider of a vaginal
laxity treatment using monopolar RF technology in the U.S. and in many other countries. (See discussion under the heading
“Patents and Proprietary Technology ”.)
Sales and Marketing
International
We currently market and sell Geneveve, including the single-use treatment tips, in 51 countries outside the U.S. through trained
sales employees and distributors. As of the date of this report, we had four sales directors (Europe, Middle East, Asia Pacific, and Latin
America), and 26 sales distributors covering 69 countries throughout the world.
By using a consultative sales process, we form strong relationships with our customers through frequent interactions. Beyond
performing initial system installation and on-site training, which can occur within two weeks of a physician’s purchase decision, our sales
consultants provide ongoing consultation to physicians on how to integrate Geneveve into their practices and market procedures to their
patients.
We also provide comprehensive training and education to each physician upon delivery of Geneveve. We require this initial
training to assist physicians in safely and effectively performing Geneveve treatment.
Our strategy to grow sales internationally is to:
●
●
●
increase penetration of Geneveve by targeting physicians and clinics that perform in-office procedures and by
implementing direct-to-consumer marketing programs to increase patient awareness of Geneveve;
expand into new international markets by gaining regulatory approval, and identifying and training qualified distributors;
and
expand the scope of physicians who offer Geneveve in addition to OB/GYNs, including plastic surgeons, dermatologists,
general surgeons, urologists, urogynecologists and primary care physicians.
Further, we intend to actively engage in promotional opportunities through participation in industry tradeshows, clinical
workshops and company-sponsored conferences with expert panelists, as well as through trade journals, brochures and our website. We
intend to actively seek opportunities to obtain positive media exposure, and plan to engage in direct-to-consumer marketing of Geneveve,
including extensive use of social media.
United States
In December 2008, we received regulatory clearance from the FDA for a previous version of the device, no longer manufactured,
for use in general surgical procedures for electrocoagulation and hemostasis. In March 2015, we submitted a Special 510(k) to the FDA
seeking clearance for the updated Viveve System to take into account the design modifications to the original 510(k) cleared device, which
include improved user interface capabilities and enhanced manufacturability. In October 2016, we received clearance from the FDA to sell
the updated device for use in general surgical procedures for electrocoagulation and hemostasis.
8
We intend to seek regulatory clearance or approval from the FDA to allow us to begin to market Geneveve for the treatment of
vaginal tissue to improve sexual function, to physicians practicing in the U.S. and to build awareness of Geneveve in patients residing in
the U.S. In September 2016, we submitted an Investigational Device Exemption (“IDE”) application to FDA to begin a U.S. clinical study
and the FDA has responded with additional questions regarding the proposed protocol and other aspects of the clinical study design, which
we are working to address. If and when approval is received, we intend to begin our U.S. clinical study to demonstrate the safety and
effectiveness of the device to treat vaginal laxity and/or improve sexual function.
Clinical Studies
We have completed several pre-clinical studies, as well as three human clinical studies and we are currently preparing to conduct
a fourth human clinical study within the U.S., if and when we receive approval of our IDE application from the FDA. While we believe the
three completed studies have shown that Geneveve has a very strong safety profile and is highly effective in the treatment of vaginal laxity
and improvement of sexual function, there is risk that the FDA will not agree with this assessment.
Pre-clinical Studies
In 2010, in collaboration with West Virginia University, we conducted an animal study in sheep to assess the safety, and further
understand the mechanism of action, of Geneveve. The vaginal introitus of five parous sheep were treated once with Geneveve using a
variety of energy levels (75−90 Joules/cm2). Each sheep then underwent serial vaginal biopsies immediately after treatment, at
approximately one week, and at one, three and six months (4-5 samples per occurrence). Control biopsies were also obtained from three
untreated parous sheep. We examined the vaginal mucosa and underlying connective tissue for thermal changes and subsequent tissue
responses over a six month period through light microscopic examination of haematoxylin and eosin (“H&E”) stained slides that were
reviewed by pathologists who were blinded as to the treated and untreated sheep.
The results of the study indicated that the optimal level of RF energy delivered was 90 J/cm2 and the biopsies supported the
hypothesis that the mechanism of action of our technology involves connective tissue remodeling with fibroblast activation and new
collagen production. Given the post-treatment absence of ulcerations, regional necrosis or diffuse fibrosis, throughout the six month
follow-up period, we believe that FDA will eventually agree with our assessment regarding the safety profile of Geneveve.
As part of our clinical studies, we have studied and continue to study, the interaction of RF energy and tissue to further
understand the mechanism of action of Geneveve. We have used transmission electron microscopy on ovine biopsied tissue samples to
corroborate that our product induces subtle collagen modification and the deposition of new collagen that leads to tissue tightening and
restoration of tissue elasticity. We have developed histology techniques to investigate the depth of heat in tissue, fibroblast activation and
collagen deposition that we believe is responsible for long-term improvement and tightening of tissue. We have also created three-
dimensional computer models to study tissue heating with our product. Determining the effectiveness of this type of treatment is
inherently a subjective evaluation. When performing our clinical studies, we attempt to utilize the most compelling measures we can in
order to provide convincing evidence of efficacy.
Clinical Studies
In 2008 and 2010, we conducted two single-arm (non-placebo controlled) human clinical studies using Geneveve, one in the U.S.
and one in Japan, respectively. Both studies were designed to assess the safety and efficacy of Geneveve for the treatment of vaginal laxity
and improvement of sexual function and were submitted to regulatory authorities in Europe and Canada for the purpose of seeking
regulatory clearance for the use and distribution of Geneveve in such locations. Each study resulted in patients reporting that Geneveve
restored vaginal tightness to pre-childbirth level and improved sexual function. The results of our clinical trials are based on information
reported by clinical patients in various response questionnaires (referred to as patient reported outcomes), designed to measure vaginal
laxity and sexual function, completed by each clinical patient prior to treatment with respect to pre and post childbirth levels and at various
times following treatment. All patient reported scores for each questionnaire and at each time point are compared to those scores reported
by the same patients at baseline (prior to treatment) in order to assess whether patients have experienced a change due to the treatment.
This change in score is then tested for statistical relevance (i.e. whether or not the change measured is due to chance). It is widely accepted
by clinical trial industry standards that if the probability is less than 5% (p< .05) that this change is due to chance, than the results are
deemed to be “Statistically Significant”. In other words, there is a 95% probability that the change in score measured is due to the
treatment. Therefore, when we indicate that our clinical patients experienced a Statistically Significant result, we are referring to the
change in responses as reported by such patients on the response questionnaires from the pre-treatment assessment (baseline) as compared
to the post-treatment assessments at the various time points specified.
9
United States
We conducted our first human study of Geneveve beginning in November 2008. The study was a single-arm study (without a
control group) conducted in 24 female subjects, ages 25-44 years old, each of whom had experienced at least one full-term vaginal
delivery. The study was designed to assess the safety and efficacy of the procedure at three RF dosing levels. Each woman was treated
once with Geneveve, with no anesthesia – three patients received 60 joules/cm2, three patients received 75 joules/cm2, and 18 patients
received 90 joules/cm2. Patient outcomes were measured at baseline, one month, three months, six months, and 12 months using several
validated patient-reported outcome measures, including a company-designed vaginal laxity/tightness questionnaire (“VSQ”), Female
Sexual Function Index (“FSFI”), Female Sexual Distress Scale-Revised (“FSDS-R”) and the Global Response Assessment.
Within one month after treatment with Geneveve, patients reported a Statistically Significant improvement in vaginal laxity
scores, sexual function and sexual satisfaction scores to pre-childbirth levels. These results continued throughout the 12 month follow-up
period. Additionally, patients reported a Statistically Significant decrease at one month, and thereafter, in their personal distress scores
from sexual activity.
Geneveve also demonstrated a strong safety profile throughout the study. The treatment was well tolerated and there were no
procedure-related adverse events or serious adverse events through the 12 month follow-up period. Notwithstanding the safety in trials to
date of Geneveve, patients may experience undesirable side effects such as temporary swelling or reddening of the treated tissue.
Japan
Our second human clinical study of Geneveve began in March 2010. This study was an open-label study conducted in 30 female
subjects, ages 21-55 years old, each of whom had experienced at least one full-term vaginal delivery. The study was designed to assess the
safety and efficacy of the procedure. Each woman was treated once with Geneveve, with no anesthesia, using 90 joules/cm2 of RF energy
as the therapeutic dose.
Patient reported outcomes were measured at baseline, one month, three months, six months, and 12 months using several
validated patient-reported outcome measures, including VSQ, FSFI, FSDS-R and the Global Response Assessment.
Within one month after Geneveve, patients reported a Statistically Significant improvement in vaginal laxity scores, sexual
function and sexual satisfaction scores to pre-childbirth levels. These results continued throughout the 12 month follow-up period.
Additionally, patients reported a Statistically Significant decrease at one month, and thereafter, in their personal distress scores from
sexual activity.
Geneveve continued to demonstrate a strong safety profile. The treatment was well tolerated and there were no procedure-related
adverse events or serious adverse events through the 12 month follow-up period.
VIVEVE I Clinical Study
In the fourth quarter of 2014, we began the VIVEVE I clinical study (VIveve Treatment of the Vaginal Introitus to EValuate
Effectiveness), sometimes referred to in this report as the “OUS Clinical Trial,” a randomized, blinded and sham-controlled trial designed
to further demonstrate the efficacy and safety of Geneveve versus a sham-control procedure for the treatment of vaginal laxity. The study
was designed to demonstrate that Geneveve was superior to the sham treatment for the primary effectiveness and safety endpoints
described below. Nine clinical sites in four countries (Canada, Italy, Spain and Japan) enrolled 174 patients, which included pre-
menopausal females 18 years of age or older who experienced at least one full term vaginal delivery at least 12 months prior to enrollment
date, randomized in a 2:1 ratio to either an active treatment group or sham-control group. Patients were followed for six months post-
treatment to assess the primary effectiveness and safety endpoints of the study with data being collected at one, three and six month
intervals. The study also included a prospective interim data analysis at the 3 month endpoint of 50% of the patients enrolled. Patients
randomized to the sham arm were offered the opportunity to receive Geneveve once they had completed the 6-month evaluation following
the sham intervention.
10
The primary endpoint of the study was the proportion of subjects in the active arm as compared to the proportion of subjects in
the sham arm reporting no vaginal laxity at six months post-intervention. “No vaginal laxity” is operationally defined as a score > 4 on the
VSQ, a patient reported global assessment of vaginal laxity based on a 7 point scale. Additionally, the primary safety endpoint was the
proportion of subjects in the active arm experiencing an adverse event (“AE”) by six months post-treatment as compared to the proportion
of the subjects in the sham arm experiencing an AE by six months post-intervention. Secondary endpoints included the adjusted change in
mean score on the FSFI, FSDS-R and the Vaginal Laxity Inventory (“VALI”). The VALI was created specifically for the assessment of
vaginal laxity by external medical experts. Its use as a comprehensive patient reported outcome questionnaire is currently being
scientifically validated by us to assess women’s vaginal laxity on a 7 point scale.
In April 2016, we completed the VIVEVE I study and reported the following results:
At 6 months (n=155), the proportion of patients reporting “no vaginal laxity” in the active arm, as measured by the VSQ, was
41.7%, while the proportion of patients reporting “no vaginal laxity” in the sham arm on the VSQ was 19.2% (p=0.005). Moreover, the
likelihood of having “no vaginal laxity” following treatment in the active arm was more than three times greater than for the sham arm
(p=0.006). Further, nearly 80% of the subjects in the active arm experienced a positive change in VSQ score versus baseline.
At 6 months, for those patients who scored less than a 26.5 total score on the FSFI at baseline (n=103), the adjusted mean change
from baseline score between the active arm and the sham arm was 3.2 (p=0.009). Moreover, for each of the six individual domains of the
FSFI, subjects in the active group reported a greater increase in score than in the sham group. Change in scores from baseline for both the
sexual arousal and orgasm domains were Statistically Significant and nearly 93% of subjects in the active arm experienced an increase in
score versus baseline.
At 6 months, FSDS-R and VALI were also assessed as part of the secondary end-point analysis. While subjects in the active arm
reported a greater increase in scores than the sham arm, the results for the FSDS-R and VALI were not Statistically Significant.
Safety for the study was assessed on the entire study population (n=174). Subjects reported the same level of unrelated (32.5%
active versus 35.1% sham), related (11.1% active versus 12.3% sham) and serious (0.0% active versus 1.8% sham) adverse events in both
the active and sham arm, further demonstrating that Geneveve is well tolerated with no safety concerns.
We believe that the consistency of results across these three clinical study populations, is indicative of the cross-cultural
similarities in this medical condition and the positive impact that an effective non-invasive treatment can have on the sexual health of
women after vaginal childbirth.
Research and Development
We intend to focus on various research and development efforts for Geneveve, including but not limited to:
●
●
conduct of the VIVEVE II study that is the subject of the pending IDE with FDA, in order to support a marketing
application for a vaginal laxity/sexual function indication in the U.S.;
expansion of the number of approved indications in the U.S. and internationally, including but not limited to;
postmenopausal vaginal atrophy and stress urinary incontinence;
●
implementing a cost improvement program to further increase gross margins and gross profit opportunity;
11
●
●
●
developing a new cooling system to maintain compliance with potential changes in environmental regulations;
designing new treatment tips to further optimize ease-of-use and reduce procedure times for patients and physicians; and
increasing security to prevent counterfeiting and refurbishment.
We have formed strategic relationships with outside contractors for assistance on research and development projects, and we
work closely with experts in the medical community to supplement our research and development resources. Research and development
expenses for the years ended December 31, 2016 and 2015 were $8,365,000 and $4,988,000, respectively. In the future, we expect to
pursue further research and development initiatives to improve and extend our technological capabilities and to foster an environment of
innovation and quality.
Manufacturing
Our manufacturing strategy involves the combined utilization of internal manufacturing resources and expertise, as well as
approved suppliers and contract manufacturers. Our internal manufacturing activities include the testing and packaging of Viveve
treatment tips and handpieces, as well as the final integration, system testing and packaging of Geneveve. We outsource the manufacture
of components, subassemblies and certain finished products that are produced to our specifications and shipped to our Sunnyvale facility
for final assembly or inspection, testing and certification. Our finished products are stored at and distributed from our Sunnyvale facility.
Quality control, risk management, efficiency and the ability to respond quickly to changing requirements are the primary goals of our
manufacturing operations.
We have arrangements with our suppliers that allow us to adjust the delivery quantities of components, subassemblies and
finished products, as well as delivery schedules, to match our changing requirements. The forecasts we use are based on historical trends,
current utilization patterns and sales forecasts of future demand. Lead times for components, subassemblies and finished products may
vary significantly depending on the size of the order, specific supplier requirements and current market demand for the components and
subassemblies. Most of our suppliers have no contractual obligations to supply us with, and we are not contractually obligated to purchase
from them, the components used in our devices.
We obtain programmable memory chips for our treatment tips and the coolant valve for the handpiece from single suppliers, for
which we attempt to mitigate risks through inventory management and utilization of 12- to 18-month purchase orders, and sterilization
services from a single vendor, for which we attempt to mitigate risks by using two sterilization chambers at each of two locations. Other
products and components come from single suppliers, but alternate suppliers have been qualified or, we believe, can be readily identified
and qualified. In addition, the availability of cryogen for our cooling module, which we can source from multiple suppliers, may fluctuate
due to changes in the global supply of this material. To date, shipments of finished products to our customers have not been delayed due to
material delays in obtaining any of our components, subassemblies or finished products.
We are required to manufacture our product in compliance with Title 21 of the Code of Federal Regulations Part 820 (“21 CFR
820”) enacted by the FDA (known as the Quality System Regulation or QSR). 21 CFR 820 regulates the methods and documentation
relating to the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our product. We
maintain quality assurance and quality management certifications to enable us to market our product in the member states of the European
Union, the European Free Trade Association and countries which have entered into Mutual Recognition Agreements with the European
Union. These certifications include EN ISO 9001:2000 and CAN/CSA ISO 13485:2003. We are also required to maintain our product
registration in a number of other foreign markets such as Canada.
12
We use small quantities of common cleaning products in our manufacturing operations, which are lawfully disposed of through a
routine waste management program. Except for costs that may be incurred in the future in connection with environmental regulations
requiring the phase out of R134a, a hydrofluorocarbon, or HFC, upon which our cooling module relies, we do not anticipate any material
costs due to compliance with environmental laws or regulations. In 2007, the European Union enacted directives aimed at the automotive
industry for the removal of HFC's from air conditioning. As a result of these directives, we anticipate that similar directives may be
imposed on the medical device industry over the next decade. While we do not anticipate that we will have to incur costs in the near future
to develop an alternative cooling module for our device which is not dependent on HFCs, if and when we are required to do so, and if we
do not do so in a timely or cost-effective manner, Geneveve may not be in compliance with environmental regulations, which could result
in fines, civil penalties and the inability to sell our products in certain major international markets.
Given our limited commercial history, we only offer a one year warranty providing for the repair, rework or replacement (at the
Company’s option) of products that fail to perform within stated specifications. To the extent that any of our components have
performance related or technical issues in the field, we typically replace those components as necessary.
Patents and Proprietary Technology
We rely on patent, copyright, trade secret and trademark laws and confidentiality agreements to protect our technology and
Geneveve. We have an exclusive license to or own 4 issued U.S. patents directed to our technology and Geneveve Additionally, we have 3
pending U.S. patent applications, 49 issued foreign patents, and 20 pending foreign patent applications, some of which foreign applications
preserve an opportunity to pursue patent rights in multiple countries.
U.S. Patent
Foreign Patents
Issued
4
Pending
3
Issued
49
Pending
20
All of our employees and consultants are required to execute confidentiality agreements in connection with their employment and
consulting relationships with us. We also require them to agree to disclose and assign to us all inventions conceived or made in connection
with the employment or consulting relationship. We cannot provide any assurance that our employees and consultants will abide by the
confidentiality or invention assignment terms of their agreements. Despite measures taken to protect our intellectual property,
unauthorized parties may copy aspects of our product or obtain and use information that we regard as proprietary.
“Viveve,” is a registered trademark in the U.S. and several foreign countries. Geneveve is a registered trademark in the European
Community and South Korea; there are pending applications in the U.S. as well as 4 foreign countries. As of the date of this report, we
have one registered trademark in the U.S., as well as various foreign registrations protecting the mark in 19 countries outside of the U.S.
We may file for additional trademarks to strengthen our trademark rights, but we cannot be certain that our trademark applications will
issue or that our trademarks will be enforceable.
Edward Knowlton Licensed Patents
On February 10, 2006, Viveve, Inc. entered into an Intellectual Property Assignment and License Agreement with Edward W.
Knowlton (“Knowlton”), as amended on May 22, 2006 and July 20, 2007 (collectively, the “Knowlton IP Agreement”), pursuant to which
Knowlton granted to Viveve, Inc. an exclusive, royalty-free and perpetual worldwide sublicense to certain intellectual property and
technology licensed to Knowlton from a third party, including rights to several patents and patent applications owned by Thermage, Inc.
outside the field of contraction, remodeling and ablation of the skin through and including (but not beyond) the subcutaneous fat layer
below the skin (collectively, the “Knowlton Licensed IP”). The sublicense under the Knowlton Licensed IP is fully-paid, transferable,
sublicensable and permits us to make, have made, use, sell, offer for sale and import any product or technology solely for use in the field
of transmucosal treatment of the vagina or vulva (the “Field”) and to practice any process, method, or procedure solely in the Field. The
Knowlton IP Agreement also assigns to us all technology and related intellectual property rights owned by Knowlton for the development
and commercialization of devices, including any improvements, in the Field (the “Knowlton Assigned IP”). We are obligated to file and
reasonably prosecute any patent applications that include a description of the Knowlton Assigned IP as prior art and maintain all patents
included in the Knowlton Assigned IP, at our expense. In consideration of the sale, assignment, transfer, release and conveyance and other
obligations of Knowlton under the Knowlton IP Agreement, Viveve, Inc. issued 200,000 shares of our common stock to Knowlton and
agreed to engage the consulting services of Knowlton.
13
Also on February 10, 2006, Viveve, Inc. entered into a Consulting Agreement with Knowlton (“Knowlton Consulting Agreement”),
pursuant to which Knowlton assigned all rights to any inventions and intellectual property developed during the course of providing
consulting services in the Field during the term of the agreement. Unless earlier terminated pursuant to the provisions described therein,
the term of the Knowlton Consulting Agreement continued until the earlier to occur of (i) the date that is six months after the closing of an
initial public offering of Viveve, Inc.’s stock; or (ii) the acquisition by a third party of all or substantially all of the business or assets of
Viveve, Inc., whether by asset or stock acquisition, merger, consolidation or otherwise. The agreement could be renewed only upon the
mutual written agreement of the parties prior to its expiration. The Knowlton Consulting Agreement expired by its terms on September 23,
2014, the effective date of the Merger. The assignment of the intellectual property developed during the term of the Knowlton Consulting
Agreement survives termination.
Agreement with Solta Medical
Effective April 30, 2010, Viveve, Inc. entered into a Supply Agreement (the “Supply Agreement”) with Solta Medical, Inc.
(“Solta”), pursuant to which Solta agreed to sell to Viveve, Inc. the cryogen cooling method and coupling fluid that Solta uses with its
ThermaCool® System (“TC3 System”) for use with our compatible radio frequency medical device for the purpose of conducting our
initial clinical trials. The applicable term of the Supply Agreement is the later of the period through completion of our initial clinical trials
or six months following the effective date. On October 14, 2010, the parties amended the term of the Supply Agreement to remain in effect
for so long as Solta supports its TC3 System. In the event that Solta discontinues support of its TC3 System and terminates the Supply
Agreement, Solta agrees to (i) provide us with information for Solta’s cryogen supplier, (ii) permit us to make any arrangement with such
supplier for a continued supply of cryogen and (iii) grant us a royalty free, non-exclusive perpetual license under any Solta intellectual
property directed to the design of the cryogen container in the field of treating vaginal tissue.
The portion of the Supply Agreement relating to coupling fluid was subsequently superseded by the parties’ Coupling Fluid
License and Product Supply Agreement on September 30, 2010, pursuant to which Solta agreed to (i) grant to Viveve, Inc. a license for the
coupling fluid and (ii) supply the coupling fluid at preferred pricing for two years and at non-preferred pricing after two years. The
agreement grants to us a royalty-free, fully paid-up, worldwide, perpetual, exclusive license in the field of treating vaginal tissue, with a
right to grant sublicenses in such field, to make, have made, use and sell coupling fluid for an aggregate license fee of $125,000. The
agreement was for an initial term of three years, after which it continues to remain in effect unless and until terminated in accordance with
the terms therein. In addition, while the terms of the original agreement permit the use of the cryogen cooling method for initial clinical
trials, Viveve also purchases the cryogen cooling method and coupling fluid from Solta for commercial purposes. We currently do not
have an alternative source of cryogen and if Solta refuses to sell to us for commercial reasons, or otherwise, our business could be
materially adversely affected.
Agreement with Stellartech Research Corporation
On June 12, 2006, Viveve, Inc. entered into the Stellartech Agreement, as amended and restated on October 4, 2007, with
Stellartech for an initial term of three years in connection with the performance of development and manufacturing services by Stellartech
and the license of certain technology and intellectual property rights to each party. Under the Stellartech Agreement, we agreed to purchase
300 units of generators manufactured by Stellartech. In conjunction with the Agreement, Stellartech purchased 37,500 shares of Viveve,
Inc.’s common stock at $0.008. Under the Stellartech Agreement, we paid Stellartech $6,485,000 and $3,446,000 for goods and services
during the years ended December 31, 2016 and 2015, respectively. In addition, Stellartech granted to us a non-exclusive, nontransferable,
worldwide, royalty-free license in the Field (defined above in the discussions titled “Edward Knowlton Licensed Patents”) to use
Stellartech’s technology incorporated into deliverables or products developed, manufactured or sold by Stellartech to us pursuant to the
Stellartech Agreement (the “Stellartech Products”) to use, sell, offer for sale, import and distribute the Stellartech Products within the
Field, including the use of software object code incorporated into the Stellartech Products. The Stellartech technology consists of know-
how applicable to the manufacturing and repair of Geneveve, including any other intellectual property which Stellartech developed or
acquired separate and apart from the Stellartech Agreement and all related derivative works. In addition, once we purchase a minimum
commitment of 300 units of the RF generator component (the “Minimum Commitment”) and the Stellartech Agreement expires,
Stellartech is to grant us a nonexclusive, nontransferable, worldwide, royalty-free, fully-paid license to use the Stellartech technology
incorporated into the Stellartech Products to make and have made Stellartech Products in the Field.
14
Stellartech also granted (i) an exclusive (even as to Stellartech), nontransferable, worldwide, royalty-free license within the Field
under those certain intellectual property rights licensed to Stellartech pursuant to a development and supply agreement between Stellartech
and Thermage, dated October 1, 1997 (the “Thermage Technology”), to use any elements of the Thermage Technology incorporated into
the Stellartech Products, solely for the use, sale, offer for sale, importation and distribution within the Field; (ii) upon our satisfaction of
the Minimum Commitment and the expiration of the Stellartech Agreement, an exclusive, nontransferable, worldwide, royalty-free, fully-
paid license within the Field under Stellartech’s license rights in the Thermage Technology to use any elements of the Thermage
Technology which are incorporated into the Stellartech Products to make and have made Stellartech Products in the Field; and (iii) the
exclusive right within the Field to prosecute infringers of the portion of Stellartech’s Thermage Technology rights exclusively licensed to
us. Our license rights in Thermage Technology also include the use of software object code for Thermage Technology used in the
Stellartech Products. As of the date of this report, the Stellartech Agreement has expired by its terms, however, the parties still continue to
operate under the terms of the agreement. In addition, we have not yet met the Minimum Commitment requirement, and therefore we are
not permitted to use the Stellartech technology with any other manufacturer. If Stellartech refuses or is unable to meet our delivery
requirements for Geneveve, our business could be materially adversely affected.
In March 2012, Viveve, Inc. entered into a Quality and Regulatory Agreement with Stellartech, pursuant to which the parties
clarified their respective quality and regulatory responsibilities under the Stellartech Agreement. The Quality and Regulatory Agreement
provides that we will serve as the legal manufacturer for all Stellartech Products developed and sold to us thereunder and that we are
obligated to maintain all relevant quality assurance and regulatory processes and requirements required by any regulatory authority and to
comply with the processes and requirements set forth in the schedule of responsibilities provided in the agreement.
Government Regulation
Geneveve is a medical device subject to extensive and rigorous regulation by international regulatory bodies as well as the FDA.
These regulations govern the following activities that we perform, or that are performed on our behalf, to ensure that medical products
exported internationally or distributed domestically are safe and effective for their intended uses:
●
●
●
●
●
product design, development and manufacture;
product safety, testing, labeling and storage;
record keeping procedures;
product marketing, sales and distribution; and
post-marketing surveillance, complaint handling, medical device reporting, reporting of deaths, serious injuries or device
malfunctions and repair or recall of products.
In addition to the regulatory approvals already received in connection with the sale of Geneveve in the foreign jurisdictions
described below and the approvals/clearances being sought in the U.S., we are currently seeking regulatory approval or clearance for the
sale of our product in many other countries around the world.
International
Sales of our product outside the U.S. are subject to foreign regulatory requirements that vary widely from country to country. In
addition, exports of medical devices from the U.S. are regulated by the FDA. Complying with international regulatory requirements can be
an expensive and time-consuming process and approval is not certain. The time required to obtain registrations or approvals, as required by
other countries, may be longer than that required for FDA clearance, and requirements for such registrations or approvals may
significantly differ from FDA requirements. We may be unable to obtain or maintain registrations or approvals in other countries. We may
also incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals. If we experience delays in receiving
necessary registrations or approvals to market our product outside the U.S., or if we fail to receive those registrations or approvals, we may
be unable to market our product or enhancements in international markets effectively, or at all, which could have a material adverse effect
on our business and growth strategy.
15
An entity that seeks to export an unapproved Class III medical device from the U.S. to a “non-Tier I” country is required to obtain
export approval from the FDA. The Tier I countries are largely defined as industrialized countries with established regulatory
infrastructure, such as, among others, Canada and the European Union. In January of 2011, we sought to obtain FDA approval to export
Geneveve to Mexico, Brazil and Korea (all non-Tier I countries). An export approval was obtained on March 7, 2011. Exportation of an
unapproved Class III medical device to a Tier I country is permitted without FDA approval provided that certain conditions are met.
Accordingly, we have exported Geneveve to Canada and the European Union without FDA approval in accordance with Section 802 of
the Federal Food, Drug, and Cosmetic Act (FDC Act).
Once an entity has obtained a marketing authorization for the product in a Tier I country (e.g., a CE mark, etc.), the device can
then be shipped from the U.S. to any country in the world without FDA approval. On December 7, 2010, we obtained a CE Mark for
Geneveve. As a result, we may now legally export Geneveve to non-Tier I countries, such as China and Hong Kong without FDA
approval.
Entities legally exporting products from the U.S. are often asked by foreign customers or foreign governments to supply an
export certificate issued by the FDA to accompany a device. An export certificate is a document prepared by the FDA containing
information about a product’s regulatory or marketing status in the U.S. Although we have requested the issuance of export certificates to
allow exports into many countries around the world, the FDA has not yet issued export certificates to us.
Currently, Geneveve is cleared for marketing in 51 countries throughout the world under the following indications for use:
Indication for Use:
General surgical procedures for electrocoagulation and hemostasis
For treatment of vaginal laxity
For treatment of the vaginal introitus, after vaginal childbirth, to improve
sexual function
For vaginal rejuvenation
No. of Countries:
3 (including the
U.S.)
34
13
1
Outside the U.S., we market and sell through an extensive network of distribution partners. In the U.S., Geneveve is indicated for
use in general surgical procedures for electrocoagulation and hemostasis and we market and sell through a direct sales force.
United States
FDA’s Premarket Clearance and Approval Requirements
Unless an exemption applies, any medical device we wish to commercially distribute in the U.S. will require either premarket
clearance or approval from the FDA. The FDA classifies medical devices into one of three classes. The classification system is risk based,
with devices deemed to pose the lowest risk being Class I, and devices posing the most risk being Class III. Most Class I devices are
exempt from the requirement to obtain FDA premarket clearance or approval. For most Class II devices (and a small number of Class I
devices), a company must submit to the FDA a premarket notification (known as 510(k) submission) requesting clearance to commercially
distribute the device. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices,
or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III, requiring FDA premarket
approval via a Premarket Approval (“PMA”) application. The FDA has issued regulations identifying the Class into which different types
of devices fall and identifying whether the device type is exempt from the 510(k) process or if a 510(k) is needed.
16
510(k) Clearance Pathway
When a 510(k) clearance is required, we must submit a premarket notification to the FDA demonstrating that our device is
substantially equivalent to a previously cleared and legally marketed device or a device that was in commercial distribution before May
28, 1976 for which the FDA has not yet called for the submission of PMAs (known as a predicate device). The FDA strives to make a
determination that the device is substantially equivalent (SE) (i.e., clear the device) or not substantially equivalent (NSE) within 90 days
of submission of the notification. As a practical matter, clearance often takes significantly longer. The FDA may require further
information, including clinical data, to make a determination regarding substantial equivalence. If the FDA determines that the device is
not substantially equivalent to a previously cleared device, the FDA will issue an NSE letter and place the device into Class III.
Any modification to a 510(k)-cleared device that would constitute a major change in its intended use, or any change that could
significantly affect the safety or effectiveness of the device, requires a new 510(k) clearance and may even, in some circumstances, require
a PMA, if the change raises complex or novel scientific issues or the product has a new intended use. The FDA requires every
manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review any
manufacturer’s decision. If the FDA were to disagree with a manufacturer’s determination that changes did not require a new 510(k), the
FDA could require the manufacturer to cease marketing and distribution and/or recall the modified device until 510(k) clearance or PMA
approval is obtained and the manufacturer could be subject to significant regulatory fines or penalties.
In December 2008, a predecessor company to Viveve received 510(k) clearance for a previous version of the Geneveve device.
Since then, we have made design modifications to the original 510(k)-cleared device. In March 2015, we submitted a Special 510(k) to the
FDA seeking clearance for the updated Viveve System to take into account the design modifications to the original 510(k)-cleared device,
which included improved user interface capabilities and enhanced manufacturability. In October 2016, we received clearance from the
FDA to sell the updated device for use in general surgical procedures for electrocoagulation and hemostasis.
De Novo Process
If FDA has not issued a regulation classifying a particular type of device as Class I, and if there is no known predicate for a device
(i.e., a legally-marketed device that is not subject to premarket approval with comparable indications for use and technological
characteristics), the device is automatically Class III, regardless of the risk the device poses. If a device is automatically/statutorily
classified into Class III in this manner, a company can petition FDA to reclassify the category of devices into Class II or Class I via a
process known as “Evaluation of Automatic Class III Designation,” which is typically referred to as the “de novo process.” The direct de
novo process allows a company to request that a new product classification be established without the company first submitting a 510(k)
notification for the device. . The reclassification petition should include a risk-benefit analysis demonstrating that, when subject to general
controls or general and special controls, the probable benefits to health from use of the device outweigh any probable injury or illness from
such use. The submitter also must describe why general controls or general and special controls are adequate to provide reasonable
assurance of safety and effectiveness and for proposed Class II devices, provide proposed special controls. If a product is classified as
Class II through the direct de novo review process, then that device may serve as a predicate device for subsequent 510(k) premarket
notifications, including by competitors.
We intend to seek FDA authorization to market Geneveve for the treatment of vaginal tissue to improve sexual function by
utilizing the direct de novo process. However, we cannot predict when or if approval of such a petition will be obtained. In addition, if
FDA fails to grant a de novo petition, we will be required to seek FDA premarket approval (via the more stringent PMA process) for
Geneveve. Delays in receipt of FDA clearance or failure to receive FDA clearance or approval could reduce our sales, profitability and
future growth prospects.
17
Clinical Trials
Clinical trials are almost always required to support an FDA de novo reclassification, and are sometimes required for 510(k)
clearance. With respect to Geneveve, the FDA has asked us to conduct a clinical study under an IDE, to support a future product
submission. In the U.S., clinical trials on medical devices generally require submission of an application for an IDE to the FDA if the
device is a “significant risk” device. The IDE application must be supported by appropriate data, such as animal and laboratory testing
results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved
in advance by the FDA for a specific number of patients. Clinical trials for significant risk devices may not begin until the IDE application
is approved by both the FDA and the appropriate institutional review boards (“IRBs”) at the clinical trial sites. Our clinical trials must be
conducted under the oversight of an IRB at the relevant clinical trial sites and in accordance with FDA regulations, including, but not
limited to, those relating to good clinical practices. We are also required to obtain the patients’ informed consent, in compliance with both
FDA requirements and state and federal privacy regulations. We, the FDA, or the IRB at each site at which a clinical trial is being
performed may suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the
benefits. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and efficacy of the device, may be
equivocal or may otherwise not be sufficient to obtain clearance or approval of the product. Similarly, in Europe and other regions, clinical
study protocols must be approved by the local ethics committee and in some cases, including studies with high-risk devices, by the
Ministry of Health in the applicable country.
In June 2012, we submitted a pre-IDE application and requested an in-person meeting with the FDA to solicit feedback in advance
of filing an IDE to conduct a clinical study of Geneveve to support regulatory submission. In August 2012, we met with the FDA and
received feedback on our pre-clinical data, historical clinical data, and a clinical protocol for a prospective randomized controlled trial. We
had a second meeting with the FDA on December 17, 2015 and received additional feedback on our clinical protocol design and indication
for use. In September 2016 we submitted an IDE application to FDA to begin a U.S. clinical study and the FDA has responded with
additional questions regarding the proposed protocol and other aspects of the clinical study design, which we are working to address. If
and when approval is received, we intend to begin our U.S. clinical study to demonstrate the safety and effectiveness of the device to treat
vaginal laxity and/or improve sexual function.
Continuing Regulation
After a device is placed on the market, numerous regulatory requirements continue to apply. These include:
●
●
●
product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;
Quality system regulations (“QSRs”), which require manufacturers, including third-party manufacturers, to follow stringent
design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing
process;
labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or “off-label” uses
to both physician and consumers;
● Medical Device Reporting (“MDR”), regulations, which require that a manufacturer report to the FDA if its device
may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute
to a death or serious injury if the malfunction were to recur;
●
●
●
post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional
safety and effectiveness data for the device;
regulations pertaining to voluntary recalls and notices of corrections or removals; and
any other postmarket requirements that FDA might impose as part of the device approval or clearance process.
The FDA has broad post-market and regulatory enforcement powers. We and our third-party manufacturers are subject to
announced and unannounced inspections by the FDA and state equivalents such as the Food and Drug Branch of the California
Department of Health Services (“CDHS”), to determine compliance with the QSR and other regulations. In the past, our facility has been
inspected, and observations were noted, including an April 2012 CDHS inspection that cited deficiencies related to signature authority of
inspection documentation, incomplete corrective action responses, and labeling indicating that our product contained no latex without
proper objective evidence. The FDA and CDHS have accepted our responses to these observations, and we believe that we and our third-
party manufacturer are in substantial compliance with the QSR.
Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any
of the following actions:
●
warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
18
●
repair, replacement, refunds, recall or seizure of our products;
●
operating restrictions, partial suspension or total shutdown of production;
●
refusing our requests for 510(k) clearance or premarket approval of new products or new intended uses;
●
refusing to grant export approval for our product;
●
withdrawing 510(k) clearance or premarket approvals that are already granted; and
●
criminal prosecution.
If any of these events were to occur, it could have a material adverse effect on our business.
We are also subject to a wide range of federal, state and local laws and regulations, including those related to the environment,
health and safety, land use, advertising, and quality assurance. We believe that compliance with these laws and regulations as currently in
effect will not have a material adverse effect on our capital expenditures, earnings and competitive and financial position.
Competition
The medical device industry is characterized by intense competition and rapid innovation. While we believe that our solution to
treat vaginal laxity is unique and offers a more effective solution from that which is on the market currently, we also believe that the
market for the treatment of vaginal laxity and women’s sexual function remains a tremendous, under-developed opportunity. Therefore,
competition is expected to increase, particularly as the market becomes more developed with further solutions. Aside from Kegel exercises
and invasive surgical procedures, such as LVR, there are many companies developing or that have developed energy-based technologies
for vaginal rejuvenation as well as others developing drug therapies and therapeutics for the treatment of various types of female sexual
dysfunction. Further, the overall size and attractiveness of the market may compel larger companies focused in the OB/GYN, aesthetic or
women’s health markets, and with much greater capital and other resources, to pursue development of or acquire technologies that may
address these areas. Potential competitors include, but are not limited to Cynosure, Syneron Medical, Fotona, Thermi Aesthetics (acquired
by Almirall, S.A.), Cutera, Apricus, and others, some of whom have more established products and customer relationships than we have.
Employees
As of February 8, 2017, we had 42 full-time employees and we retain the services of several qualified consultants. We believe
that our future success will depend in part on our continued ability to attract, hire and retain qualified personnel. None of our employees is
represented by a labor union, and we believe that our employee relations are good.
Continuance into Delaware
On July 22, 2015, at our 2015 Annual and Special Meeting of Stockholders, our stockholders approved a special resolution
authorizing a continuance of the Company (the “Continuance”) into the State of Delaware under the Delaware General Corporation Law
(the “DGCL”) and the adoption of charter documents that comply with the DGCL in connection therewith, effective as of a date to be
determined by the Board, in its sole discretion, no more than 12 months from the date of the meeting. On May 9, 2016, the Company filed
the necessary Application for Authorization to Continue into Another Jurisdiction and Statutory Declaration with the Yukon registrar. On
May 10, 2016, the Company filed a Certificate of Conversion and Certificate of Incorporation with the Secretary of State of the State of
Delaware to move its domicile from the Yukon Territory to Delaware.
The Continuance did not involve any change in our business, properties, corporate headquarters or management. The officers of
the Company immediately prior to the Continuance continued to serve as our officers following the Continuance, and the current members
of the Board of Directors continued to serve as the members of the Board following the Continuance. There was no change in our
operations, assets, liabilities or obligations as a result of the Continuance. Other than the approval of our stockholders and the filings with
the Yukon Registrar of Corporations and the Secretary of State of Delaware, there were no federal or state regulatory requirements that we
were required to comply with or approvals that we were required to obtain in connection with the Continuance.
19
Upon the effectiveness of the Continuance, each outstanding share of our common stock continued to be an outstanding share of
our common stock as incorporated in Delaware and each outstanding option, right or warrant to acquire shares of our common stock
continued to be an option, right or warrant to acquire an equal number of shares of common stock under the same terms and conditions.
Upon effectiveness of the Continuance, we were governed by the Certificate of Incorporation filed with the Secretary of State of Delaware
and by bylaws prepared in accordance with the DGCL, which were approved by our stockholders at the 2015 Annual and Special Meeting.
Following the Continuance, we were governed by the DGCL instead of the Yukon Business Corporation Act.
Item 1A. Risk Factors
Investing in our common stock involves a high degree of risk. Prospective investors should carefully consider the risks described
below, together with all of the other information included or referred to in this Annual Report on Form 10-K, before purchasing shares of
our common stock. There are numerous and varied risks that may prevent us from achieving our goals. If any of these risks actually
occurs, our business, financial condition or results of operations may be materially adversely affected. In such case, the trading price of
our common stock could decline and investors in our common stock could lose all or part of their investment.
Risks Related to Our Business
We are dependent upon the success of Geneveve, which has a limited commercial history. If Geneveve fails to gain or loses market
acceptance, our business will suffer.
In 2012, we began marketing Geneveve in Canada, Hong Kong and Japan, and we expect that sales of Geneveve, including the
Viveve System (radio frequency generator), single-use treatment tips and other ancillary consumables, will account for substantially all of
our revenue for the foreseeable future. Geneveve may not significantly penetrate current or new markets, including the U.S. and
elsewhere. If demand for Geneveve does not increase as we anticipate, or if demand declines, our business, financial condition and results
of operations will be harmed.
We compete against companies that have more established products, longer operating histories and greater resources, which may
prevent us from achieving significant market penetration or increased operating results.
The medical device and aesthetics markets are highly competitive and dynamic, and are marked by rapid and substantial
technological development and product innovations. Demand for Geneveve could be diminished by equivalent or superior products and
technologies developed by competitors. Specifically, Geneveve competes against other offerings in these markets, including laser and
other light-based medical devices, pharmaceutical and consumer products, surgical procedures and exercise therapies.
Competing in these markets could result in price-cutting, reduced profit margins and loss of market share, any of which
would harm our business, financial condition and results of operations. Our ability to compete effectively depends upon our ability to
distinguish our company and Geneveve from our competitors and their products, on such factors as:
●
●
●
●
●
●
●
safety and effectiveness;
product pricing;
success of our marketing initiatives;
compelling clinical data;
intellectual property protection;
quality of customer support; and
development of successful distribution channels, both domestically and internationally
Some of our competitors have more established products and customer relationships than we have, which could inhibit our market
penetration efforts. For example, we may encounter situations where, due to pre-existing relationships, potential customers decide to
purchase additional products from our competitors. Potential customers may need to recoup the cost of expensive products that they have
already purchased to perform LVR surgery or vaginoplasty and thus may decide not to purchase, or to delay the purchase of, Geneveve. If
we are unable to achieve continued market penetration, we will be unable to compete effectively and our business will be harmed.
20
In addition, potential competitors could have significantly greater financial, research and development, manufacturing, and sales
and marketing resources than we have and could utilize their greater resources to acquire or develop new technologies or products that
could effectively compete with our existing product. Given the relatively few competitors currently in the market, any such action could
exacerbate existing competitive pressures, which could harm our business.
Performing clinical studies on, and collecting data from, Geneveve is inherently subjective, and we have limited data regarding the
efficacy of Geneveve. If future data is not positive or consistent with our prior experience, rates of physician adoption will likely be
harmed.
We believe that in order to significantly grow our business, we will need to conduct future clinical studies of the effectiveness of
Geneveve. Clinical studies of vaginal laxity and sexual function are subject to a number of limitations. First, these studies do not involve
objective standards for measuring the effectiveness of treatment. Subjective, patient reported outcomes are the most common method of
evaluating effectiveness. As a result, clinical studies may conclude that a treatment is effective even in the absence of objective measures.
Second, as with other non-invasive, energy-based devices, the effect of Geneveve varies from patient to patient and can be influenced by a
number of factors, including the age, ethnicity and level of vaginal laxity and sexual function of the patient, among other things.
Current published studies of Geneveve conducted in the U.S. and Japan have investigated the tissue-tightening effect of Viveve’s
monopolar RF technology using single-arm studies where all patients enrolled in the trial received the same treatment without comparison
to a control group. Clinical studies designed in a randomized, blinded and controlled fashion (e.g., assessing the efficacy of a product or
therapy versus a placebo or sham group) represent the gold-standard in clinical trial design. A sham-controlled treatment or procedure
refers to a procedure performed as a control and that is similar to the treatment or procedure under investigation without the key therapeutic
element being investigated. Future clinical studies, which may be required to drive physician adoption or support regulatory clearance or
approval, will likely require randomized, blinded and controlled trial designs. In the fourth quarter of 2014, we initiated a new randomized,
blinded and sham-controlled clinical trial in Europe and Canada designed to demonstrate the efficacy of Geneveve versus a sham-
controlled procedure for the treatment of vaginal laxity and sexual function (the “OUS Clinical Trial”). In April 2016, we completed this
study. (See discussion under the heading “Clinical Studies”.)
Additionally, we have not conducted any head-to-head clinical studies that compare results from treatment with Geneveve to
surgery or treatment with other therapies. Without head-to-head studies against competing alternative treatments, which we have no
current plans to conduct, potential customers may not find clinical studies of our technology sufficiently compelling to purchase Geneveve.
If we decide to pursue additional studies in the future, such studies could be expensive and time consuming, and the data collected may not
produce favorable or compelling results. If the results of such studies do not meet physicians’ expectations, Geneveve may not become
widely adopted, physicians may recommend alternative treatments for their patients, and our business may be harmed.
We currently have clearance to market Geneveve in the U.S. for general surgical procedures for electrocoagulation and hemostasis but
not for vaginal laxity or sexual function. If we want to sell Geneveve and single-use treatment tips in the U.S. for the treatment of
vaginal laxity or sexual function, we will need to obtain additional FDA clearance or approval, which may not be granted.
Developing and promoting Geneveve in additional countries for additional indications, including the U.S., is a key element of our
future growth strategy. We currently do not have FDA clearance or approval to market Geneveve in the U.S. for the treatment of vaginal
laxity or sexual function. We intend to seek clearance or approval from the FDA to expand our marketing efforts and have engaged with
the FDA to help improve our likelihood of success. However, we cannot predict whether we will receive such clearances or approvals.
The FDA will require us to conduct clinical trials to support regulatory clearance or approval, which trials may be time-consuming and
expensive, and may produce results that do not result in clearance or approval of our FDA marketing application. In the event that we do
not obtain FDA clearance or approval of Geneveve for the treatment of vaginal laxity or sexual function, we will be unable to promote
Geneveve in the U.S. for those indications, and the ability to grow our revenues may be adversely affected.
21
Our business is not currently profitable, and we may not be able to achieve profitability even if we are able to generate significant
revenue.
As of December 31, 2016, we have incurred losses since inception of approximately $68.6 million. In 2016, we incurred a loss of
$20.1 million and in 2015 a loss of $12.4 million. Even though our revenue may increase, we expect to incur significant additional losses
while we grow and expand our business. We cannot predict if and when we will achieve profitability. Our failure to achieve and sustain
profitability could negatively impact the market price of our common stock and may require us to seek additional financing for our
business. There are no assurances that we will be able to obtain any additional financing or that any such financing will be on terms that
are favorable to us.
If there is not sufficient consumer demand for the procedures performed with our products, demand for our products could decline,
which would adversely affect our operating results.
The medical device and aesthetic markets in which we operate are particularly vulnerable to economic trends. The procedures
performed using our aesthetic treatment systems are elective procedures that are not reimbursable through government or private health
insurance. The cost of these elective procedures must be borne by the patient. As a result, the decision to undergo a procedure that uses our
products may be influenced by the cost.
Consumer demand, and therefore our business, is sensitive to a number of factors that affect consumer spending, including
political and macroeconomic conditions, health of credit markets, disposable consumer income levels, consumer debt levels, interest rates,
consumer confidence and other factors. If there is not sufficient consumer demand for the procedures performed with our products,
practitioner demand for our products would decline, and our business would suffer.
It is difficult to forecast future performance, which may cause our financial results to fluctuate unpredictably.
Our limited operating history makes it difficult to predict future performance. Additionally, the demand for Geneveve may vary
from quarter to quarter. A number of factors, over which we have limited or no control, may contribute to fluctuations in our financial
results, such as:
●
●
●
●
●
●
●
delays in receipt of anticipated purchase orders;
performance of our independent distributors;
positive or negative media coverage of Geneveve, the Viveve Treatment or products of our competitors;
our ability to obtain further regulatory clearances or approvals;
delays in, or failure of, product and component deliveries by our subcontractors and suppliers;
customer response to the introduction of new product offerings; and
fluctuations in foreign currency.
Our limited operating history has limited our ability to determine an appropriate sales price for our products.
Our historical operating performance has limited our ability to determine the proper sales prices for Geneveve and the single-use
treatment tips. Establishing appropriate pricing for our capital equipment and components has been challenging because there have not
existed directly comparable competitive products. We may experience similar pricing challenges in the future as we enter new markets or
introduce new products, which could have an unanticipated negative impact on our financial performance.
If there is not sufficient patient demand for our treatments, practitioner demand for Geneveve could drop, resulting in unfavorable
operating results.
All procedures performed using Geneveve are elective procedures, the cost of which must be borne by the patient, and are not
reimbursable through government or private health insurance. The decision to undergo Geneveve is thus driven by consumer demand,
which may be influenced by a number of factors, such as:
●
whether our marketing efforts directed toward increasing consumer awareness of Geneveve, for which we have limited
experience and resources, are successful;
22
●
●
●
●
the extent to which physicians recommend Geneveve to their patients;
the cost, safety and effectiveness of Geneveve versus alternative treatments;
general consumer sentiment about the benefits and risks of such procedures; and
consumer confidence, which may be impacted by economic and political conditions.
Our financial performance could be materially harmed in the event that any of the above factors discourage patients from seeking
Geneveve.
The failure of Geneveve to meet patient expectations or the occurrence of unpleasant side effects from Geneveve could impair our
financial performance.
Our future success depends upon patients having a positive experience with Geneveve in order to increase physician demand for
our products, as a result of positive feedback and word-of-mouth referrals. Patients may be dissatisfied if their expectations of the
procedure, side effects and results, among other things, are not met. Despite what we believe to be the safety of Geneveve, patients may
experience undesirable side-effects such as temporary swelling or reddening of the treated tissue. Experiencing any of these side effects
could discourage a patient from completing Geneveve or discourage a patient from having future procedures or referring Geneveve to
others. In order to generate referral business, we believe that patients must be satisfied with the effectiveness of Geneveve. Results
obtained from Geneveve are subjective and may be subtle. Geneveve may produce results that may not meet patients’ expectations. If
patients are not satisfied with the procedure or feel that it is too expensive for the results obtained, our reputation and future sales will
suffer.
Our success depends on growing physician adoption of Geneveve and continued use of treatment tips.
Some of our target physician customers already own self-pay device products. Our ability to grow our business and convince
physicians to purchase Geneveve depends on the success of our sales and marketing efforts. Our business model involves both a capital
equipment purchase of Geneveve and continued purchases by our customers of single-use treatment tips and ancillary consumables. This
may be a novel business model for many potential customers who may be used to competing products that are exclusively capital
equipment, such as many laser-based systems. We must be able to demonstrate that the cost of Geneveve and the revenue that the
physician can derive from performing procedures using it are compelling when compared to the cost and revenue associated with
alternative products or therapies. When marketing to plastic surgeons, we must also, in some cases, overcome a bias against non-invasive
procedures. If we are unable to increase physician adoption of Geneveve and use of the treatment tips, our financial performance will be
adversely affected.
To successfully market and sell Geneveve internationally, we must address many issues with which we have limited experience.
Sales outside the U.S. accounted for 96% of our revenue during the year ended December 31, 2016 and 100% of our
revenue during the years ended December 31, 2015 and 2014. We believe that a significant portion of our business will continue to come
from sales outside the U.S. through increased penetration in countries where we currently sell Geneveve, combined with expansion into
new international markets. However, international sales are subject to a number of risks, including:
●
●
●
●
●
●
●
●
●
●
difficulties in staffing and managing international operations;
difficulties in penetrating markets in which our competitors’ products may be more established;
reduced or no protection for intellectual property rights in some countries;
export restrictions, trade regulations and foreign tax laws;
fluctuating foreign currency exchange rates;
foreign certification and regulatory clearance or approval requirements;
difficulties in developing effective marketing campaigns for unfamiliar, foreign countries;
customs clearance and shipping delays;
political and economic instability; and
preference for locally produced products.
If one or more of these risks were realized, it could require us to dedicate significant resources to remedy the situation, and even
if we are able to find a solution, our revenues may still decline.
23
We depend on distributors to market and sell Geneveve internationally. If they are not successful, our marketing and sales efforts will
be harmed.
We currently depend exclusively on third-party distributors to sell and service Geneveve internationally and to train our
international customers, and if these distributors terminate their relationships with us or under-perform, we may be unable to maintain or
increase our level of international revenue. We will also need to engage additional international distributors to grow our business and
expand the territories in which we sell Geneveve. Distributors may not commit the necessary resources to market, sell and service
Geneveve to the level of our expectations. If current or future distributors do not perform adequately, or if we are unable to engage
distributors in particular geographic areas, our revenue from international operations will be adversely affected.
We currently have limited sales and marketing resources or experience and failure to build and manage a sales force or to market and
distribute Geneveve effectively could have a material adverse effect on our business.
We expect to rely on a direct sales force to sell Geneveve in the U.S. In order to meet our future anticipated sales objectives, we
expect to grow our domestic sales organization significantly over the next several years. There are significant risks involved in building
and managing our sales organization, including risks related to our ability to:
●
●
●
hire qualified individuals as needed;
provide adequate training for the effective sale of Geneveve; and
retain and motivate sales employees.
It is difficult to predict how well our sales force will perform. Our failure to adequately address these risks could have a material
adverse effect on our ability to sell Geneveve, causing our revenue to be lower than expected and harming our results of operations.
Competition among providers of devices for the medical device and aesthetics markets is characterized by rapid innovation, and we
must continuously innovate Geneveve and develop new products or our revenue may decline.
While we attempt to protect Geneveve through patents and other intellectual property rights, there are few barriers to entry that
would prevent new entrants or existing competitors from developing products that compete directly with our products. For example, while
we believe our monopolar RF technology maintains a strong intellectual property position, there may be other companies employing
competing technologies which claim to have a similar clinical effect to our technology. Additionally, there are others who may market
monopolar RF technology for competing purposes in a direct challenge to our intellectual property position. As we continue to create
market demand for a non-surgical, non-invasive way to treat vaginal laxity and sexual dysfunction, competitors may enter the market with
other products making similar or superior claims. We expect that any competitive advantage we may enjoy from our current and future
innovations may diminish over time, as companies successfully respond to our innovations, or create their own. Consequently, we believe
that we will have to continuously innovate and improve Geneveve and technology or develop new products to compete successfully. If we
are unable to develop new products or innovate successfully, Geneveve could become obsolete and our revenue will decline as our
customers purchase competing products.
We outsource the manufacturing and repair of key elements of Geneveve to a single manufacturing partner.
We outsource the manufacture and repair of Geneveve to a single contract manufacturer, Stellartech. If Stellartech’s operations
are interrupted or if Stellartech is unable to meet our delivery requirements due to capacity limitations or other constraints, we may be
limited in our ability to fulfill new customer orders or to repair equipment at current customer sites, and we may be required to seek new
manufacturing partners in the future. Stellartech has limited manufacturing capacity, is itself dependent upon third-party suppliers and is
dependent on trained technical labor to effectively repair components making up Geneveve. In addition, Stellartech is a medical device
manufacturer and is required to demonstrate and maintain compliance with the FDA’s Quality System Regulation, or QSR. If Stellartech
or any future manufacturing partner fails to comply with the FDA’s QSR, its manufacturing and repair operations could be halted. In
addition, both the availability of our product to support the fulfillment of new customer orders as well as our ability to repair those
products installed at current customer sites would be impaired. In addition, as of the date of this report, the development and
manufacturing agreement under which Viveve and Stellartech operate has expired without any subsequent extension or renewal by the
parties and the minimum conditions to the licenses granted therein have not been satisfied by us. Although the parties continue to operate
under the terms of this agreement, our manufacturing operations could be adversely impacted if we are unable to enforce Stellartech’s
performance under this agreement, or enter into a new agreement with Stellartech or a potential new manufacturer, if necessary, upon
favorable terms or at all.
24
Our manufacturing operations and those of our key manufacturing subcontractors are dependent upon third-party suppliers, making
us vulnerable to supply shortages and price fluctuations, which could harm our business.
The single source supply of Geneveve from Stellartech could not be replaced without significant effort and delay in production.
Also, several other components and materials that comprise Geneveve are currently manufactured by a single supplier or a limited number
of suppliers. In many of these cases, we have not yet qualified alternate suppliers and we rely upon purchase orders, rather than long-term
supply agreements. A supply interruption or an increase in demand beyond our current suppliers’ capabilities could harm our ability to
manufacture Geneveve until new sources of supply are identified and qualified. Our reliance on these suppliers subjects us to a number of
risks that could harm our business, including:
● interruption of supply resulting from modifications to or discontinuation of a supplier’s operations;
● delays in product shipments resulting from uncorrected defects, reliability issues or a supplier’s variation in a component;
● a lack of long-term supply arrangements for key components with our suppliers;
● inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;
● difficulty locating and qualifying alternative suppliers for our components in a timely manner;
● production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory
qualifications;
● delay in delivery due to suppliers prioritizing other customer orders over our orders;
● damage to our brand reputation caused by defective components produced by our suppliers;
● increased cost of our warranty program due to product repair or replacement based upon defects in components produced by
our suppliers; and
● fluctuation in delivery by our suppliers due to changes in demand from us or from their other customers.
Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from
alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers, which would have
an adverse effect on our business.
If, in the future, we decide to perform additional manufacturing functions internally that we currently outsource, our business could be
harmed by our limited manufacturing experience and related capabilities.
In the future, for financial or operational purposes, we may elect to perform component or system manufacturing functions
internally. Our limited experience with manufacturing processes could lead to difficulties in producing sufficient quantities of
manufactured items that meet our quality standards and that comply with applicable regulatory requirements in a timely and cost-effective
manner. In addition, if we experience these types of manufacturing difficulties, it may be expensive and time consuming to engage a new
or previous subcontractor or supplier to fulfill our replacement manufacturing needs. The occurrence of any of these events could harm
our business.
If Geneveve malfunctions or if we discover a manufacturing defect that could lead to a malfunction, we may have to initiate a product
recall or replace components, which could adversely impact our business.
Problems in our manufacturing processes, or those of our manufacturers or subcontractors, which lead to an actual or possible
malfunction in any of the components of Geneveve, may require us to recall product from customers or replace components and could
disrupt our operations. For example, in December 2012, we began replacing handpiece assemblies that were causing system malfunctions
due to fiber optic damage that occurred during the manufacturing process. We subsequently worked with our manufacturer to redesign and
test the reliability of the newly designed handpiece. The problem was resolved within several weeks and did not have a significant impact
on our ability to supply products to our customers or, more generally, on our results of operations. However, our results of operations,
reputation and market acceptance of our products could be harmed if we encounter difficulties in manufacturing that result in a more
significant issue or significant patient injury, and delays our ability to fill customer orders.
25
We may not be able to develop an alternative cooling module that will be in compliance with changing environmental regulations in a
timely or cost-effective manner.
Our cooling module relies upon a hydrofluorocarbon, or HFC, called R134a, to protect the outer layer of the tissue from over-
heating while the device delivers RF energy to the submucosal tissue. New environmental regulations phasing out HFCs over the next
decade have been adopted or are under consideration in a number of countries. Since 2007, European Union directives aimed at the
automotive industry require the phase-out of HFCs and prohibit the introduction of new products incorporating HFCs and it is currently
anticipated that such directives may impact the medical device industry. As a result, if we are unable to develop an alternative cooling
module for our device which is not dependent on HFCs in a timely or cost-effective manner, Geneveve may not be in compliance with
environmental regulations, which could result in fines, civil penalties and the inability to sell our products in certain major international
markets.
In addition, the impending restrictions on HFCs have reduced their current availability, as suppliers have less of an incentive to
expand production capacity or maintain existing capacity. This change in supply could expose us to supply shortages or increased prices
for R134a, which could impair our ability to manufacture Geneveve and adversely affect our results or operations. HFCs may also be
classified by some countries as a hazardous substance and, therefore, subject to significant shipping surcharges that may negatively impact
profit margins.
We rely on a limited number of suppliers and third-party manufacturers, and if they are unable or unwilling to continue to work with
us, our business could be materially adversely affected.
We rely on a limited number of suppliers and third-party manufacturers. Our reliance on them increases our risk since in the
event of an interruption from one or more of them, we may not be able to develop alternative resources without incurring additional costs
or delays. For example, we entered into a Coupling Fluid License and Product Supply Agreement with Solta Medical (“Solta”) pursuant to
which Solta agreed to grant to us a license for the coupling fluid and supply the coupling fluid at preferred pricing for two years and at
non-preferred pricing after two years. The agreement was for an initial term of three years, after which it continues to remain in effect
unless and until terminated in accordance with the terms therein. We use the cryogen cooling method and coupling fluid with our
compatible radio frequency medical device for the purpose of conducting our clinical trials as well as for commercial purposes. Since we
currently do not have any alternative sources of cryogen, if Solta refuses to sell to us for commercial reasons, or otherwise, our business
could be materially adversely affected.
We forecast sales to determine requirements for components and materials used in Geneveve, and if our forecasts are incorrect, we
may experience delays in shipments or increased inventory costs.
We keep limited materials, components and finished product on hand. To manage our manufacturing operations with our
suppliers, we forecast anticipated product orders and material requirements to predict our inventory needs up to six months in advance and
enter into purchase orders on the basis of these requirements. Our limited historical experience may not provide us with enough data to
accurately predict future demand. If our business expands, our demand for components and materials would increase and our suppliers
may be unable to meet our demand. If we overestimate our component and material requirements, we will have excess inventory, which
would increase our expenses. If we underestimate our component and material requirements, we may have inadequate inventory, which
could interrupt, delay or prevent delivery of Geneveve to our customers. Any of these occurrences would negatively affect our financial
performance and the level of satisfaction that our customers have with our business.
Even though we require training for users of Geneveve and we do not sell Geneveve to non-physicians, there exists a potential for
misuse, which could harm our reputation and our business.
Outside of the U.S., our independent distributors sell in many jurisdictions that do not require specific qualifications or training
for purchasers or operators of Geneveve. We do not supervise the procedures performed with Geneveve, nor can we be assured that direct
physician supervision of our equipment occurs according to our recommendations. We and our distributors require purchasers of Geneveve
to undergo an initial training session as a condition of purchase, but do not require ongoing training. In addition, we prohibit the sale of
Geneveve to companies that rent Geneveve to third parties, but we cannot prevent an otherwise qualified physician from contracting with a
rental company in violation of his or her purchase agreement with us.
26
In the U.S., we only sell Geneveve to licensed physicians who have met certain training requirements. However, current federal
regulations will allow us to sell Geneveve to “licensed practitioners,” if we receive FDA approval. The definition of “licensed
practitioners” varies from state to state. As a result, Geneveve may be operated by licensed practitioners with varying levels of training,
and in many states by non-physicians, including physician assistants, registered nurses and nurse practitioners. Thus, in some states, the
definition of “licensed practitioner” may result in the legal use of Geneveve by non-physicians.
The use of Geneveve by non-physicians, as well as noncompliance with the operating guidelines set forth in our training
programs, may result in product misuse and adverse treatment outcomes, which could harm our reputation and expose us to costly product
liability litigation.
Product liability suits could be brought against us due to defective design, labeling, material or workmanship, or misuse of Geneveve,
and could result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates.
If Geneveve is defectively designed, manufactured or labeled, contains defective components or is misused, we may become
subject to substantial and costly litigation by our customers or their patients. Misusing Geneveve or failing to adhere to operating
guidelines could cause serious adverse events. In addition, if our operating guidelines are found to be inadequate, we may be subject to
liability. We may, in the future, be involved in litigation related to the use of Geneveve. Product liability claims could divert
management’s attention from our business, be expensive to defend and result in sizable damage awards against us. We may not have
sufficient insurance coverage for all future claims. We may not be able to obtain insurance in amounts or scope sufficient to provide us
with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could
increase our product liability insurance rates or prevent us from securing continuing coverage, could harm our reputation in the industry
and reduce product sales. Product liability claims in excess of our insurance coverage would be paid out of cash reserves, harming our
financial condition and adversely affecting our operating results.
After-market modifications to treatment tips by third parties and the development of counterfeit products could reduce our sales, expose
us to product liability litigation and dilute our brand quality.
Third parties may introduce adulterated after-market modifications to our treatment tips, which enable re-use of treatment tips in
multiple procedures. Because the treatment tips are designed to withstand a finite number of pulses, modifications intended to increase the
number of pulses could result in patient injuries caused by the use of worn-out or damaged treatment tips. In addition, third parties may
seek to develop counterfeit products that are compatible with Geneveve and available to practitioners at lower prices. If security features
incorporated into the design of Geneveve are unable to prevent after-market modifications to the treatment tips or the introduction of
counterfeit products, we could be subject to reduced sales, product liability lawsuits resulting from the use of damaged or defective goods
and damage to our reputation.
We depend on skilled and experienced personnel to operate our business effectively. If we are unable to recruit, hire and retain these
employees, our ability to manage and expand our business will be harmed, which would impair our future revenue and profitability.
Our success largely depends on the skills, experience and efforts of our officers and other key employees. While we have
employment contracts with our Chief Executive Officer and our Chief Financial Officer, these officers and other key employees may
terminate their employment at any time. The loss of any senior management team members could weaken our management expertise and
harm our business.
Our ability to retain our skilled labor force and our success in attracting and hiring new skilled employees will be a critical factor
in determining whether we will be successful in the future. We may not be able to meet our future hiring needs or retain existing
personnel. We will face particularly significant challenges and risks in hiring, training, managing and retaining engineering and sales and
marketing employees, as well as independent distributors, most of whom are geographically dispersed and must be trained in the use and
benefits of Geneveve. Failure to attract and retain personnel, particularly technical and sales and marketing personnel, would materially
harm our ability to compete effectively and grow our business.
27
Any acquisitions or in-licenses that we make could disrupt our business and harm our financial condition.
We expect to evaluate potential strategic acquisitions of complementary businesses, products or technologies. We may also
consider joint ventures and other collaborative projects, including in-license opportunities. We may not be able to identify appropriate
acquisition candidates or strategic partners, or successfully negotiate, finance or integrate acquisitions of any businesses, products or
technologies, as applicable, on favorable terms or at all. Furthermore, the integration of any acquisition or in-license and management of
any collaborative project may divert management’s time and resources from our business and disrupt our operations. We do not have any
experience with acquiring companies or products or in-licensing of technologies. If we decide to expand our product offerings, we may
spend time and money on projects that do not increase our revenues. Our inability to identify and secure such opportunities may harm our
financial condition and our ability to compete and grow our business.
Risks Related to Regulatory Matters
We or our distributors may be unable to obtain or maintain international regulatory clearances or approvals for our current or future
products, or our distributors may be unable to obtain necessary qualifications, which could harm our business.
Sales of Geneveve internationally are subject to foreign regulatory requirements that vary widely from country to country. In
addition, the FDA regulates exports of medical devices from the U.S. Complying with international regulatory requirements can be an
expensive and time-consuming process, and marketing approval or clearance is not certain. The time required to obtain clearances or
approvals, if required by other countries, may be longer than that required for FDA clearance or approvals, and requirements for such
clearances or approvals may significantly differ from FDA requirements. We may rely on third-party distributors to obtain all regulatory
clearances and approvals required in other countries, and these distributors may be unable to obtain or maintain such clearances or
approvals. Our distributors may also incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals or
clearances, which could increase the difficulty of attracting and retaining qualified distributors. If our distributors experience delays in
receiving necessary qualifications, clearances or approvals to market our products outside the U.S., or if they fail to receive those
qualifications, clearances or approvals, we may be unable to market our products or enhancements in international markets effectively, or
at all.
Foreign governmental authorities that regulate the manufacture and sale of medical devices have become increasingly stringent
and, to the extent we market and sell our products outside of the U.S., we may be subject to rigorous international regulation in the future.
In these circumstances, we would be required to rely on our foreign independent distributors to comply with the varying regulations, and
any failures on their part could result in restrictions on the sale of our product in foreign countries.
If we fail to maintain regulatory approvals and clearances, or if we are unable to obtain, or experience significant delays in obtaining,
FDA clearances or approvals for Geneveve or any future products we may develop or acquire, including product enhancements, our
business and results of operations could be adversely affected.
Geneveve is, and any future products we may acquire or develop will be, subject to rigorous regulation by the FDA and
numerous other federal, state and foreign governmental authorities. The process of obtaining regulatory clearances or approvals to market
a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at
all. In particular, the FDA permits commercial distribution of a new medical device only after the device has received clearance under
section 510(k) of the Federal Food, Drug, and Cosmetic Act, or FDCA, (unless the device is exempt from the 510(k) requirements), has
been classified pursuant to a de novo classification request, or is the subject of an approved premarket approval application, or PMA. The
FDA will permit marketing of a lower risk medical device through the 510(k) process if the manufacturer demonstrates that the new
product is substantially equivalent to another 510(k)-cleared product, referred to as a predicate device. Devices deemed to pose the greatest
risk, such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared
device, require the approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k) clearance process. A PMA
application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and
labeling data, to demonstrate to the FDA a reasonable assurance of the safety and efficacy of the device for its intended use.
28
If FDA has not issued a regulation classifying a particular type of device as Class I, and if there is no known predicate for a
device, the device is automatically Class III, regardless of the risk the device poses. If a device is automatically/statutorily classified into
Class III in this manner, a company can petition FDA to reclassify the category of devices into Class II or Class I via a process known as
“Evaluation of Automatic Class III Designation,” which is typically referred to as the de novo process. The direct de novo process allows a
company to request that a new product classification be established without the company first submitting a 510(k) notification for the
device. Our plan is to seek FDA authorization to market Geneveve for the treatment of vaginal tissue to improve sexual function by
utilizing the direct de novo process. However, we cannot predict when or if such de novo classification will be obtained. If FDA fails to
reclassify the device pursuant to the de novo process, we will be required to seek FDA premarket approval (via the more stringent PMA
process) for Geneveve. Delays in receipt of FDA clearance or approval or failure to receive FDA clearance or approval could adversely
affect our business, results of operations and future growth prospects.
Our marketed products may be used by physicians for indications that are not cleared by the FDA. If the FDA finds that we marketed
our products in a manner that promoted off-label use, we may be subject to civil or criminal penalties.
Under the FDCA and other laws, we are prohibited from promoting our products for off-label uses. This means that we may not
make claims about the use of any of our marketed medical device products outside of their approved or cleared indications, and that our
website, advertising promotional materials and training methods may not promote or encourage unapproved uses. Therefore, we may not
provide information to physicians or patients that promote off-label uses, except in limited circumstances, such as in response to
unsolicited requests for off-label information or the distribution of scientific and medical publications under certain circumstances. The
FDA does not generally restrict physicians from prescribing products for off-label uses (or using products in an off-label manner) in their
practice of medicine. Should the FDA determine that our activities constitute the promotion of off-label uses, the FDA could bring action
to prevent us from distributing our devices for the off-label use and could impose fines and penalties on us and our executives. In addition,
failure to follow FDA rules and guidelines relating to promotion and advertising can result in, among other things, the FDA’s refusal to
approve or clear products, the withdrawal of an approved/cleared product from the market, product recalls, fines, disgorgement of profits,
operating restrictions, injunctions or criminal prosecutions. Any of these adverse regulatory actions could result in substantial costs and
could significantly and adversely impact our reputation and divert management’s attention and resources, which could have a material
adverse effect on our business.
If the Office of Inspector General within the Department of Health and Human Services, the DOJ, or another federal or state agency
determines that we have promoted off-label use of our products, we may be subject to various penalties, including civil or criminal
penalties, and the off-label use of our products may result in injuries that lead to product liability suits, which could be costly to our
business.
In addition to the FDA restrictions on our marketed products, other state and federal healthcare laws have been applied by DOJ
and state attorneys general to restrict certain marketing practices in the medical device industry. While physicians may generally prescribe
and administer products for off-label uses, if we engage in off-label promotion, we may be subject to civil or criminal penalties including
signifigant fines and could be prohibited from participating in government healthcare programs such as Medicaid and Medicare. Even if we
are successful in resolving such matters without incurring penalties, responding to investigations or prosecutions will likely result in
substantial costs and could significantly and adversely impact our reputation and divert management’s attention and resources, which
could have a material adverse effect on our business, operating results, financial condition and ability to finance our operations. In
addition, the off-label use of our products may increase the risk of injury to patients, and, in turn, the risk of product liability claims.
Product liability claims are expensive to defend and could divert our management’s attention and result in substantial damage awards
against us.
If we modify an FDA-cleared device, we may need to seek and obtain new clearances, which, if not granted, would prevent the sale of
our modified product or require us to redesign the product.
Any modifications to an FDA-cleared device that could significantly affect its safety or effectiveness or that would constitute a
major change in its intended use would require a new 510(k) clearance or possibly a premarket approval. We may not be able to obtain
additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our existing
product in a timely fashion, or at all. Delays in obtaining future clearances or approvals would adversely affect our ability to introduce new
or enhanced products in a timely manner, which in turn could harm our revenue and potential future profitability. We have made
modifications to our device in the past and may make additional modifications in the future that we believe do not or will not require
additional clearances or approvals. If the FDA disagrees, and requires new clearances or approvals for the modifications, we may be
required to recall and to stop marketing the modified device, which could harm our operating results and require us to redesign the
product.
29
Clinical trials necessary to support a 510(k)notification, de novo petition or PMA application will be expensive and will require the
enrollment of large numbers of patients. Suitable patients may be difficult to identify and recruit. Delays or failures in our clinical
trials may prevent us from commercializing our current product or any modified or new products and will adversely affect our
business, operating results and prospects.
The FDA has asked us to conduct a clinical study, pursuant to the agency’s investigational device exemption, or IDE,
regulations, to support a future product submission for Geneveve. Initiating and completing clinical trials necessary to support a 510(k)
notification, de novo petition, or PMA application for Geneveve, as well as other possible future product candidates, will be time
consuming and expensive and the outcome is uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future
results, and any product we advance into clinical trials may not have favorable results in later clinical trials.
Conducting successful clinical studies will require the enrollment of patients, and suitable patients may be difficult to identify and
recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the
size of the patient population, the nature of the trial protocol, the desirability of, or the discomforts and risks associated with, the
treatments received by enrolled subjects, the availability of appropriate clinical trial investigators and support staff, the proximity of
patients to clinical sites, the ability of patients to comply with the eligibility and exclusion criteria for participation in the clinical trial and
patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to
undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product or if they determine that the
treatments received under the trial protocols are not desirable or involve unacceptable risk or discomfort.
Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not
adequately develop such protocols to support clearance or approval. Further, the FDA may require us to submit data on a greater number
of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis
applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an
increase in costs and delays in the approval or clearance and attempted commercialization of our product or result in the failure of the
clinical trial. In addition, despite considerable time and expense invested in clinical trials, the FDA may not consider our data adequate to
demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and
prospects.
If the third parties on which we rely to conduct our clinical trials and to assist us with preclinical development do not perform as
contractually required or expected, we may not be able to obtain the regulatory clearance or approval which would permit us to
commercialize our products.
We do not have the ability to independently conduct the preclinical studies and clinical trials for our product, therefore we must
rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to
conduct the studies and trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet
expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the
failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical
trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory clearance or approval for, or be able
to successfully commercialize, our product on a timely basis, if at all. In that event, our business, operating results and prospects may be
adversely affected.
The results of our clinical trials may not support our proposed product claims or may result in the discovery of adverse side effects.
Any of these events could have a material adverse impact on our business.
Even if our clinical trials are completed as planned, it cannot be certain that the results of the clinical trials will support our
proposed claims for Geneveve, that the FDA or foreign authorities will agree with our conclusions regarding them or that even if our
product receives regulatory approval or clearance, that it will not later result in adverse side effects that limit or prevent its use. Success in
preclinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later
trials will replicate the results of prior trials and preclinical studies. The clinical trial process may fail to demonstrate that our product is
safe and effective for the proposed indicated uses. Any delay of our clinical trials or failure by the FDA or other foreign authorities to
accept our product claims will delay, or even prevent, our ability to commercialize our product and generate revenues.
30
Even if our product is approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA or other foreign
regulatory authority requirements, or if we experience unanticipated problems with our product, the product could be subject to
restrictions or withdrawal from the market.
Any product for which we obtain clearance or approval, and the manufacturing processes, reporting requirements, post-approval
clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections
by the FDA and other domestic and foreign regulatory bodies, such as the Food and Drug Branch of the California Department of Health
Services, or CDHS. In particular, we and our suppliers are required to comply with the FDA’s QSR, and International Standards
Organization, or ISO, standards for the manufacture of our product and other regulations which cover the methods and documentation of
the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain
clearance or approval. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. In the
past, our facility has been inspected by the FDA and CDHS, and observations were noted. The FDA and CDHS have accepted our
responses to these observations, and we believe that we are in substantial compliance with the QSR. Any future failure by us or one of our
suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely
and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the
following enforcement actions and unanticipated expenditures to address or defend such actions:
● untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
● customer notifications for repair, replacement or refunds;
● recall, detention or seizure of our products;
● operating restrictions or partial suspension or total shutdown of production;
● refusing or delaying our requests for 510(k) clearance, de novo classification, or premarket approval of new products or
modified products;
● operating restrictions;
● reclassifying a device that previously received a 510(k) clearance or withdrawing a PMA approval that was previously
granted;
● refusal to grant export approval for our product; or
● criminal prosecution.
If any of these actions were to occur it would harm our reputation and cause our product sales to suffer and may prevent us from
generating revenue. Furthermore, our third party manufacturers may not currently be, or may not continue to be, in compliance with all
applicable regulatory requirements which could result in a failure to produce our product on a timely basis and in the required quantities, if
at all.
Even if regulatory clearance or approval of a product is granted for Geneveve or future products, such clearance or approval may
be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully
commercialize the product and generate revenue from the product. If the FDA determines that our promotional materials, labeling,
training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify
our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign
enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an
unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims
for reimbursement.
In addition, we may be required by the FDA or other foreign regulatory bodies to conduct costly post-market testing and
surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements,
including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with
our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or
failure to comply with regulatory requirements such as the QSR, may result in changes to labeling, restrictions on such products or
manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or
refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions
or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.
31
Geneveve may also be subject to state regulations which are, in many instances, in flux. Changes in state regulations may impede
sales. For example, federal regulations may allow Geneveve to be sold to, or on the order of, “licensed practitioners,” as determined on a
state-by-state basis. As a result, in some states, non-physicians may legally purchase and operate Geneveve. However, a state could change
its regulations at any time, disallowing sales to particular types of end users. We cannot predict the impact or effect of future legislation or
regulations at the federal or state levels.
If we or our third-party manufacturers fail to comply with the FDA’s QSR, our business would suffer.
We and our third-party manufacturers are required to demonstrate and maintain compliance with the FDA’s QSR. The QSR is a
complex regulatory scheme that covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality
assurance, packaging, storage and shipping of our product. The FDA enforces the QSR through periodic unannounced inspections. We
anticipate that in the future we will be subject to such inspections. Our failure, or the failure of our third-party manufacturers, to take
satisfactory corrective action in response to an adverse QSR inspection could result in enforcement actions, including a public warning
letter, a shutdown of our manufacturing operations, a recall of our product, civil or criminal penalties or other sanctions, which would
cause our reputation, sales and business to suffer.
If our product causes or contributes to a death or a serious injury, or malfunctions in certain ways, we will be subject to medical device
reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.
Under the FDA’s medical device reporting regulations, medical device manufacturers are required to report to the FDA
information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would be
likely to cause or contribute to death or serious injury if the malfunction of the device were to recur. If we fail to report these events to the
FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Any such adverse event involving
Geneveve or future products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action,
such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as mounting a defense to a legal
action, if one were to be brought, would require the dedication of our time and capital, distract management from operating our business,
and may harm our reputation and financial results.
Geneveve may, in the future, be subject to product recalls that could harm our reputation, business and financial results.
The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the
event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on
an FDA finding that there is a reasonable probability that the device would cause serious, adverse health consequences or death.
Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or
voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling
defects or other deficiencies and issues. A recall of our product would divert managerial and financial resources and have an adverse effect
on our financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to the FDA within
10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to
the FDA. In the future, we may initiate one or more voluntary correction or removal actions involving our product that we determine do
not require notification to the FDA. If the FDA disagrees with our determinations, the FDA could require us to report those actions as
recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA
could take enforcement action for failing to report the recalls when they were conducted.
32
Federal and state regulatory reforms may adversely affect our ability to sell our product profitably.
From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions
governing the clearance or approval, manufacture and marketing of a medical device. In addition, FDA regulations and guidance are often
revised or reinterpreted by the agency in ways that may significantly affect our business and our product. It is impossible to predict
whether legislative changes will be enacted or FDA regulations, guidance or interpretations will be changed, and what the impact of such
changes, if any, may be.
For example, in August 2010, the FDA issued its preliminary recommendations on reform of the 510(k) premarket notification
process for medical devices. On January 19, 2011, the FDA announced its “Plan of Action” for implementing these recommendations. The
Plan of Action included 25 action items, many of which have now been implemented by the agency, and to streamline the review process
for innovative, lower risk products (the “de novo” process); improving training for the Center for Devices and Radiological Health staff;
increasing reliance on external experts; and addressing and improving internal processes. In August 2016, the FDA released its proposals
for reforming long-standing procedures and requirements related to modifications to medical devices already on the market. In December
2016, Congress passed the 21 Century Cures Act, which makes multiple changes to FDA’s rules for medical devices as well as for
clinical trials, and Congress is expected to pass another large piece of legislation related to medical devices during 2017 (the Medical
Device User Fee reauthorization package).
st
The FDA or Congress may implement other reforms in the future. Future reforms could have the effect of making it more
difficult and expensive for us to obtain FDA clearance or approval. Such changes may also be made by legislators or regulators in the
foreign jurisdictions in which we do business and could similarly affect our operations and profitability in those markets.
In addition, a state could change its statutes or regulations at any time, disallowing sales to particular types of end users or placing
restrictions on certain chemicals, such as those used in our cryogen. We cannot predict the impact or effect of future legislation or
regulations at the federal or state levels, or in any foreign jurisdiction in which we do business.
Failure to comply with the U.S. Foreign Corrupt Practices Act and similar laws associated with our activities outside the U.S. could
subject us to penalties and other adverse consequences.
A significant portion of our revenues is and will be from jurisdictions outside of the U.S. We are subject to the U.S. Foreign
Corrupt Practices Act, or the FCPA, which generally prohibits U.S. companies and their intermediaries from making payments to foreign
officials for the purpose of directing, obtaining or keeping business, and requires companies to maintain reasonable books and records and
a system of internal accounting controls. The FCPA applies to companies and individuals alike, including company directors, officers,
employees and agents. Under the FCPA, U.S. companies may be held liable for the corrupt actions taken by employees, strategic or local
partners or other representatives. In addition, the government may seek to rely on a theory of successor liability and hold us responsible for
FCPA violations committed by companies or associated with assets which we acquire. In recent years, the medical device and
pharmaceutical industries have been a focus of the U.S. government’s FCPA enforcement priorities, and settlements often include very
significant payments potentially consisting of millions of dollars. Other countries have similar laws to which we may be subject, including
the United Kingdom Bribery Act.
In many foreign countries where we operate, particularly in countries with developing economies, it may be a local custom for
businesses to engage in practices that are prohibited by the FCPA or other similar laws and regulations. In contrast, we have implemented
a company policy requiring our employees and consultants to comply with the FCPA and similar laws. At the present time, we have not
conducted formal FCPA compliance training for our foreign distributors and partners, but we are in the process of devising a training
schedule for certain of our employees, agents and partners. Nevertheless, there can be no assurance that our employees, partners and
agents, as well as those companies to which we outsource certain of our business operations, will not take actions in violation of the FCPA
or our policies for which we may be ultimately held responsible. As a result of our anticipated growth, our development of infrastructure
designed to identify FCPA matters and monitor compliance is at an early stage. If we or our intermediaries fail to comply with the
requirements of the FCPA or similar legislation, governmental authorities in the U.S. and elsewhere could seek to impose civil and/or
criminal fines and penalties which could have a material adverse effect on our reputation, business, operating results and financial
conditions. We may also face collateral consequences, such as debarment and the loss of our export privileges.
Viveve’s relationships with customers and healthcare providers and professionals may be subject to applicable anti-kickback,
fraud and abuse and other healthcare laws and regulations, as well as comparable state and foreign laws, which could expose Viveve
to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
Healthcare providers and physicians play a primary role in the recommendation and prescription of any medical product,
including the Geneveve system marketed by the Company. Viveve’s future arrangements with customers, healthcare providers and other
medical professionals could expose Viveve to broadly applicable fraud and abuse and other healthcare laws and regulations that may
constrain the business or financial arrangements and relationships through which Viveve markets, sells and distributes its medical device
products. There are various federal and state healthcare laws and regulations that impose restrictions that may apply to Viveve, and there
may also be comparable foreign laws and regulations that similarly could apply to the Company.
The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an
individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federally funded
healthcare programs. This statute has been broadly interpreted to apply to manufacturer arrangements with prescribers and purchasers,
among others. There are similar laws at the state level in the U.S., and several other countries, including the United Kingdom, have
enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations.
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any healthcare
benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information. HIPAA also imposes criminal liability for knowingly and willfully
falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or
payment for healthcare benefits, items or services.
33
The federal Physician Sunshine Act requirements under the Patient Protection and Affordable Care Act of 2010, as amended by
the Health Care and Education Reconciliation Act of 2010, referred to together as the Affordable Care Act, require manufacturers of
drugs, devices, biologics and medical supplies for which payment is available under title XVIII of the Social Security Act [Medicare] or
under a State plan under title XIX [Medicaid] or XXI [SCHIP] of the Social Security Act (or a waiver of such a plan) to report to the
Department of Health and Human Services information related to payments and other transfers of value made to or at the request of
covered recipients, such as physicians and teaching hospitals, and physician ownership and investment interests in such manufacturers.
Payments made to physicians and research institutions for clinical trials are included within the scope of this federal disclosure law.
Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private
insurers. Some state laws also require pharmaceutical and medical device companies to comply with the relevant industry’s voluntary
compliance guidelines, in addition to requiring manufacturers to report information related to payments to physicians and other health care
providers or marketing expenditures. There may also be comparable foreign laws and regulations that could impact Viveve’s business and
operations.
If Viveve’s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it,
the Company may be subject to significant civil, criminal and administrative penalties, damages, or fines. Moreover, if any of the
physicians or other providers or entities with whom Viveve expects to do business are found to be not in compliance with applicable laws,
they may be subject to criminal, civil or administrative sanctions, or potentially to other sanctions in foreign jurisdictions.
Risks Related to Our Intellectual Property
Intellectual property rights may not provide adequate protection for Geneveve, which may permit third parties to compete against us
more effectively.
We rely on patent, copyright, trade secret and trademark laws and confidentiality agreements to protect our technology and
Geneveve. We have an exclusive license to or own 4 issued U.S. patents primarily covering our technology and Geneveve and methods of
use. Additionally, we have 3 pending U.S. patent applications; 49 issued foreign patents; and 20 pending foreign patent applications, some
of which foreign applications preserve an opportunity to pursue patent rights in multiple countries. Some of Geneveve components are not,
and in the future may not be, protected by patents. Additionally, our patent applications may not issue as patents or, if issued, may not
issue in a form that will be advantageous to us. Any patents we obtain may be challenged, invalidated or legally circumvented by third
parties. Consequently, competitors could market products and use manufacturing processes that are substantially similar to, or superior to,
ours. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants,
vendors, former employees or current employees, despite the existence generally of confidentiality agreements and other contractual
restrictions. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps
we have taken to protect our intellectual property will be effective. Moreover, we do not have patent rights in all foreign countries in which
a market may exist, and where we have applied for foreign patent rights, the laws of many foreign countries may not protect our
intellectual property rights to the same extent as the laws of the U.S.
In addition, competitors could purchase Geneveve and attempt to replicate some or all of the competitive advantages we derive
from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their
own competitive technologies that fall outside of our intellectual property rights. If our intellectual property is not adequately protected so
as to defend our market against competitors’ products and methods, our competitive position and business could be adversely affected.
We are currently involved in and may be involved in future costly intellectual property litigation, which could impact our future
business and financial performance.
Our industry has been characterized by frequent intellectual property litigation. Our competitors or other patent holders may
assert that Geneveve and the methods we employ are covered by their patents. If Geneveve or methods are found to infringe, we could be
prevented from marketing Geneveve. In addition, we do not know whether our competitors or potential competitors have applied for, or
will apply for or obtain, patents that will prevent, limit or interfere with our ability to make, use, sell, import or export Geneveve. We may
also initiate litigation against third parties to protect our intellectual property that may be expensive, protracted or unsuccessful. In the
future there may be companies that market products for competing purposes in direct challenge to our intellectual property position, and
we may be required to initiate litigation in order to stop them. For example, in October, 2016 we filed a patent infringement lawsuit against
ThermiGen, LLC, ThermiAesthetics, LLC and Dr. Dred Alinsod alleging unauthorized use of certain of our patented technologies. If we
initiate additional litigation to protect our rights, we run the risk of having our patents invalidated, which would undermine our competitive
position.
Litigation related to infringement and other intellectual property claims, with or without merit, is unpredictable, can be expensive
and time-consuming and could divert management’s attention from our business. If we lose this kind of litigation, a court could require us
to pay substantial damages, and prohibit us from using technologies essential to Geneveve, any of which would have a material adverse
effect on our business, results of operations and financial condition. In that event, we do not know whether necessary licenses would be
available to us on satisfactory terms, or whether we could redesign Geneveve or processes to avoid infringement.
Competing products may also appear in other countries in which our patent coverage might not exist or be as strong. If we lose a
foreign patent lawsuit, we could be prevented from marketing Geneveve in one or more countries.
In addition, we may hereafter become involved in litigation to protect our trademark rights associated with our name or the
names used with Geneveve. Names used with Geneveve and procedures may be claimed to infringe names held by others or to be
ineligible for proprietary protection. If we have to change the name of the company or Geneveve, we may experience a loss in goodwill
associated with our brand name, customer confusion and a loss of sales.
34
Risks Related to our Securities
Public company compliance may make it more difficult to attract and retain officers and directors.
The Sarbanes-Oxley Act and rules implemented by the Securities and Exchange Commission have required changes in corporate
governance practices of public companies. As a public company, these rules and regulations increase our compliance costs and make
certain activities more time consuming and costly. These rules and regulations may also make it more difficult and expensive for us to
maintain our director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur
substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified
persons to serve on our board of directors or as executive officers, and to maintain insurance at reasonable rates, or at all.
Concentration of ownership of our common stock may have the effect of delaying or preventing a change in control.
As of February 7, 2017, our officers, directors and principal stockholders, i.e., stockholders who beneficially own greater than
10% of our outstanding common stock, collectively beneficially own approximately 40% of our outstanding common stock. As a result,
these stockholders, if they act together, will be able to control the management and affairs of our company and most matters requiring
stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of
ownership may have the effect of delaying or preventing a change in control and might adversely affect the market price of our common
stock. This concentration of ownership may not be in the best interests of our other stockholders.
We are a holding company with no business operations of our own and we depend on cash flow from Viveve, Inc. to meet our
obligations.
As a result of the Merger, we are a holding company with no business operations of our own or material assets other than the
stock we own in Viveve, Inc. All of our operations are conducted by Viveve, Inc. As a holding company, we will require dividends and
other payments from our subsidiary to meet cash requirements. The terms of any agreements governing indebtedness that we may enter
into may restrict our subsidiary from paying dividends and otherwise transferring cash or other assets to us. If there is an insolvency,
liquidation or other reorganization of our subsidiary, our stockholders likely will have no right to proceed against its assets. Creditors of
our subsidiary will be entitled to payment in full from the sale or other disposal of the assets of our subsidiary before we, as an equity
holder, would be entitled to receive any distribution from that sale or disposal. If Viveve, Inc. is unable to pay dividends or make other
payments to us when needed, we will be unable to satisfy our obligations.
Our stock price may be volatile.
The market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various
factors, many of which are beyond our control, including the following:
● actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived
to be similar to us;
● changes in the market’s expectations about our operating results;
● success of competitors;
● our operating results failing to meet the expectations of securities analysts or investors in a particular period;
● changes in financial estimates and recommendations by securities analysts concerning our business, the market for our
products, the health services industry, or the healthcare and health insurance industries in general;
● operating and stock price performance of other companies that investors deem comparable to us;
● our ability to market new and enhanced products on a timely basis;
● changes in laws and regulations affecting our business;
● commencement of, or involvement in, litigation involving us;
● changes in our capital structure, such as future issuances of securities or the incurrence of debt;
● the volume of shares of our common stock available for public sale;
● any major change in our board of directors or management;
● sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the
perception that such sales could occur; and
● general economic and political conditions such as recessions, fluctuations in interest rates and international currency
fluctuations.
In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price
of our common stock.
35
Our shares of common stock are thinly traded, the price may not reflect our value, and there can be no assurance that there will be an
active market for our shares of common stock either now or in the future.
Our shares of common stock are thinly traded, our common stock is held by a small number of holders, and the price may not
reflect our actual or perceived value. There can be no assurance that there will be an active market for our shares of common stock either
now or in the future. The market liquidity will be dependent on the perception of our operating business, among other things. We will take
certain steps including utilizing investor awareness campaigns, investor relations firms, press releases, road shows and conferences to
increase awareness of our business. Any steps that we might take to bring us to the awareness of investors may require that we compensate
consultants with cash and/or stock. There can be no assurance that there will be any awareness generated or the results of any efforts will
result in any impact on our trading volume. Consequently, investors may not be able to liquidate their investment or liquidate it at a price
that reflects the value of the business, and trading may be at a depressed price relative to the performance of the Company due to, among
other things, the availability of sellers of our shares. If an active market should develop, the price may be highly volatile. Because there is
currently a relatively low per-share price for our common stock, many brokerage firms or clearing firms are not willing to effect
transactions in the securities or accept our shares for deposit in an account. Many lending institutions will not permit the use of low priced
shares of common stock as collateral for any loans.
Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to
decline.
If our stockholders sell substantial amounts of our common stock in the public market upon the expiration of any statutory
holding period under Rule 144, or shares issued upon the exercise of outstanding options or warrants, it could create a circumstance
commonly referred to as an “overhang” and, in anticipation of which, the market price of our common stock could fall. The existence of an
overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing
through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.
In general, under Rule 144, a non-affiliated person who has held restricted shares of our common stock for a period of six months
may sell into the market all of their shares, subject to the Company being current in our periodic reports filed with the Commission.
As of February 7, 2017, there were approximately 3,552,465 shares of common stock of the 10,700,606 shares issued and
outstanding that could be sold pursuant to Rule 144, 18,750 shares of restricted stock, 425,274 shares subject to outstanding warrants,
1,909,764 shares subject to outstanding options and an additional538,855 shares reserved for future issuance under our 2013 Employee
Stock Option and Incentive Plan, as amended, all of which will become eligible for sale in the public market to the extent permitted by any
applicable vesting requirements or Rule 144 under the Securities Act.
We do not expect to declare or pay dividends in the foreseeable future.
We have never paid cash dividends on our common stock and have no plans to do so in the foreseeable future. We intend to
retain any earnings to develop, carry on, and expand our business.
Item 1B. Unresolved Staff Comments
None
Item 2. Properties
We currently lease office and laboratory facilities at 150 and 154 Commercial St., Sunnyvale, California 94086. The space
consists of approximately 7,777 square feet, leased from the Castine Group. The term of the lease agreement, dated January 25, 2012, as
amended in January 2015 and September 2016, commenced in March 2012 and will terminate on March 31, 2018. Rent expense for the
years ended December 31, 2016 and 2015 was $236,000 and $210,000, respectively. Future minimum payments under the lease are
approximately as follows:
Year Ending December
31,
2017
2018
–
–
$303,000
$ 82,000
On February 1, 2017, the Company entered into a sublease agreement (the “Sublease”) for approximately 12,400 square feet of
building space for the relocation of the Company’s corporate headquarters to Englewood, Colorado (the “Sublease Premises”), which was
effective as of January 26, 2017. Physical relocation is planned toward the end of the first quarter of 2017 pending completion of the
build-out of all office and warehouse facilities.
36
The term of the Sublease will commence on the later of (i) 120 days after the date sublandlord delivers possession of the
Sublease Premises to the Company or (iii) upon substantial completion of the tenant improvements pursuant to the Sublease (the
“Commencement Date”), and will expire 36 months after the Commencement Date, or such earlier date as the Master Lease may be
terminated pursuant to the terms thereof.
The monthly base rent under the Sublease will be equal to $20.50 per rentable square foot of the Sublease Premises during the
first year. The monthly base rent will be equal to $21.12 and 21.75 per rentable square foot during the second and third years, respectively.
We believe that these facilities are adequate for our current business operations.
Item 3. Legal Proceedings
On March 11, 2016, the Company filed a demand for Arbitration with the American Arbitration Association ("AAA") against a
former employee asserting common law and statutory negligence claims against the former employee arising from the former employee's
negligent performance of certain work duties. The demand seeks damages for lost profits, along with attorney's fees, interest, and costs.
The former employee filed a counterclaim in the proceeding, alleging discrimination, retaliation, wrongful termination, and various claims
for alleged wage and hour violations under the California Labor Code, stemming from the cessation of her employment with the
Company. The former employee seeks damages for lost wages, punitive damages, statutory penalties, injunctive relief, and attorney’s
fees, interest and costs.
Item 4. Mine Safety Disclosures
Not applicable.
37
PART II
Item 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
As of February 7, 2017, our common stock is trading on The NASDAQ Capital Market under the symbol “VIVE”. Prior to June
14, 2016, our common stock traded on the OTCQB of the OTC Markets Group Inc. under the symbol VIVMF, and prior to October 22,
2014, our common stock traded under the symbol “PLCSF” and “PLCSD”.
The following table sets forth, (i) for the periods during which the Company was listed on the OTCQB, the high and low bid
prices for our common stock for the periods indicated as reported by the OTCQB, and (ii) for the periods during which the Company has
been listed on The NASDAQ Capital Market, the high and low sales price for the periods indicated as reported by The NASDAQ Capital
Market. The bid quotations reported by the OTCQB reflect inter-dealer prices, without retail mark-up, mark-down or commission, and
may not represent actual transactions. The bid quotations reflect a one-for-100 reverse stock split we effected on September 23, 2014.
Period (Listed on The NASDAQ Capital Market)
October 1, 2016 through December 31, 2016
July 1, 2016 through September 30, 2016
June 14, 2016 through June 30, 2016
Period (Listed on the OTCQB)
April 1, 2016 through June 13, 2016
January 1, 2016 through March 31, 2016
October 1, 2015 through December 31, 2015
July 1, 2015 through September 30, 2015
April 1, 2015 through June 30, 2015
January 1, 2015 through March 31, 2015
High
Low
7.99 $
10.00 $
5.14 $
High
Low
9.00 $
6.80 $
0.97 $
1.05 $
1.15 $
0.65 $
4.38
4.10
4.02
1.01
4.80
0.67
0.80
0.30
0.32
$
$
$
$
$
$
$
$
$
The last reported closing price of our common stock on The NASDAQ Capital Market on February 7, 2017 was $4.91 per share.
Holders
As of February 7, 2017 there were 598 holders of record of our common stock.
Dividends
We have not declared or paid any cash dividends on our common stock, and we currently intend to retain future earnings, if any,
to finance the expansion of our business; we do not expect to pay any cash dividends in the foreseeable future. The decision whether to pay
cash dividends on our common stock will be made by our board of directors, in their discretion, and will depend on our financial condition,
results of operations, capital requirements and other factors that our board of directors considers significant.
Securities Authorized For Issuance Under Equity Compensation Plans
The Company has issued equity awards in the form of stock options from three employee benefit plans. The plans include the
Company’s 2005 Stock Incentive Plan (the “2005 Plan”), the Viveve Amended and Restated 2006 Stock Plan (the “2006 Plan”) and the
Company’s Amended and Restated 2013 Stock Option and Incentive Plan (the “2013 Plan”).
38
The following table sets forth information about the 2005 Plan, the 2006 Plan and the 2013 Plan as of December 31, 2016:
Number of
securities
to be issued upon
exercise of
outstanding
options,
warrants and
rights
Weighted
average
exercise
price of
outstanding
options,
warrants
and rights
Number of
securities
remaining
available for
future
issuance under
equity
compensation
plans
1,892 $
116.29
1,869,494 $
38,378 $
1,909,764
5.99
10.49
0
10,236
0
10,236
Plan Category
Equity compensation plans approved by security holders
(2005 Plan)
Equity compensation plans approved by security holders
(2013 Plan)
Equity compensation plans not approved by security holders
(2006 Plan)
Total
The 2006 Plan was adopted by the board of directors of Viveve and was terminated in conjunction with the Merger.
Outstanding stock option awards have been assumed by Viveve Medical and will continue to be administered in accordance with the terms
of the 2006 Plan until such awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards
issued from the 2006 Plan covering a total of 38,378 shares of our common stock and no shares available for future awards. The weighted
average exercise price of the outstanding stock options is $10.49 per share and the weighted average remaining contractual term is 5.88
years. Additionally, prior to the Merger, the board of directors voted to accelerate the vesting of all unvested options that were outstanding
as of the date of the Merger such that all options would be immediately vested and exercisable by the holders. Furthermore, at the Merger,
outstanding options to purchase shares of Viveve, Inc. common stock issued from the 2006 Plan were converted into options to purchase
shares of Viveve Medical common stock (rounded down to the nearest whole share). The number of shares of Viveve Medical common
stock into which the 2006 Plan options were converted was determined by multiplying the number of shares covered by each 2006 Plan
option by the exchange ratio of 0.0080497. The exercise price of each 2006 Plan option was determined by dividing the exercise price of
each 2006 Plan option immediately prior to the Merger by the exchange ratio of 0.0080497 (rounded up to the nearest cent).
On August 22, 2016, the Company’s stockholders approved an amendment to the 2013 Plan increasing the maximum number
of shares of common stock reserved and available for awards under the 2013 Plan (the “Stock Issuable”) by 737,500 shares
from 1,262,500 shares to a total of 2,000,000 shares and to add an “evergreen” provision to the 2013 Plan which will automatically increase
annually, on the first day of each January, the Stock Issuable by an amount equal to the lesser of (i) the number of shares that will increase
the Stock Issuable by 4% of the total number of shares of common stock outstanding (on a fully diluted basis) or (ii) an amount determined
by the board of directors. On December 23, 2016, the board of directors approved the 2017 evergreen increase equal to 4% of the total
number of fully diluted common shares or 523,209 shares, which is effective January 1, 2017.
Issuances of Unregistered Securities
Not applicable.
Item 6. Selected Financial Data
As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information
required by this Item.
39
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify forward-looking statements by terminology including, "could" "may",
"will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other
comparable terminology. These statements are only predictions. Actual events or results may differ materially.
While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our
current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates,
predictions, projections, assumptions or other future performance suggested in this Annual Report.
The following discussion should be read in conjunction with the consolidated financial statements and the related notes contained
elsewhere in this Annual Report. In addition to historical information, the following discussion contains forward looking statements based
upon current expectations that are subject to risks and uncertainties. Actual results may differ substantially from those referred to herein
due to a number of factors, including, but not limited to, risks described in the section entitled “Risk Factors”.
Overview of Our Business
In the discussion below, when we use the terms “we”, “us” and “our”, we are referring to Viveve Medical, Inc. and our wholly-
owned subsidiaries, Viveve, Inc. and Viveve BV.
We design, develop, manufacture and market a medical device for the non-invasive treatment of vaginal laxity, for improved
sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that we refer to as
Geneveve™, which includes a radio frequency (RF) generator, which we refer to as the Viveve System, single-use treatment tips and other
ancillary disposables. Currently, Geneveve is cleared for marketing in 51 countries throughout the world under the following indications
for use:
Indication for Use:
General surgical procedures for electrocoagulation and hemostasis
For treatment of vaginal laxity
For treatment of the vaginal introitus, after vaginal childbirth, to improve
sexual function
For vaginal rejuvenation
No. of Countries:
3 (including the
U.S.)
34
13
1
In the U.S., Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis and we market
and sell through a direct sales force. Outside the U.S., we market and sell through distribution partners. As of December 31, 2016, we have
sold 217 Viveve Systems and approximately 4,050 single-use treatment tips in countries primarily outside of the U.S.
Because the revenues we have earned to date have not been sufficient to support our operations, we have relied on sales of our
securities, loans from related parties and bank term loans to fund our operations. We are currently located in Sunnyvale, California. We
plan to relocate the corporate headquarters toward the end of the first quarter of 2017 as discussed below in “Recent Events.”
Recent Events
On April 15, 2016, we effected a 1-for-8 reverse stock split of our common stock. On the effective date of the reverse stock split,
(i) each 8 shares of outstanding common stock were reduced to one share of common stock; (ii) the number of shares of common stock
into which each outstanding warrant or option to purchase common stock is exercisable were proportionately reduced on an 8-to-1 basis;
and (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1-to-8
basis. All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1-for-8 reverse
stock split.
40
On May 9, 2016, we filed the necessary Application for Authorization to Continue into Another Jurisdiction and Statutory
Declaration with the Yukon registrar. On May 10, 2016, we filed a Certificate of Incorporation with the Secretary of State of the State of
Delaware to move our domicile from the Yukon Territory to Delaware.
On June 17, 2016, in connection with the closing of a public offering (the “June 2016 Offering”), we issued an aggregate of
3,105,000 shares of common stock, including the shares issued in connection with the exercise of the underwriters’ overallotment option,
at a public offering price of $5.00 per share for gross proceeds of approximately $15.5 million. The net proceeds to us, after the deduction
of underwriting discounts, commissions and other offering expenses, were approximately $13.9 million.
On June 20, 2016, we entered into a Loan and Security Agreement (the “2016 Loan Agreement”) with Western Alliance Bank
(“WAB”), pursuant to which WAB agreed to loan us up to an aggregate of $10.0 million payable in two tranches of $7.5 million and $2.5
million. The funding conditions for both tranches were satisfied as of the closing date, and therefore, the aggregate principal amount of
$10.0 million was provided to us on June 20, 2016. The proceeds received were used to repay outstanding existing indebtedness under a
Loan and Security Agreement, as amended on February 19, 2015, May 14, 2015, November 30, 2015 and March 18, 2016 (collectively,
the “2014 Loan Agreement”), with Pacific Western Bank (as successor in interest by merger to Square 1 Bank), and the remaining balance
will be used for working capital purposes and to fund general business requirements. The borrowings are repayable in interest only
payments until July 1, 2017 and then 30 monthly equal installments of principal and interest. The term loan bears interest on the
outstanding obligations under the loan at a floating per annum rate equal to the greater of (i) the Index Rate (i.e., the 30 day U.S. LIBOR
rate reported in the Wall Street Journal) plus 6.96%, determined as of the last day of each month, and (ii) 7.40%.
On January 13, 2017, we entered into a waiver and amendment (the “First Amendment”) to the 2016 Loan Agreement with
WAB. Pursuant to the First Amendment, WAB agreed to waive the default resulting from the failure to comply with the performance to
plan revenue covenants described in the 2016 Loan Agreement for the measuring periods ended October 31, 2016 and November 30,
2016. In addition, the First Amendment added a financial covenant that until the Company maintains a ratio of minimum unrestricted cash
in accounts with WAB to indebtedness of at least 1.25 to 1.00, the Company must at all times maintain unrestricted cash in accounts with
WAB in an amount equal to or greater than $2,000,000, which financial covenant shall no longer apply at such time that the Company
achieves a ratio of minimum unrestricted cash in accounts with WAB to indebtedness of at least 1.25 to 1.00.
On February 1, 2017, the Company entered into a sublease agreement (the “Sublease”) for approximately 12,400 square feet of
building space for the relocation of the Company’s corporate headquarters to Englewood, Colorado (the “Sublease Premises”), which is
effective as of January 26, 2017. Physical relocation is planned toward the end of the first quarter of 2017 pending completion of the
build-out of all office and warehouse facilities.
The term of the Sublease will commence on the later of (i) 120 days after the date sublandlord delivers possession of the
Sublease Premises to the Company or (iii) upon substantial completion of the tenant improvements pursuant to the Sublease (the
“Commencement Date”), and will expire 36 months after the Commencement Date, or such earlier date as the Master Lease may be
terminated pursuant to the terms thereof.
The monthly base rent under the Sublease will be equal to $20.50 per rentable square foot of the Sublease Premises during the
first year. The monthly base rent will be equal to $21.12 and 21.75 per rentable square foot during the second and third years, respectively.
In connection with the execution of the Sublease, the Company also agreed to pay a security deposit of approximately $22,000. The
Company is entitled to an allowance of approximately $88,000 for certain tenant improvements relating to the engineering, design and
construction of the Sublease Premises.
We are subject to risks, expenses and uncertainties frequently encountered by companies in the medical device industry. These
risks include, but are not limited to, intense competition, whether we can be successful in obtaining U.S. Food and Drug Administration
(the “FDA”) approval for the sale of our product and whether there will be a demand for the Geneveve, given that the cost of the
procedure will likely not be reimbursed by the government or private health insurers. In addition, we will continue to require substantial
funds to support our clinical trials and fund our efforts to expand regulatory approval for our products in locations in which we do not
currently have approval to market our product, including the U.S. We cannot be certain that any additional required financing will be
available when needed or on terms which are favorable to us. As noted above, our operations to date have been primarily funded through
the sales of our securities, loans from related parties and bank term loans. Various factors, including our limited operating history with
minimal revenues to date and our limited ability to market and sell our product have resulted in limited working capital available to fund
our operations. The merger that took place on September 23, 2014 between PLC Systems Inc., Viveve, Inc. and PLC Systems Acquisition
Corp. (the “Merger”) and the concurrent private offering was consummated in an effort to raise additional capital and increase public
awareness of Viveve, as well as to create opportunities for access to additional capital by increasing liquidity. There are no assurances that
we will be successful in securing additional financing in the future to fund our operations going forward. Failure to generate sufficient cash
flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on our ability
to achieve our intended business objectives. These factors raise substantial doubt about our ability to continue as a going concern.
41
Plan of Operation
We intend to increase our sales both internationally and in the United States market by seeking regulatory approvals for the sale
and distribution of our products, identifying and training qualified distributors and expanding the scope of physicians who offer the
Geneveve to include plastic surgeons, dermatologists, general surgeons, urologists, urogynecologists and primary care physicians.
In addition, we intend to use the strategic relationships that we have developed with outside contractors and medical experts to
improve our products by focusing our research and development efforts on various areas including, but not limited to:
●
●
designing new treatment tips optimized for both ease-of-use and to reduce procedure times for patients and physicians; and
Developing new RF consoles, which may include increased security features to prevent piracy, or new cooling systems to
maintain compliance with environmental regulations.
The net proceeds received from sales of our securities and the term loans have been used to support commercialization of our
product in existing and new markets, for our research and development efforts and for protection of our intellectual property, as well as for
working capital and other general corporate purposes. We expect that our cash will be sufficient to fund our activities for the next six
months, however, we will continue to require funds to fully implement our plan of operation. Our operating costs include employee
salaries and benefits, compensation paid to consultants, professional fees and expenses, costs associated with our clinical trials, capital
costs for research and other equipment, costs associated with research and development activities including travel and administration, legal
expenses, sales and marketing costs, general and administrative expenses, and other costs associated with an early stage public company
subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We also expect to incur
expenses related to obtaining regulatory approvals in the U.S. and internationally as well as legal and related expenses to protect our
intellectual property. We expect capital expenditures, for the foreseeable future, to be less than $500,000 annually.
We intend to continue to meet our operating cash flow requirements through the sales of our products and by raising additional
funds from the sale of equity or debt securities. If we sell our equity securities, or securities convertible into equity, to raise capital, our
current stockholders will likely be substantially diluted. We may also consider the sale of certain assets, or entering into a strategic
transaction, such as a merger, with a business complimentary to ours, although we do not currently have plans for any such transaction.
While we have been successful in raising capital to fund our operations since inception, other than as discussed in this Annual Report on
Form 10-K, we do not have any committed sources of financing and there are no assurances that we will be able to secure additional
funding, or if we do secure additional financing that it will be on terms that are favorable to us. If we cannot obtain financing, then we may
be forced to curtail our operations or consider other strategic alternatives.
42
Results of Operations
Year Ended December 31, 2016 Compared to the Year Ended December 31, 2015
Revenue
Year Ended
December 31,
Change
2016
2015
$
%
(in thousands, except percentages)
Revenue
$
7,141 $
1,447 $
5,694
394%
We recorded revenue of $7,141,000 for the year ended December 31, 2016, compared to revenue of $1,447,000 for the year
ended December 31, 2015, an increase of $5,694,000. The increase in revenue was primarily due to sales of 175 Viveve Systems and
disposable treatment tips and other ancillary consumables to our new distributors. Sales in 2015 included only 34 Viveve Systems and
were limited primarily because of insufficient commercial inventory available for sale and the majority of inventory during the first half of
2015 was used to support our OUS Clinical Trial.
Gross Profit
Year Ended
December 31,
Change
2016
2015
$
%
(in thousands, except percentages)
Gross profit
$
2,529 $
462 $
2,067
447%
Gross profit was $2,529,000, or 35% of revenue, for the year ended December 31, 2016, compared to gross profit of $462,000,
or 32% of revenue, for the year ended December 31, 2015. The increase in gross profit was primarily due to sales of 175 Viveve Systems
to our new distributors in 2016. Sales in 2015 included only 34 Viveve Systems and were limited to smaller quantities of disposable
treatment tips and other ancillary consumables primarily because of insufficient commercial inventory available for sale and the majority
of inventory during the first half of 2015 was used to support our OUS Clinical Trial.
Research and development expenses
Year Ended
December 31,
2016
2015
Change
$
%
(in thousands, except percentages)
Research and development
$
8,365 $
4,988 $
3,377
68%
Research and development expenses totaled $8,365,000 for the year ended December 31, 2016, compared to research and
development expenses of $4,988,000 for the year ended December 31, 2015, an increase of $3,377,000, or approximately 68%. Spending
on research and development increased in 2016 primarily due to costs associated with increased engineering and development work with
our contract manufacturer related to product improvement efforts. Research and development expense during 2016 also included higher
personnel costs for new employees and related additional stock-based compensation expense for stock options granted to new employees
and additional stock options granted to existing employees for performance bonuses.
43
Selling, general and administrative expenses
Year Ended
December 31,
2016
2015
Change
$
%
(in thousands, except percentages)
Selling, general and administrative
$
12,868 $
7,464 $
5,404
72%
Selling, general and administrative expenses totaled $12,868,000 for the year ended December 31, 2016, compared to $7,464,000
for the year ended December 31, 2015, an increase of $5,404,000, or approximately 72%. The increase in selling, general and
administrative expenses in 2016 was primarily attributable to increased sales and marketing efforts to build brand and market awareness,
expenses associated with being a public company and financing efforts. Selling, general and administrative expenses during 2016 also
included higher personnel costs for new employees (primarily in connection with our sales and marketing efforts) and related additional
stock-based compensation expense for stock options granted to new employees and additional options granted to existing employees for
performance bonuses.
Interest expense
Year Ended
December 31,
2016
2015
Change
$
%
(in thousands, except percentages)
Interest expense, net
$
1,370 $
415 $
955
230%
During the year ended December 31, 2016, we had interest expense of $1,370,000, compared to $415,000 for the year ended
December 31, 2015. The increase of $955,000, or approximately 230%, resulted primarily from the additional interest expense in
connection with the payoff in June 2016 of the term loan under the 2014 Loan Agreement, and interest expense for the term loan in 2016,
which was computed on a higher loan balance compared to the loan balance in 2015.
Other income (expense), net
Year Ended
December 31,
2016
2015
Change
$
%
(in thousands, except percentages)
Other expense, net
$
37 $
21 $
16
76%
During the year ended December 31, 2016 we had other expense, net, of $37,000 as compared to other expense, net, of $21,000 for
the year ended December 31, 2015.
Liquidity and Capital Resources
Year Ended December 31, 2016
Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In
addition, liquidity includes the ability to obtain appropriate financing or to raise capital. We have funded our operations since inception
through the sale of our securities, loans from related parties and bank term loans. To date, we have not generated sufficient cash flows from
operating activities to meet our obligations and commitments, and we anticipate that we will continue to incur losses for the foreseeable
future. We expect that our cash will be sufficient to fund our activities for the next six months, however, we will continue to require funds
to fully implement our plan of operation.
Because we have incurred losses and reported negative cash flow from operations since inception, our consolidated financial
statements have been prepared assuming that we will continue as a going concern. These conditions raise substantial doubt about our
ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the
outcome of this uncertainty.
44
The following table summarizes the primary sources and uses of cash for the periods presented below (in thousands):
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net increase in cash and cash equivalents
Operating Activities
Year Ended
December 31,
2016
2015
$
$
(18,087) $
(256)
19,069
726 $
(12,195)
(109)
18,769
6,465
We have incurred, and expect to continue to incur, significant expenses in the areas of research and development, regulatory and
clinical study costs associated with Geneveve.
Operating activities used $18,087,000 for the year ended December 31, 2016 compared to $12,195,000 used for the year ended
December 31, 2015. The primary use of our cash was to fund selling, general and administrative expenses and research and development
expenses associated with Geneveve. Net cash used during the year ended December 31, 2016 consisted of a net loss of $20,111,000
adjusted for non-cash expenses including depreciation and amortization of $111,000, stock-based compensation of $981,000, fair value of
warrants issued to distributor and consultants of $162,000, a restricted stock award granted to a consultant of $39,000, non-cash interest
expense of $456,000 and cash inflows from changes in operating assets and liabilities of $275,000. Net cash used during the year ended
December 31, 2015 consisted of a net loss of $12,426,000 adjusted for non-cash expenses including depreciation and amortization of
$77,000, stock-based compensation of $220,000, fair value of warrants issued to employees for performance bonuses of $286,000, fair
value of warrants issued to service providers of $251,000 (primarily related to nonemployee contractors), non-cash interest expense of
$197,000, and cash outflows from changes in operating assets and liabilities of $800,000.
Investing Activities
Net cash used in investing activities during the year ended December 31, 2016 and 2015 was $256,000 and $109,000, respectively.
Net cash used in investing activities during 2016 and 2015 was used for the purchase of property and equipment. We expect to continue to
purchase property and equipment in the normal course of our business. The amount and timing of these purchases and the related cash
outflows in future periods is difficult to predict and is dependent on a number of factors including, but not limited to, any increase in the
number of our employees and any changes to the capital equipment requirements related to our development programs and clinical trials.
Financing Activities
Net cash provided by financing activities during year ended December 31, 2016 was $19,069,000 which was the was primarily
the result of the net proceeds of $13,886,000 from our June 2016 Offering, the proceeds of $10,000,000 from the drawdown of funds
from the first and second tranches of the new term loan under the 2016 Loan Agreement (partially offset by debt issuance costs of
$90,000), and proceeds from the exercise of warrants and stock options of $106,000, partially offset by the repayment of the existing
term loan under the 2014 Loan Agreement of $4,833,000.
Net cash provided by financing activities during year ended December 31, 2015 was $18,769,000, which was primarily the result
of the net proceeds of $11,040,000 from the May 2015 Offering, the net proceeds of $5,393,000 from our November 2015 Offering, the
proceeds of $2,500,000 from the drawdown of funds from the second and third tranches of the term loan under the 2014 Loan
Agreement.
45
Contractual Payment Obligations
We have obligations under a non-cancelable operating lease, a bank term loan and a purchase commitment for inventory. As of
December 31, 2016, our contractual obligations are as follows (in thousands):
Contractual Obligations:
Non-cancellable operating lease obligations
Debt obligations (including interest)
Total
Total
Less than
1 Year
1 - 3 Year
3 -5 Years
More than
5 Years
$
$
385 $
11,694
12,079 $
303 $
2,719
3,022 $
82 $
8,975
9,057 $
- $
- $
-
-
-
In June 2006, we entered into a Development and Manufacturing Agreement with Stellartech Research Corporation (the
"Agreement"). The Agreement was amended on October 4, 2007. Under the Agreement, we agreed to purchase 300 generators
manufactured by Stellartech. As of December 31, 2016, we have purchased 345 units. The price per unit is variable and dependent on the
volume and timing of units ordered.
In January 2012, we entered into a lease agreement for office and laboratory facilities in Sunnyvale, California. The lease
agreement, as amended in September 2016, commenced in March 2012 and will terminate in March 2018.
As described above, on February 1, 2017, we entered into a Sublease for approximately 12,400 square feet of building space for the
relocation of the Company’s corporate headquarters to Englewood, Colorado. The lease term is 36 months and the monthly base rent for
the first, second and third years is $20.50, $21.12 and $21.75 per rentable square foot, respectively. In connection with the execution of the
Sublease, the Company paid a security deposit of approximately $22,000. The Company is also entitled to an allowance of approximately
$88,000 for certain tenant improvements relating to the engineering, design and construction of the Sublease Premises.
As described above, on June 20, 2016, we entered into the 2016 Loan Agreement with WAB pursuant to which we received a
term loan in the amount of $10.0 million. The proceeds from the term loan were used to repay the existing outstanding indebtedness with
another financial institution and to provide general working capital to fund our operations. As of December 31, 2016 and the date of this
filing, the outstanding term loan principal balance was $10.0 million.
Critical Accounting Policies and Estimates
The discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements,
which have been prepared in conformity with accounting principles generally accepted in the United States of America. Certain
accounting policies and estimates are particularly important to the understanding of our financial position and results of operations and
require the application of significant judgment by our management or can be materially affected by changes from period to period in
economic factors or conditions that are outside of our control. As a result, they are subject to an inherent degree of uncertainty. In applying
these policies, management uses their judgment to determine the appropriate assumptions to be used in the determination of certain
estimates. Those estimates are based on our historical operations, our future business plans and projected financial results, the terms of
existing contracts, observance of trends in the industry, information provided by our customers and information available from other
outside sources, as appropriate. Please see Note 2 to our consolidated financial statements for a more complete description of our
significant accounting policies.
Inventory
Inventory is stated at the lower of cost or market, cost being determined on an actual cost basis on a first-in, first-out method and
market being determined as the lower of replacement cost or net realizable value. Inventory as of December 31, 2016 is mainly finished
goods but also includes a small quantity of raw materials. All inventory as of December 31, 2015 is finished goods. We regularly assess
the valuation of inventory and write down inventory which is obsolete or in excess of forecasted usage to their estimated realizable value.
Estimates of realizable value are based upon our analysis and assumptions including, but not limited to, forecasted sales by product,
expected product life cycle, product development plans and future demand requirements. If market conditions are less favorable than our
forecast or actual demand from customers is lower than our estimates, we may be required to record additional inventory write-downs. At
the point of write down, a new lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances do not
result in the restoration or increase in that newly established cost basis. If there were to be a sudden and significant decrease in demand for
our products, or if there were a higher incidence of inventory obsolescence because of rapidly changing technology and customer
requirements, we could be required to increase inventory write-downs, and our gross margin could be adversely affected. If demand is
higher than expected, we may sell inventories that had previously been written down.
46
Impairment of Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment
by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired,
the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the
nature of the asset. The Company has not identified any such impairment losses to date.
Revenue Recognition
The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary
consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or
determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements
that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries
throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia
Pacific.
The Company does not provide its customers with a right of return.
Allowance for Doubtful Accounts
We make ongoing assumptions relating to the collectibility of our accounts receivable in our calculation of the allowance for
doubtful accounts. In determining the amount of the allowance, we make judgements about the creditworthiness of customers based on
ongoing credit evaluations and assess current economic trends affecting our customers that might impact the level of credit losses in the
future and result in different rates of bad debts than previously seen. We also consider our historical level of credit losses. As of December
31, 2016 and 2015, there was no allowance for doubtful accounts.
Product Warranty
The Company’s products are generally subject to a one year warranty, which provides for the repair, rework or replacement of
products (at the Company’s option) that fail to perform within stated specification. The Company has assessed the historical claims and, to
date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going
forward.
Research and Development
Research and development costs are charged to operations as incurred. Research and development costs include, but are not
limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including
rent, equipment depreciation, and utilities.
Income Taxes
Accounting for income taxes requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of
temporary differences between the book and tax bases of recorded assets and liabilities. The liability method is used in accounting for
income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of
assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. Deferred tax assets may be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax asset
will not be realized. We evaluate annually the realizability of our deferred tax assets by assessing our valuation allowance and by adjusting
the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include our forecast of future taxable
income and available tax planning strategies that could be implemented to realize the net deferred tax assets. As of December 31, 2016 and
2015, the Company has recorded a full valuation allowance for our deferred tax assets based on our historical losses and the uncertainty
regarding our ability to project future taxable income. In future periods if we are able to generate income, we may reduce or eliminate the
valuation allowance.
Accounting for Uncertainty in Income Taxes
We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic
adjustments and which may not accurately anticipate actual outcomes. The first step is to evaluate the tax position for recognition by
determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit,
including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely of being realized upon ultimate settlement. Whether the more-likely-than-not recognition threshold is met for
a tax position is a matter of judgment based on the individual facts and circumstances of that position evaluated in light of all available
evidence.
47
Accounting for Stock-Based Compensation
Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over
the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of
the award.
We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair
value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which
determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock.
Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic
adjustment as the underlying equity instruments vest.
Recent Accounting Pronouncements
In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting
Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09,
“Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which
replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue
recognition guidance that have historically existed in US GAAP. The underlying principle of the new standard is that a business or other
organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it
expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for
transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial
adoption and is effective for annual and interim periods beginning after December 15, 2017. The FASB has issued several updates to the
standard which i) defer the original effective date from January 1, 2017 to January 1, 2018, while allowing for early adoption as of January
1, 2017 (ASU 2015-14); ii) clarify the application of the principal versus agent guidance (ASU 2016-08); iii) clarify the guidance on
inconsequential and perfunctory promises and licensing (ASU 2016-10); and clarify the guidance on certain sections of the guidance
providing technical corrections and improvements (ASU 2016-10). In May 2016, the FASB issued ASU 2016-12, “Revenue from
Contracts with Customers (Topic 606) Narrow-Scope Improvements and Practical Expedients”, to address certain narrow aspects of the
guidance including collectibility criterion, collection of sales taxes from customers, noncash consideration, contract modifications and
completed contracts. This issuance does not change the core principle of the guidance in the initial topic issued in May 2014. We are
currently evaluating the impact that this standard will have on our consolidated financial statements.
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40):
Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This guidance is effective for our annual reporting
period ending December 31, 2016 and all annual and interim reporting periods thereafter. We adopted this standard for the year ended
December 31, 2016. This guidance requires us to evaluate whether there is substantial doubt about our ability to continue as a going
concern for at least 12 months from the issuance date of the consolidated financial statements and to provide related footnote disclosures
In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”). ASU 2015-11
requires that an entity should measure inventory within the scope of this pronouncement at the lower of cost and net realizable value. Net
realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal,
and transportation. The pronouncement does not apply to inventory that is being measured using the last-in, first-out (“LIFO”) method or
the retail inventory method. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method.
We plan to adopt this guidance as of January 1, 2017 and believe the adoption of the guidance will not have a significant impact on the
consolidated financial statements.
48
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize
right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers
specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose
qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount,
timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after December
15, 2018, including interim periods within the reporting period, and requires a modified retrospective adoption, with early adoption
permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements.
In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting”. This guidance identifies areas for simplification involving several aspects of accounting for share-
based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to
recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the
statement of cash flows. We plan to adopt this guidance as of January 1, 2017 and believe the adoption of the guidance will not have a
significant impact on the consolidated financial statements.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows, Classification of Certain Cash Receipts and Cash
Payments (Topic 230). This guidance addresses specific cash flow issues with the objective of reducing the diversity in practice for the
treatment of these issues. The areas identified include: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt
instruments; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims;
proceeds from the settlement of corporate-owned life insurance policies; distributions received from equity method investees; beneficial
interests in securitization transactions and application of the predominance principle with respect to separately identifiable cash flows.
This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting
period, with early adoption permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial
statements.
In August 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, Restricted Cash (Topic 230). This guidance
requires that a statement of cash flows explain the total change during the period of cash, cash equivalents, and amounts generally
described as restricted cash or restricted cash equivalents. Amounts described as restricted cash and restricted cash equivalents should be
included with cash and cash equivalents when reconciling the beginning of period and end of period to total amounts shown on the
statement of cash flows. This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim
periods within that reporting period, with early adoption permitted. We are currently evaluating the effect of the adoption of this guidance
on our consolidated financial statements.
Off-Balance Sheet Transactions
We do not have any off-balance sheet transactions.
Trends, Events and Uncertainties
Research, development and commercialization of new technologies and products is, by its nature, unpredictable. Although we will
undertake development efforts, including efforts, with commercially reasonable diligence, there can be no assurance that we will have
adequate capital to develop or commercialize our technology to the extent needed to create future sales to sustain our operations.
We cannot assure you that our technology will be adopted, that we will ever earn revenues sufficient to support our operations, or
that we will ever be profitable. Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to
raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required
to severely curtail, or even to cease, our operations.
Other than as discussed above and elsewhere in this Annual Report on Form 10-K, we are not aware of any trends, events or
uncertainties that are likely to have a material effect on our financial condition.
49
Item 7A. Quantitative and Qualitative Disclosures about Market Risk.
As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information
required by this Item.
Item 8. Financial Statements and Supplementary Data
See pages beginning with page F-1.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in
Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal
executive officer and principal financial officer and effected by our board of directors, management, and other personnel, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP and includes those policies and procedures that:
●
●
●
Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions
of our assets;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in
accordance with authorizations of our management and directors; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of
our assets that could have a material effect on the financial statements.
Because of our inherent limitations, our internal control over financial reporting may not prevent or detect misstatements.
Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement
preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2016. In making
this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control – Integrated Framework (2013 Framework).
Based on this assessment, our management, with the participation of our Chief Executive Officer (principal executive officer) and
our Chief Financial Officer (principal financial and accounting officer), has concluded that, as of December 31, 2016, our internal control
over financial reporting was effective based on those criteria.
Evaluation of Disclosure Controls and Procedures.
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are
designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed,
summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such
information is accumulated and communicated to our management, including our principal executive officer and principal financial and
accounting officer, as appropriate, to allow timely decisions regarding required disclosure.
We carried out an evaluation under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of
December 31, 2016, the end of the period covered by this Annual Report on Form 10-K. Based upon the evaluation of our disclosure
controls and procedures as of December 31, 2016, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date,
our disclosure controls and procedures were effective at the reasonable assurance level.
50
Changes in Internal Control over Financial Reporting
There were no changes during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.
Item 9B. Other Information
None.
51
Item 10. Directors, Executive Officers and Corporate Governance
PART III
Set forth below is certain information regarding our current executive officers and directors. Each of the directors was elected to
serve until our next annual meeting of stockholders or until his or her successor is elected and qualified. Our officers are appointed by, and
serve at the pleasure of, the board of directors.
Name
Patricia Scheller
Lori Bush
Daniel Janney
Debora Jorn
Arlene Morris
Jon Plexico
Scott Durbin
James Atkinson
Age
56
60
51
58
65
48
48
59
Position
Chairperson of the Board of Directors and Chief Executive
Officer
Director
Director
Director
Director
Director
Chief Financial Officer
President and Chief Business Officer
Biographical information with respect to our executive officers and directors is provided below. There are no family relationships
between any of our executive officers or directors.
Patricia Scheller. Ms. Scheller was elected as a director of Viveve Medical, Inc. on September 18, 2014 (with her service
beginning following the merger with PLC Systems Acquisition Corporation that was completed on September 23, 2014) and has been a
director of our wholly-owned subsidiary, Viveve, Inc., since June 2012. Ms. Scheller also serves as our Chief Executive Officer and, since
May 2012, as Chief Executive Officer of Viveve, Inc. Prior to joining Viveve, Inc., she served as the Chief Executive Officer of Prescient
Medical, Inc. (“PMI”), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce
deaths from heart attacks, from September 2004 through April 2012 and as a director of PMI from July 2004 to September 2011. Prior to
joining PMI, from August 2003 to September 2004, she was the Chief Executive Officer of SomaLogic, a biotechnology company focused
on the development of diagnostic products using aptamer technology. From December 2000 to April 2003, Ms. Scheller also managed
several business units at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and from October 1997 to November 2000 served in
key executive positions at Dade Behring, a clinical diagnostics firm. While at Dade Behring Holdings, Inc., she directed the
commercialization of the hsCRP diagnostic test, a screening test for systemic inflammation, which has been shown to increase the risk of
heart attacks. The hsCRP test was the first diagnostic test added to the cardiac test panel by the Centers for Disease Control and
Prevention and the American Heart Association in over 30 years. As Director of Cardiology Systems at Cordis Corporation (a Johnson &
Johnson company) from February 1994 to February 1996, Ms. Scheller managed the launch of the first Palmaz-Schatz® balloon-
expandable coronary stent, the first major product entry into what became a $6 billion market. Ms. Scheller received a B.S.E. degree in
Biomedical Engineering from Duke University and completed executive business education programs at Harvard University,
Massachusetts Institute of Technology, Columbia University and Northwestern University. Because of her extensive experience in the
healthcare industry, we concluded that Ms. Scheller should serve as a director.
Lori Bush. Ms. Bush joined our Board on May 11, 2016. Since January 2016, Ms. Bush has been a consultant, speaker, advisor
and activist for micro-entrepreneurship and women’s leadership. From October 2007 to January 2016, Ms. Bush served as the President
and General Manager, then President and CEO of Rodan + Fields, LLC (Rodan + Fields). Prior to joining Rodan + Fields, Ms. Bush
served as Chief Operating Officer of Helix BioMedix, Inc., a biopharmaceutical discovery and development company from October 2006
to October 2007, and was the Managing Director of the Gremlin Group, a health and consumer product consulting company from March
2006 to October 2007. From May 2001 to May 2006, Ms. Bush served as President of Nu Skin, a division of Nu Skin Enterprises, a
NYSE-listed direct selling company that markets premium quality personal care and nutrition products through a global network of sales
representatives. Ms. Bush served as Vice President of Marketing of Nu Skin from February 2000 to May 2001. Prior to joining Nu Skin,
she worked at Johnson & Johnson Consumer Products Companies as the worldwide executive director over skin care ventures from May
1998 to February 2000. She also served as Vice President of Professional Marketing at Neutrogena Corporation. Ms. Bush earned a
Masters of Business Administration from Temple University and a Bachelor of Science degree from Ohio State University. Until its
merger with Wonder Holdings Acquisition Corp., Ms. Bush was a director of Matrixx Initiatives Inc., formerly a publicly traded company.
We determined that Ms. Bush should serve as a director because of her extensive executive and marketing experience in the over-the-
counter healthcare industry.
52
Daniel Janney. Mr. Janney was elected as a director of Viveve Medical, Inc. on September 18, 2014 (with his service beginning
following the merger with PLC Systems Acquisition Corporation that was completed on September 23, 2014). Since November 2012, Mr.
Janney has served as a director of Esperion Therapeutics, Inc. (NASDAQ: ESPR). Mr. Janney is a managing director at Alta Partners, a life
sciences venture capital firm, which he joined in 1996. Prior to joining Alta, from 1993 to 1996, he was a Vice President in Montgomery
Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of a
number of companies including Alba Therapeutics Corporation, Lithera, Inc., Prolacta Bioscience, Inc., Sutro Biopharma and ViroBay,
Inc. He holds a Bachelor of Arts in History from Georgetown University and an M.B.A. from the Anderson School at the University of
California, Los Angeles. Because of Mr. Janney's experience working with and serving on the board of directors of various life sciences
companies and his experience working in the venture capital industry, we concluded that he should serve as a director.
Debora Jorn. Ms. Jorn joined our Board on May 11, 2016. Ms. Jorn is currently serving as the Executive Vice President
Corporate and Commercial Development at pSivida Corp. Ms. Jorn joined pSivida in November 2016. From August 2013 through March
2016, Ms. Jorn was Executive Vice President and Group Company Chair of Valeant Pharmaceuticals International, Inc. Ms. Jorn served as
Chief Global Marketing Officer of Bausch & Lomb Pharmaceuticals from June 2010 to August 2013. She served as Group Vice President
Women’s Healthcare and Fertility at Schering Plough from June 2008 to January 2010. She was the World Wide Vice President Internal
Medicine and Early Commercial Input at Johnson & Johnson and the Vice President, Urology at Pharmacia Corporation. From 1989 to
2010, Ms. Jorn served as Acting Head of the ACE Inhibitor Franchise – Merck and Company. She served as Worldwide Vice President of
Internal Medicine, Executive Director (Respiratory Franchise), Director of Marketing (Merck Frosst Canada), and various other roles for
Merck. Since May 2016 Ms. Jorn has served on the board of directors of Orexigen Therapeutics, Inc., a biopharmaceutical company
located in La Jolla, California. Ms. Jorn received her M.B.A from NYU Stern Graduate School of Business Administration and her B.A.
from Rutgers University. Ms. Jorn’s extensive executive and marketing experience in the healthcare industry led us to believe that she
should serve as a director.
Arlene Morris. Ms. Morris joined our Board of Directors on May 11, 2016. Ms. Morris has served as the CEO of Willow
Advisors, LLC since May 2015. From May 2011 to April 2015, Ms. Morris was the President and CEO and a member of the Board of
Directors of Syndax Pharmaceutical, a Boston based epigenetic company. Prior to her employment with Syndax, from June 2003 to
February 2011 she was the President, CEO and a member of the board of directors of Affymax, Inc. During her eight years at Affymax,
Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda, an initial public
offering, and several follow on offerings. Prior to Affymax, Ms. Morris was the President and CEO of Clearview Projects, an advisory
firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that, she was the Senior Vice
President of Business Development at both Coulter Pharmaceuticals, Inc. and Scios. Ms. Morris began her career at Johnson & Johnson as
a sales representative, rising to Vice President of Business Development. Ms. Morris serves on the board of directors of Neovacs SA,
Palatin Technologies, Dimension Therapeutics and the Medical University of South Carolina Foundation for Research and Development.
We believe Ms. Morris’ qualifications to serve on our Board include her many years serving as a senior executive with companies in the
biopharma industry and her extensive experience serving on boards of directors.
Jon Plexico. Mr. Plexico was appointed as a director of Viveve Medical, Inc. on March 14, 2016. Mr. Plexico is currently one of
two Managing Members of Stonepine Capital Management, LLC (“Stonepine Management”). Stonepine Management is the General
Partner of Stonepine Capital, L.P. (“Stonepine”), a holder of approximately 25% of the outstanding common stock of the Company. Mr.
Plexico was appointed to the Board of Directors as a representative of Stonepine, at Stonepine’s election, under the terms of that certain
letter agreement dated May 12, 2015 (the “Letter Agreement”) by and between the Company and Stonepine, pursuant to which, among
other things, for so long as Stonepine owns at least 15% of the Company’s outstanding equity securities, Stonepine shall have the option,
but not the obligation, to designate a Stonepine representative to serve on the Board. The Company and Stonepine entered into the Letter
Agreement in connection with a private offering of our securities undertaken in May 2015.
53
Mr. Plexico has approximately 25 years of life science industry operational and advisory experience, including ten years as
Managing Member and Founder of Stonepine Management. Previously, Mr. Plexico was Managing Director at Merriman Curhan Ford &
Co., now known as Merriman Capital, where he managed healthcare corporate finance focusing on private investments in public equity,
secondary offerings, and mergers and acquisitions. Prior to that, Mr. Plexico was co-founding partner of Venture Ready Partners, a life
science advisor providing capital raising services to private biotechnology companies. Mr. Plexico served as director of business
development at Chemdex Corporation, an electronic life-science commerce company that grew to 500 employees and completed an initial
public offering during his tenure. He began his career at Quidel Corporation, where he became National Sales Manager for the
Autoimmune Division. He has served on the boards of directors of Zila, Inc. and Immunetech, Inc. Mr. Plexico is a graduate of Colgate
University. Mr. Plexico’s extensive experience in advising life sciences companies and in raising funds for them led us to believe that he
should serve as a director.
Scott Durbin. Mr. Durbin joined Viveve, Inc. as its Chief Financial Officer in February 2013 and was appointed as the Chief
Financial Officer and Secretary of Viveve Medical, Inc. on September 23, 2014. From June 2012 to January 2013, he served as an advisor
and Acting Chief Financial Officer for Viveve, Inc. Prior to joining Viveve, Inc., from June 2010 to October 2011, he was Chief Financial
Officer of Aastrom Biosciences (“Aastrom”), a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years
as Chief Operating and Financial Officer for Prescient Medical (“Prescient”) from May 2004 to June 2010, a privately held company that
developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to Prescient, from January
2003 to April 2004, he spent several years as a financial consultant for two publicly traded biotech companies, Scios Inc., a Johnson &
Johnson company, and Alteon Inc. Mr. Durbin began his career in corporate finance as an investment banker in the Healthcare and M&A
groups at Lehman Brothers Inc. from August 1999 to January 2003, where he focused on mergers and acquisitions and financings for the
life science industry. At Lehman, he successfully executed over $5 billion in transactions for medical device and biotechnology companies.
He began his career as a Director of Neurophysiology for Biotronic, Inc. Mr. Durbin received a B.S. from the University of Michigan and
an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.
James Atkinson. Mr. Atkinson was appointed to serve as the Chief Business Officer and President of the Company and Viveve,
Inc. effective as of February 4, 2015. Mr. Atkinson has over 30 years of experience in medical device sales, marketing and business
development with both Fortune 50 and start-up medical device companies. Mr. Atkinson was a founding principal at Ulthera, Inc. where he
served as Senior Vice President of Sales and Marketing from October 2006 through April 2014. While at Ulthera, he assisted in growing
the company from 3 to 165 employees and established a global distribution network that included 42 distributors, covering 52 countries.
Mr. Atkinson’s prior experience includes various executive positions, including (i) Vice President of Sales and Marketing for the Cardiac
Surgery Division at St. Jude Medical, Inc. from October 2004 to October 2006 where his responsibilities included launching the Biocor®
stented tissue valve, recognized as the fastest growing heart valve brand in the industry, (ii) Vice President of Sales for Medtronic
Vascular, a $200 million division of Medtronic, Inc., a company whose stock is traded on the New York Stock Exchange (Ticker: MDT),
from January 2003 to September 2004 and (iii) co-founder and Vice President of Sales and Business Development for Medical Simulation
Corporation. Mr. Atkinson’s career began as a sales representative at Ethicon Endosurgery, a Johnson & Johnson company, where he
progressed through positions with increasing responsibility to Regional Manager.
Legal Proceedings
To the best of our knowledge, none of our directors or executive officers has, during the past ten years, been involved in any legal
proceedings described in subparagraph (f) of Item 401 of Regulation S-K.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than 10% of a registered class
of our equity securities, to file reports of ownership and changes in ownership (Forms 3, 4 and 5) with the SEC. Officers, directors and
greater than 10% stockholders are required to furnish us with copies of all such forms which they file.
We believe that, during the year ended December 31, 2016, our directors, executive officers and beneficial owners of more than
10% of the Company’s common stock complied with all Section 16(a) filing requirements, except that one Form 4 filed on behalf of
Patricia Scheller, one Form 4 filed on behalf of James Atkinson, one Form 4 filed on behalf of Jim Robbins, one Form 4 filed on behalf of
Debora Jorn, one Form 4 filed on behalf of Lori Bush and one Form 4 filed on behalf of Arlene Morris were inadvertently filed late due to
administrative error. In making this statement, we have relied upon examination of the copies of Forms 3, 4 and 5, and amendments
thereto, provided to the Company and the written representations of its directors and executive officers.
54
Code of Ethics
The Company has adopted a Code of Conduct that applies to every director, officer and employee of the Company. Such Code of
Conduct includes written standards that are reasonably designed to deter wrongdoing and to promote:
●
●
●
●
●
Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and
professional relationships;
Full, fair, accurate, timely, and understandable disclosure in reports and documents that the Company files with, or submits
to, the Commission and in other public communications made by the Company;
Compliance with applicable governmental laws, rules and regulations;
The prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and
Accountability for adherence to the code.
Director Nominations
The Company does not have any defined procedures by which stockholders may submit nominations for directors and there has
been no change to that policy.
Audit Committee and Audit Committee Financial Expert
The board of directors of the Company has an audit committee to oversee the accounting and financial reporting processes of the
Company and the audits of the Company’s consolidated financial statements. The members of our audit committee are Daniel Janney,
Arlene Morris and Jon Plexico. The board of directors has determined that Daniel Janney is an “audit committee financial expert” as
defined by applicable SEC rules.
55
Item 11. Executive Compensation
2016 Summary Compensation Table
The following table provides information regarding the total compensation for services rendered in all capacities that was earned
during the fiscal year indicated by our named executive officers for 2016.
Name and Principal Position
Patricia Scheller,
Chief Executive Officer
Scott Durbin,
Chief Financial Officer
James Atkinson,
Chief Business Officer and
President
Fiscal
Year
2016
2015
2016
2015
2016
2015
Non-Equity
Incentive
Plan
Compensation
($)
Salary
($)
Bonus
($)(1)
380,000 190,000 335,337
346,000 154,696 785,552
Option
Awards
($)(2)
323,440 130,000 111,779
311,000
97,695 314,059
329,600 132,000 172,699
All Other
Compensation
($)
Total
($)
930,730
1,331,495
25,393(3)
45,247
27,368(3)
24,222
592,587
746,976
—
634,299
—
—
—
—
—
290,667 144,904 417,442
120,444
973,457
(1) The amounts reported represent bonuses awarded with respect to the years indicated based upon the achievement of corporate
performance goals related to (a) strengthening financial position; (b) expanding market opportunities and ensure competitiveness; (c)
providing clinically proven solutions; and (d) ensuring reliable quality supply of products for the years indicated. The amounts reported for
2015 were paid in January 2016 and the amounts reported for 2016 are payable upon the closing of the Company’s next equity financing,
which is expected to occur in 2017. Bonuses for the year ended December 31, 2015 were paid in a combination of cash and restricted stock
(and for Mr. Atkinson a combination of restricted stock and a common tock warrant) and the amounts reported represent above the amount
of cash paid and the grant date fair value of the restricted stock as follows: (i) Ms. Scheller received $108,990 in cash and restricted stock
with a grant date fair value of $45,706, (ii) Mr. Durbin received $97,695 in cash and no restricted stock and (iii) Mr. Atkinson received $0
in cash, a restricted stock with a grant date fair value of $114,904 and a common stock warrant with a grant date fair value of $30,250. The
warrant issued to Mr. Atkinson has a contractual life of ten years and is exercisable immediately in whole or in part, on or before 10 years
from the issuance date. See Note 9 of the notes to our financial statements in this annual report on Form 10-K for a discussion of our
assumptions in determining the grant date fair values of equity awards.
(2) The amounts reported represent the aggregate grant date fair value of option awards granted to our named executive officers computed
in accordance with FASB ASC Topic 718. See Note 9 of the notes to our consolidated financial statements in this Annual Report on Form
10-K for a discussion of our assumptions in determining the grant date fair values of equity awards. These amounts do not correspond to
the actual value that may be recognized by the named executive officers.
(3) The amounts reported represent cash-out of accrued PTO hours in accordance with the Company’s PTO Policy.
56
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth certain information regarding outstanding equity awards granted to our named executive officers that
were outstanding as of December 31, 2016. These awards were granted under the 2006 Plan and the 2013 Plan.
Name
Patricia Scheller
Scott Durbin
James Atkinson
Option Awards
Number of Securities
Underlying
Unexercised Options (#)(1)
Exercisable Unexercisable
150,000
—
181,501
60,500
51,369
66,045
—
27,711
—
24,187
26,888
10,322
2,250
—
22,000
30,651
50,000
72,563
20,914
—
—
75,000
66,000
36,224
Vesting Start
Date
12/23/2016
12/16/2015
9/26/2014
10/24/2012 (2)
12/23/2016
12/16/2015
9/26/2014
2/2/2013 (2)
12/23/2016 (3)
12/23/2016
12/16/2015
2/4/2015 (4)
Option
Exercise
Price
($)
Option
Expiration
Date
12/22/2026
12/16/2025
9/26/2024
10/24/2022
12/22/2026
12/16/2025
9/26/2024
2/2/2023
12/22/2026
12/22/2026
12/16/2025
2/4/2025
5.22
6.00
4.80
9.92
5.22
6.00
4.80
9.92
5.22
5.22
6.00
3.76
(1) Except as otherwise set forth below, the shares of our common stock underlying each of the outstanding stock options vest and become
exercisable in equal monthly installments over 48 months following the grant date.
(2) This stock option was fully vested upon the merger that took place on September 23, 2014 between PLC Systems Inc., Viveve, Inc. and
PLC Systems Acquisition Corp. Prior to merger, the board of directors voted to accelerate the vesting of all unvested options that were
outstanding as of the date of the merger such that all options would be immediately vested and exercisable by the holders.
(3) This stock option was fully vested on the date of grant.
(4) The shares of common stock underlying this stock option vest and become exercisable as follows: ¼ of the shares vested on the one-
year anniversary of the grant date and the remaining shares vest in equal monthly installments over the following 36 months.
57
Employment Agreements, Severance and Change-in Control Arrangements
Patricia Scheller
On May 14, 2012, Viveve, Inc. entered into an employment agreement with Patricia Scheller, the terms of which we have
assumed. Pursuant to the agreement, Ms. Scheller serves as our Chief Executive Officer on an at-will basis and as a director. Ms. Scheller
currently receives a base salary of $402,000, which is subject to periodic review and adjustment. Ms. Scheller is also eligible for an annual
performance bonus targeted at 50% of her base salary and to participate in the employee benefit plans generally available to employees,
subject to the terms of those plans.
Pursuant to the terms of the employment agreement, if Ms. Scheller’s employment is terminated by us without cause (as defined
in her employment agreement), Ms. Scheller terminates her employment with us for good reason (as defined in her employment
agreement) or Ms. Scheller’s employment is terminated due to her death or disability, Ms. Scheller will be entitled to receive: (i) base
salary continuation for 12 months following termination and (ii) continued payment of the employer portion of her monthly health
insurance premium until the earlier of 12 months following the date of termination, the expiration of her continuation coverage under
COBRA or the date she becomes eligible for substantially equivalent health insurance coverage in connection with new employment or
self-employment. Receipt of the severance payments and benefits described above is conditioned upon Ms. Scheller returning all
Company property, resigning as a member of our board of directors and the boards of directors of any of our subsidiaries and entering into
an effective release of claims against the Company and our affiliates.
Scott Durbin
On January 23, 2013, Viveve, Inc. entered into an employment agreement with Scott Durbin, the terms of which we have
assumed. Pursuant to the agreement, Mr. Durbin serves as our Chief Financial Officer on an at-will basis. Mr. Durbin currently receives a
base salary of $336,000, which is subject to periodic review and adjustment. Mr. Durbin is also eligible for an annual performance bonus
targeted at 40% of his base salary and to participate in the employee benefit plans generally available to employees, subject to the terms of
those plans.
Pursuant to the terms of the employment agreement, if Mr. Durbin’s employment is terminated by us without cause (as defined in
his employment agreement), Mr. Durbin terminates his employment with us for good reason (as defined in his employment agreement) or
Mr. Durbin’s employment is terminated due to his death or disability, Mr. Durbin will be entitled to receive: (i) base salary continuation
for 10 months following termination and (ii) continued payment of the employer portion of his monthly health insurance premium until the
earlier of 10 months following the date of termination, the expiration of his continuation coverage under COBRA or the date he becomes
eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. Receipt of the
severance payments and benefits described above is conditioned upon Mr. Durbin returning all Company property, resigning as a member
of the board of directors and the boards of directors of any of our subsidiaries and entering into an effective release of claims against the
Company and our affiliates.
James Atkinson
On January 30, 2015, Viveve, Inc. entered into an employment agreement with James Atkinson, the terms of which we have
assumed. Pursuant to the agreement, Mr. Atkinson serves as our Chief Business Officer and President on an at-will basis. Mr. Atkinson
currently receives a base salary of $343,000, which is subject to periodic review and adjustment. Mr. Atkinson is also eligible for an annual
performance bonus targeted at 40% of his base salary and to participate in the employee benefit plans generally available to employees,
subject to the terms of those plans.
58
Pursuant to the terms of the employment agreement, if Mr. Atkinson’s employment is terminated by us without cause (as defined
in his employment agreement), Mr. Atkinson terminates his employment with us for good reason (as defined in his employment
agreement) or Mr. Atkinson’s employment is terminated due to his death or disability, Mr. Atkinson will be entitled to receive: (i) base
salary continuation for six months following termination and (ii) continued payment of the employer portion of his monthly health
insurance premium until the earlier of six months following the date of termination, the expiration of his continuation coverage under
COBRA or the date he becomes eligible for substantially equivalent health insurance coverage in connection with new employment or
self-employment. Receipt of the severance payments and benefits described above is conditioned upon Mr. Atkinson returning all
Company property, resigning as a member of the board of directors and the boards of directors of any of our subsidiaries and entering into
an effective release of claims against the Company and our affiliates.
Employee Benefits
Our executive officers are eligible to participate in all of our employee benefit plans, in each case on the same basis as other
employees, including the 401(k) plan. The Company has not made any contributions to the 401(k) plan to date.
Director Compensation
Director Compensation Policy
On December 23, 2016, the board of directors adopted an independent director compensation policy, effective immediately, that
is designed to compensate non-employee directors of the Company for their time, commitment and contributions to the Company’s board
of directors. Under this policy, all non-employee directors will be paid cash compensation as set forth below, pro-rated to reflect the
number of days served during any calendar quarter:
Board of Directors:
Chairperson
All Independent Directors
Audit Committee:
Chairperson
Non-Chairperson members
Compensation Committee:
Chairperson
Non-Chairperson members
Governance and Nominating Committee:
Chairperson
Non-Chairperson members
59
Annual
Retainer($)
25,000
35,000
20,000
10,000
10,000
5,000
7,500
3,750
In addition, under the policy, each new non-employee director who is initially appointed or elected to the board of directors after
effectiveness of the policy will be granted an equity-based award with a value at the time of issuance equal to two times the Subsequent
Award (defined below) in effect at the time of election, which will vest in three equal annual installments on each of the first three
anniversaries of the date of grant, subject to the director’s continued service on the board of directors (the “Initial Award”). In addition, on
the date of each annual meeting of the Company’s stockholders, each continuing non-employee director will be eligible to receive an
annual option grant to purchase 17,500 shares of common stock, which will vest in full on the first anniversary of the grant date, subject to
the director’s continued service on the board of directors (each a “Subsequent Award”). A non-employee director elected for the first time
to the board of directors at an annual meeting of the Company’s stockholders shall only receive an Initial Award in connection with such
election, and shall not receive a Subsequent Award until the annual meeting for the next fiscal year. In the event a non-employee
director’s service on the board of directors terminates, the vesting and exercise of such director’s unvested stock options shall be subject to
the terms of the applicable award agreement.
The Company has also agreed to reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending
board of directors and committee meetings.
2016 Director Compensation Table
The following table presents information regarding the compensation of our non-employee directors for the year ended December
31, 2016. Patricia Scheller, our Chief Executive Officer, serves on our board of directors but did not receive compensation for her service
as a director and the compensation paid to Ms. Scheller as an employee during the year ended December 31, 2016 is set forth in the “2016
Summary Compensation Table” above.
Name
Lori Bush
Mark Colella (1)
Daniel Janney
Deborah Jorn
Arlene Morris
Jon Plexico
Carl Simpson (2)
Brigette Smith (3)
Fees
Earned or
Paid in
Cash ($)(4)
Stock
Awards
($)(5)(6)
Option
Awards
($)(5)(6)
10,000
20,582
39,669
Total
($)
111,160
—
—
—
—
15,625
20,582
39,669
78,875
9,688
12,866
88,294
110,848
13,750
16,728
88,294
118,772
11,250
12,866
88,294
112,410
—
—
—
—
—
10,091
—
10,091
(1) On May 11, 2016, Mr. Collela notified the board of directors of his resignation from the board of directors and all committees of the
board of directors, effective immediately.
60
(2) On May 11, 2016, Mr. Simpson notified the board of directors of his resignation from the board of directors and all committees of the
board of directors, effective immediately.
(3) On September 13, 2016, Ms. Smith notified the board of directors of his resignation from the board of directors and all committees of
the board of directors, effective as of September 30, 2016.
(4) The amounts reported represent the cash retainers for the fourth quarter of 2016, which were paid in January 2017.
(5) The amounts reported represent the aggregate grant date fair value of restricted stock awards and stock options granted to our non-
employee directors in 2016, computed in accordance with FASB ASC Topic 718. See Note 9 of the notes to our consolidated financial
statements in this annual report on Form 10-K for a discussion of our assumptions in determining the grant date fair values of equity
awards. These amounts do not correspond to the actual value that may be recognized by the directors.
(6) As of December 31, 2016, our non-employee directors serving on that date held outstanding stock options to purchase the following
number of shares of common stock: Ms. Bush – 35,000; Mr. Janney – 35,000; Ms. Jorn – 35,000; Ms. Morris – 35,000; and Mr. Plexico –
35,000. Ms. Smith and Messrs. Colella and Simpson did not hold any outstanding stock options or other equity awards as of December 31,
2016. None of our non-employee directors held unvested restricted stock or other unvested equity awards as of December 31, 2016.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The disclosure in Item 5 under the heading “Securities Authorized for Issuance Under Equity Compensation Plans” is hereby
incorporated by reference.
Security Ownership of Certain Beneficial Owners and Management
The following table sets forth certain information as of February 7, 2017 regarding the beneficial ownership of our common stock
by the following persons:
● each person who, to our knowledge, owns more than 5% of our common stock;
● each of our named executive officers;
● each director; and
● all of our executive officers and directors as a group.
61
Unless otherwise indicated in the footnotes to the following table, each person named in the table has sole voting and investment
power. The address for each of our named executive officers and directors is c/o Viveve Medical, Inc., 150 Commercial Street, Sunnyvale,
California 94086. Shares of common stock subject to options, warrants or other rights currently exercisable or exercisable within 60 days
of February 7, 2017, are deemed to be beneficially owned and outstanding for computing the share ownership and percentage of the
stockholder holding the options, warrants or other rights, but are not deemed outstanding for computing the percentage of any other
stockholder. As of February 7, 2017, we had 10,700,606 shares of common stock outstanding.
Name and Address of Beneficial Owner
Amount and Nature of
Beneficial Ownership (1)
Percent of Class
Named Executive Officers and Directors
Patricia Scheller
Scott Durbin
James Atkinson
Arlene Morris
Lori Bush
Debora Jorn
Daniel Janney
Jon Plexico
All named executive officers and directors as a group (8 persons)
(2)
(3)
(4)
244,487
106,146
651,316
(5)
6,679
4,618
6,106
894,610
2,605,817
(7)
(6)
(8)(12)
(9)(10)
4,519,779
Owners of More than 5% of Our Common Stock
2.2%
1.0%
6.0%
*
*
*
8.4%
24.3%
42%
Stonepine Capital, L.P. (9)
919 NW Bond Street, Suite 208
Bend, Oregon 97701
5AM Ventures II, L.P. (11)
2200 Sand Hill Road, Suite 110
Menlo Park, California 94025
Alta BioEquities, L.P. (8)
One Embarcadero Center, Suite 3700
San Francisco, California 94111
Laurence W. Lytton (13)
467 CPW
N.Y., NY 10025
RTW Master Fund, Ltd. (14)
c/o Intertrust Corporate Services (Cayman) Limited
190 Elgin Avenue, George Town
Grand Cayman KY1-9001, Cayman Islands
Wexford Spectrum Investors LLC (15)
2,599,711
24.3%
913,780
907,204
600,000
794,226
8.5%
8.5%
5.6%
7.4%
5.9%
627,123
* Represents beneficial ownership of less than 1% of the shares of common stock.
(1) Based on 10,700,606 shares issued and outstanding as of February 7, 2017. Beneficial ownership is determined in accordance with
Rule 13d-3 under the Exchange Act and is generally determined by voting power and/or investment power with respect to
securities. Unless otherwise noted, the shares of common stock listed above are owned as of February 7, 2017, and are owned of
record by each individual named as the beneficial owner and such individual has sole voting and dispositive power with respect to
the shares of common stock owned by each of them.
(2) Included in this amount are (i) 32,664 shares of common stock, and (ii) warrants and options to purchase 211,283 shares of
common stock that are exercisable within 60 days of February 7, 2017.
(3) Included in this amount are (i) 6,568 shares of common stock and (ii) warrants and options to purchase 99,578 shares of common
stock that are exercisable within 60 days of February 7, 2017.
(4) Included in this amount are (i) 433,737 shares of common stock owned of record by Charles Schwab & Co. Inc. for the benefit of
James Gregory Atkinson IRA Contributory Account #3027-4954, of which James Atkinson is the sole beneficiary, (ii) 98,099
shares of common stock owned of record by the Atkinson Family Revocable Trust Dated 08/26/2013, of which Mr. Atkinson is
co-trustee, (iii) 3,825 shares of common stock owned of record by Mr. Atkinson as custodian for the account of a minor child, (iv)
11,525 shares of common stock owned of record by Mr. Atkinson, and (v) warrants and options to purchase 104,130 shares of
common stock that are exercisable within 60 days of February 7, 2017.
62
(5) Included in this amount are (i) 2,482 shares of common stock, and (ii) options to purchase 4,197 shares of common stock that are
exercisable within 60 days of February 7, 2017.
(6) Included in this amount are (i) 2,709 shares of common stock, and (ii) options to purchase 1,909 shares of common stock that are
exercisable within 60 days of February 7, 2017.
(7) Included in this amount are (i) 1,909 shares of common stock, and (ii) options to purchase 4,197 shares of common stock that are
exercisable within 60 days of February 7, 2017.
(8) Based on information disclosed in a Schedule 13D/A filed on June 21, 2016 on behalf of Alta BioEquities, L.P. Includes 881,954
shares of common stock owned of record by Alta BioEquities, L.P. and a 10-year warrant to purchase 25,250 shares of common
stock. Alta BioEquities Management, LLC is the general partner of Alta BioEquities, L.P. Daniel Janney, one of our directors, is
the Managing Director of Alta BioEquities Management, LLC and has voting and investment power over the shares beneficially
owned by Alta BioEquities, L.P.
(9) Based on information disclosed in a Schedule 13D/A filed on November 21, 2016 on behalf of Stonepine Capital, L.P. Includes
2,599,711 shares of common stock owned of record by Stonepine Capital, L.P., Stonepine Capital Management, LLC is the
general partner of Stonepine Capital, L.P. Jon M. Plexico and Timothy P. Lynch are the Managing Members of Stonepine Capital
Management, LLC and have shared voting and investment power over the shares beneficially owned by Stonepine Capital, L.P.
(10)Included in this amount are options to purchase 4,197 shares of common stock that are exercisable within 60 days of February 7,
2017.
(11)Based on information disclosed in a Schedule 13D/A filed on June 1, 2015 on behalf of 5AM Co-Investors II, L.P. Dr. John
Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, the managing members of 5AM Partners II, LLC, have shared voting
and investment power over the shares beneficially owned by 5AM Ventures II, L.P. As the managing members of 5AM Partners
II, LLC, these individuals also have voting and investment power over 913,780 shares of common stock owned of record by 5AM
Co-Investors II, L.P. 5AM Partners II, LLC is the general partner of both 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P.
(12) Included in this amount are (i) 885,009 shares of common stock, and (ii) options to purchase 9,601 shares of common stock that
are exercisable within 60 days of February 7, 2017.
(13)Based upon information disclosed in a Schedule 13G filed on June 24, 2016 on behalf of Laurence W. Lytton.
(14)Based upon information disclosed in a Schedule 13G/A filed on February 9, 2016 on behalf of RTW Investments, LLC. RTW
Investments, LLC is the investment manager of RTW Master Fund, Ltd. Roderick Wong is the Managing Member of RTW
Investments, LLC and has sole voting and investment power over the shares beneficially owned by RTW Master Fund, Ltd.
(15)Based upon information disclosed in Schedule 13 G/A filed on February 7, 2017 on behalf of Wexford Spectrum Investors LLC.
Wexford Capital LP is a manager of Wexford Spectrum Investors LLC. Wexford GP LLC is the General Partner of Wexford
Capital LP. Each of Charles E. Davidson and Joseph M. Jacobs is a controlling person of Wexford GP LLC. Each of Wexford
Capital LP, Wexford GP LLC, and Mr. Davidson and Mr. Jacobs have shared voting and investment power over the shares
beneficially owned by Wexford Spectrum Investors LLC.
Change in Control
As of the date of this report, we are not aware of any arrangements, including any pledge by any person of our securities, the
operation of which may at a subsequent date result in a change in control of the Company.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Commission regulations define the related person transactions that require disclosure to include any transaction, arrangement or
relationship in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year end for the last
two completed fiscal years in which we were or are to be a participant and in which a related person had or will have a direct or indirect
material interest. A related person is: (i) an executive officer, director or director nominee of the Company, (ii) a beneficial owner of more
than 5% of our common stock, (iii) an immediate family member of an executive officer, director or director nominee or beneficial owner
of more than 5% of our common stock, or (iv) any entity that is owned or controlled by any of the foregoing persons or in which any of the
foregoing persons has a substantial ownership interest or control.
For the period from January 1, 2015, through the date of this Annual Report on Form 10-K, described below are certain
transactions or series of transactions between us and certain related persons. Information relating to employment agreements entered into
by the Company and its executive officers and executive officer compensation can be found at Item 11 – Executive Compensation.
63
Agreement for Consulting Services
On November 11, 2014, Viveve, Inc. entered into an Independent Contractor Agreement for Rendering Consulting Services with
James Atkinson (the “Consulting Agreement”), which provided that Mr. Atkinson shall provide certain consulting services related to
product distribution and international sales in exchange for (i) $30,000 per month to be paid in cash, 5-year warrants to purchase the
Company’s common stock at an exercise price of $0.53 per share, or a combination thereof, to be determined by the board of directors, (ii)
reimbursement of any costs and expenses incurred by Mr. Atkinson for travel in connection with the performance of his services under the
Consulting Agreement and (iii) compensation at a rate of 35% of the total annual cash compensation for each zone director hired by the
Company as a result of a direct introduction by Mr. Atkinson, to be paid solely in equity securities of the Company. The Consulting
Agreement was terminated effective as of February 3, 2015. On February 4, 2015, the Company entered into an offer letter with James
Atkinson in connection with his appointment as Chief Business Officer and President of Viveve, Inc. For information on the offer letter,
see the discussion at Item 11 – Executive Compensation.
Private Placement
On November 24, 2015, the Company completed a private offering pursuant to which it issued 8,573,385 shares of common
stock, no par value, at a per share purchase price of $0.70 for gross proceeds of approximately $6,000,000 (the “Private Placement”) to 12
accredited investors pursuant to the terms of a Securities Purchase Agreement, by and among the Company and the purchasers, dated as of
November 20, 2015 (the “Securities Purchase Agreement”). Purchasers in the offering included Stonepine Capital, L.P., Alta BioEquities
L.P., an affiliate of director Dan Janney, Patricia Scheller, the Company’s Chief Executive Officer, and James Atkinson, the Company’s
Chief Business Officer and President.
In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the purchasers, dated
as of November 20, 2015, pursuant to which the Company agreed to register the shares on a registration statement to be filed with the
Securities and Exchange Commission within 60 days after the closing of the offering and to use its commercially reasonable efforts to
cause the registration statement to be declared effective within 90 days after the filing date. If the Company (i) failed to file the
registration statement by the filing date, (ii) did not obtain effectiveness of the registration statement within 90 days after the filing date or
(iii) allows certain lapses in effectiveness, the Company is obligated to pay to the purchasers liquidated damages equal to 1.5% of the
original subscription amount paid by the purchasers upon the occurrence of the event and for every seven days after the occurrence of an
event until cured. The Company filed the registration statement within 60 days after the closing of the Private Placement and the
registration statement was declared effective by the SEC within 90 days after the filing date.
Policies and Procedures for Related Person Transactions
While our board of directors has not adopted a formal written related person transaction policy that sets forth the policies and
procedures for the review and approval or ratification of related person transactions, it the Company’s practice and procedure to present all
transactions arrangements, relationships, or any series of similar transactions, arrangements, or relationships, in which the Company was or
is to be a participant and a related person had or will have a direct or indirect material interest, to the board of directors for approval.
Director Independence
Our determination of the independence of our directors is made using the definition of “independent” contained in the listing
standards of the Nasdaq Stock Market. On the basis of information solicited from each director, the board has determined that each of Jon
Plexico, Arlene Morris, Lori Bush, Debora Jorn and Daniel Janney are independent within the meaning of such rules.
64
Item 14. Principal Accounting Fees and Services
The following table sets forth fees billed and to be billed to us by our independent registered public accounting firm for the years
ended December 31, 2016 and 2015 for (i) services rendered for the audit of our annual consolidated financial statements and the review
of our quarterly condensed consolidated financial statements, (ii) services rendered that are reasonably related to the performance of the
audit or review of our consolidated financial statements that are not reported as Audit Fees, and (iii) services rendered in connection with
tax preparation, compliance, advice and assistance.
Audit fees
Audit-related fees
Tax fees
All other fees
Total fees
Year Ended
December 31,
2016
2015
$
$
304,000 $
0
12,000
0
316,000 $
190,000
0
13,000
0
203,000
Audit Fees: Represents fees for professional services provided for the audit of our annual consolidated financial statements,
review of our condensed consolidated financial statements included in our quarterly reports and services in connection with statutory and
regulatory filings.
Audit-Related Fees: Represents the fees for assurance and related services that are reasonably related to the performance of the
audit or review of our consolidated financial statements.
The audit committee of the board of directors of the Company approves all auditing services and the terms thereof and non-audit
services (other than non-audit services published under Section 10A(g) of the Exchange Act or the applicable rules of the SEC or the
Pubic Company Accounting Oversight Board) to be provided to us by the independent auditor; provided, however, the pre-approval
requirement is waived with respect to the provisions of non-audit services for us if the "de minimus" provisions of Section 10A(i)(1)(B) of
the Exchange Act are satisfied.
Tax Fees: Represents professional services rendered for tax compliance, tax advice and tax planning.
All Other Fees: Our independent registered public accounting firm was not paid any other fees for professional services during
the fiscal years ended December 31, 2016 and 2015.
65
PART IV
Item 15. Exhibits, Financial Statement Schedules
Financial Statements
See Index to Consolidated Financial Statements at Item 8 herein.
Financial Statement Schedules have been omitted as they are either not required, not applicable, or the information is otherwise
included.
Exhibit Index
Exhibit No.
Description
2.1
2.1.1
2.2
3.1
3.2
3.3
3.4
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
10.1
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
10.10
10.11
10.12
10.13
10.14
Agreement and Plan of Merger dated May 9, 2014 by and among Viveve, Inc., PLC Systems, Inc. and PLC Systems
Acquisition Corporation (1)
Amendment to Agreement and Plan of Merger (1)
RenalGuard Reorganization Agreement (2)
Certificate of Conversion for Delaware(3)
Certificate of Incorporation(3)
Articles of Amendment to the Articles of Continuance of Viveve Medical, Inc.(4)
Bylaws(3)
Common Stock Purchase Warrant issued on February 17, 2015 to Scott Durbin(5)+
Common Stock Purchase Warrant issued on February 17, 2015 to Jim Robbins(5)+
Common Stock Purchase Warrant issued on February 17, 2015 to Patricia Scheller(5)+
Common Stock Purchase Warrant issued on May 12, 2015 to James Atkinson(5)+
Common Stock Purchase Warrant issued on December 16, 2015 to James Atkinson(5)+
Common Stock Purchase Warrant issued on December 16, 2015 to Jim Robbins(5)+
Warrant to Purchase Common Stock issued on April 1, 2016 to Dynamic Medical Technologies (Hong Kong) Limited(3)
Warrant to Purchase Common Stock issued on May 11, 2016 to Theresa Stern(6)
Warrant to Purchase Common Stock issued on May 11, 2016 to Chris Rowan(6)
Warrant to Purchase Common Stock issued on June 20, 2016 to Western Alliance Bank(7)
Form of Securities Purchase Agreement dated May 9, 2014 (8)
Securities Purchase Agreement, dated May 9, 2014, by and among the Registrant and GBS Venture Partners as trustee for
GBS BioVentures III Trust (8)
Escrow Deposit Agreement, dated May 9, 2014 by and among the Registrant, Palladium Capital Advisors LLC,
Middlebury Securities and Signature Bank, as escrow agent (8)
Registration Rights Agreement, dated May 9, 2014 (8)
First Amendment to Registration Rights Agreement, dated February 19, 2015 (9)
Right to Shares Letter Agreement dated May 9, 2014 between the Registrant and GCP IV LLC (8)
Amendment dated September 10, 2014 to Securities Purchase Agreement dated February 22, 2013 (10)
Amendment dated September 11, 2014 to Securities Purchase Agreement dated February 22, 2013 (10)
PLC Systems Inc. 2013 Stock Option and Incentive Plan, as amended (11) +
Offer of Employment dated May 14, 2012 from Viveve, Inc. to Patricia K. Scheller (12)+
Offer of Employment dated January 23, 2013 from Viveve, Inc. to Scott C. Durbin (12)+
Loan and Security Agreement dated September 30, 2014 between Viveve, Inc. and Square 1 Bank (13)
First Amendment to Loan and Security Agreement dated February 19, 2015 between Viveve, Inc. and Square 1 Bank (9)
Intellectual Property Security Agreement dated September 30, 2014 between Viveve, Inc. and Square 1 Bank (13)
66
10.15
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
10.26
10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
10.35
10.36
10.37
10.38
10.39
10.40
10.41
10.42
14.1
21
23.1
24.1
31.1
31.2
32.1
Unconditional Guaranty issued by the Registrant in favor of Square 1 Bank (13)
Intellectual Property Assignment and License Agreement dated February 10, 2006, as amended, between Dr. Edward
Knowlton and TivaMed, Inc (11)
Development and Manufacturing Agreement dated June 12, 2006 between TivaMed, Inc. and Stellartech Research
Corporation (11)
Amended and Restated Development and Manufacturing Agreement dated October 4, 2007 between TivaMed, Inc. and
Stellartech Research Corporation (11)
Right to Shares Letter Agreement, dated as of September 23, 2014 by and between the Registrant and GCP IV LLC (11)
Right to Shares Letter Agreement, dated as of September 23, 2014 by and between the Registrant and G-Ten Partners LLC
(11)
Convertible Note Termination Agreement, dated May 9, 2014 by and between Viveve, Inc. and 5AM Ventures II, LP (14)
Convertible Note Termination Agreement, dated May 9, 2014 by and between Viveve, Inc. and 5AM Co-Investors II, LP
(14)
Convertible Note Exchange Agreement, dated May 9, 2014 by and between Viveve, Inc. and GBS Venture Partners
Limited, trustee for GBS BioVentures III (14)
Warrant Termination Agreement, dated as of May 9, 2014, by and between the Viveve, Inc. and 5AM Ventures II, LP (14)
Warrant Termination Agreement, dated as of May 9, 2014, by and between the Viveve, Inc. and 5AM Co-Investors II, LP
(14)
Warrant Termination Agreement, dated as of May 9, 2014, by and between the Viveve, Inc. and GBS Venture Partners
Limited, trustee for GBS BioVentures III (14)
Offer Letter to James G. Atkinson, dated February 4, 2015 (15)+
First Amendment to Lease dated January 15, 2015 between The Castine Group and Viveve, Inc. (16)
Second Amendment to Loan and Security Agreement dated May 14, 2015 between Viveve, Inc. and Square 1 Bank (16)
Form of Securities Purchase Agreement dated May 12, 2015 (16)
Form of Registration Rights Agreement dated May 12, 2015 (16)
Letter Agreement with Stonepine Capital dated May 12, 2015 (16)
Form of Securities Purchase Agreement dated November 20, 2015 (17)
Form of Registration Rights Agreement dated November 20, 2015 (17)
Third Amendment to Loan and Security Agreement dated November 30, 2015 between Pacific Western Bank, as successor
in interest by merger to Square 1 Bank, and Viveve, Inc. (18)
Fourth Amendment to Loan and Security Agreement dated March 18, 2016 between Pacific Western Bank, as successor in
interest by merger to Square 1 Bank, and Viveve, Inc. (5)
Viveve Medical, Inc. Independent Director Compensation Policy(19)
Viveve Medical, Inc. Amended and Restated 2013 Stock Option and Incentive Plan(20)
Second Amendment to Standard Industrial/Commercial Multi-Tenant Lease- Gross, dated September 12, 2016 between
Viveve, Inc. and Commercial Street Properties, LLC. (21)
Loan and Security Agreement dated as of June 20, 2016 by and among Viveve Medical, Inc., Viveve, Inc. and Western
Alliance Bank(7)
Intellectual Property Security Agreement dated as of June 20, 2016 between Viveve Medical, Inc. and Western Alliance
Bank(7)
Sublease Agreement, entered into on February 1, 2017 and effective as of January 26, 2017, between Viveve Medical, Inc.
and Ingredion Incorporated (22)
Code of Conduct, adopted September 23, 2014 (23)
List of the Registrant’s Subsidiaries*
Consent of BPM LLP*
Power of Attorney* (included on signature page hereto)
Certification of the Company’s Principal Executive Officer pursuant to 15d-15(e), under the Securities and Exchange Act
of 1934.*
Certification of the Company’s Principal Financial Officer pursuant to 15d-15(e), under the Securities and Exchange Act of
1934.*
Certification of the Company’s Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.**
67
32.2
Certification of the Company’s Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.**
XBRL Instance Document*
101.INS
101.SCH XBRL Taxonomy Extension Schema Document*
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB XBRL Taxonomy Extension Label Linkbase Document*
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document*
Filed herewith.
These exhibits are furnished, not filed.
*
**
+ Management contract or compensation plan, contract or arrangement.
(1)
Incorporated by reference to Annex A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Securities and
Exchange Commission on August 11, 2014.
(2)
Incorporated by reference to Annex B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Securities and
Exchange Commission on August 11, 2014.
(3)
(4)
(5)
(6)
Incorporated by reference from the Form 10-Q filed with the Securities and Exchange Commission on May 13, 2016.
Incorporated by reference from the Form 8-K filed with the Securities and Exchange Commission on April 14, 2016.
Incorporated by reference from the Form 10-K filed with the Securities and Exchange Commission on March 24, 2016.
Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on
August 11, 2016.
(7)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June
21, 2016.
(8)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May
14, 2014.
(9)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on
February 25, 2015.
(10) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on
September 16, 2014.
(11) Incorporated by reference to the Registrant’s on Form S-1 filed with the Securities and Exchange Commission on November 21, 2014.
(12) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on
September 29, 2014.
(13) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on
October 3, 2014.
(14) Incorporated by reference to the Amendment No. 1 Registrant’s Form S-1 filed with the Securities and Exchange Commission on
January 26, 2015.
(15) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on
February 10, 2015.
(16) Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed with the
Securities and Exchange Commission on May 15, 2015.
(17) Incorporated by reference to the registrants Current Report on Form 8-K filed with the Securities and Exchange Commission on
November 25, 2015.
(18) Incorporated by reference to the registrants Current Report on Form 8-K filed with the Securities and Exchange Commission on
December 4, 2015.
(19) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on December 29, 2016.
(20) Incorporated by reference to Appendix A to the Registrant’s Proxy Statement on Schedule 14A filed with the Securities and Exchange
Commission on July 28, 2016.
(21) Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 10, 2016.
(22) Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2017.
(23) Incorporated by reference to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March 16, 2015.
68
In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.
SIGNATURES
February 16, 2017
VIVEVE MEDICAL, INC.
(Registrant)
By:
/s/ Patricia Scheller
Patricia Scheller
Chief Executive Officer
POWER OF ATTORNEY
We, the undersigned officers and directors of Viveve Medical, Inc., hereby severally constitute and appoint Patricia Scheller and
Scott Durbin, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution in each of them for him or her and, place and stead, and in any and all capacities, to sign
conformed for us and in our names in the capacities indicated below any and all signatures and amendments to this report, and to file the
same, with all exhibits thereto filing date and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing
requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person,
hereby ratifying and confirming all that said attorneys-infact and agents or any of them, or their or his substitute or substitutes, may
lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf
of the Registrant in the capacities and on the dates indicated.
Signature
Title
Date
/s/Patricia Scheller
Patricia Scheller
Chief Executive Officer and Director
(Principal Executive Officer)
/s/Scott Durbin
Scott Durbin
/s/Debora Jorn
Debora Jorn
/s/Lori Bush
Lori Bush
/s/Arlene Morris
Arlene Morris
/s/Daniel Janney
Daniel Janney
/s/Jon Plexico
Jon Plexico
Chief Financial Officer
(Principal Financial and Accounting Officer)
Director
Director
Director
Director
Director
69
February 16, 2017
February 16, 2017
February 16, 2017
February 16, 2017
February 16, 2017
February 16, 2017
February 16, 2017
VIVEVE MEDICAL, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets - December 31, 2016 and 2015
Consolidated Statements of Operations - Years Ended December 31, 2016 and 2015
Consolidated Statements of Stockholders’ Equity (Deficit) - Years Ended December 31, 2016 and 2015
Consolidated Statements of Cash Flows - Years Ended December 31, 2016 and 2015
Notes to Consolidated Financial Statements
F-1
Page
F-2
F-3
F-4
F-5
F-6
F-7 – F26
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of
Viveve Medical, Inc.
We have audited the accompanying consolidated balance sheets of Viveve Medical, Inc. (a Delaware corporation) and its subsidiaries (the
“Company”) as of December 31, 2016 and 2015, and the related consolidated statements of operations, stockholders’ equity (deficit) and
cash flows for each of the two years in the period ended December 31, 2016. These financial statements are the responsibility of the
Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of
material misstatement. The Company is not required to have, nor have we been engaged to perform, an audit of its internal control over
financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of
Viveve Medical, Inc. and its subsidiaries as of December 31, 2016 and 2015, and the results of their operations and their cash flows for
each of the two years in the period ended December 31, 2016 in conformity with accounting principles generally accepted in the United
States of America.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As
discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring losses and negative cash flow from
operations since inception. These conditions raise substantial doubt about its ability to continue as a going concern. Management’s plans
regarding those matters also are described in Note 1. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
/s/ BPM LLP
San Jose, California
February 16, 2017
F-2
VIVEVE MEDICAL, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable
Inventory
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable
Accrued liabilities
Note payable, current portion
Total current liabilities
Note payable, noncurrent portion
Other noncurrent liabilities
Total liabilities
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value;
10,000,000 shares authorized as of December 31, 2016; no shares issued
Preferred stock, no par value;
unlimited shares authorized as of December 31, 2015; no shares issued
Common stock, $0.0001 par value;
75,000,000 shares authorized as of December 31, 2016;
10,661,201 shares issued and outstanding as of December 31, 2016
Additional paid-in capital
Common stock and paid-in capital, no par value;
unlimited shares authorized as of December 31, 2015;
7,490,288 shares issued and outstanding as of December 31, 2015
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)
December 31,
December 31,
2016
2015
$
$
$
$
8,086 $
2,091
2,687
1,066
13,930
483
136
14,549 $
3,086 $
2,186
1,867
7,139
7,762
53
14,954
-
-
1
68,216
-
(68,622)
(405)
14,549 $
7,360
593
1,549
1,228
10,730
239
138
11,107
1,432
1,293
4,446
7,171
-
-
7,171
-
-
-
-
52,447
(48,511)
3,936
11,107
Note: All share and per share data has been adjusted to reflect the 1-for-8 reverse stock split which became effective April 15, 2016, as
discussed in Note 2.
The accompanying notes are an integral part of these consolidated financial statements.
F-3
VIVEVE MEDICAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
Revenue
Cost of revenue
Gross profit
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Interest expense, net
Other expense, net
Comprehensive and net loss
Net loss per share:
Basic and diluted
Weighted average shares used in computing net loss per common share
Basic and diluted
$
$
$
Year Ended
December 31,
2016
2015
7,141 $
4,612
2,529
8,365
12,868
21,233
(18,704)
(1,370)
(37)
(20,111) $
1,447
985
462
4,988
7,464
12,452
(11,990)
(415)
(21)
(12,426)
(2.18) $
(2.47)
9,222,348
5,023,080
Note: All share and per share data has been adjusted to reflect the 1-for-8 reverse stock split which became effective April 15, 2016, as
discussed in Note 2.
The accompanying notes are an integral part of these consolidated financial statements.
F-4
VIVEVE MEDICAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
For each of the two years in the period ended December 31, 2016
(in thousands, except share data)
Common Stock,
Additional Common Stock and
Total
Balances as of January 1, 2015
$0.0001 par value
Shares
Amount
- $
-
Paid-In
Capital
- $
-
Amount
Shares
- 2,293,057 $ 35,244 $
-
-
-
Deficit
Accumulated Stockholders’
Equity (Deficit)
(841)
-
(36,085) $
-
Paid-in Capital: no par
value
-
-
-
-
-
-
-
-
-
-
-
-
-
-
18,792
-
35,490
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
May 2015 Offering, net of
issuance costs
November 2015 Offering, net of
issuance costs
Issuance of warrants to
employees for performance
bonuses
Issuance of warrants to vendors
and service providers
Issuance of warrant in
connection with note payable
Stock-based compensation
expense
Issuance of shares pursuant to
rights to shares
Exercise of warrant
Comprehensive and net loss
Balances as of December 31,
2015
Reverse stock split - rounding
adjustment
Stock-based compensation
expense
Issuance of restricted stock
awards to employees for
performance bonuses
Issuance of restricted stock
awards to directors and
consultants
Issuance of warrants
Exercise of warrants
Exercise of stock options
Reclassification upon change in
corporate domicile
June 2016 Offering, net of
issuance costs
Issuance of warrant in
connection with note payable
Comprehensive and net loss
Balances as of December 31,
2016
- 4,054,062
11,040
- 1,071,679
5,393
-
-
-
-
-
-
-
-
-
-
-
-
70,755
735
-
-
286
251
10
220
-
3
-
-
-
-
-
-
-
-
11,040
5,393
286
251
10
220
-
-
(12,426)
-
-
3
(12,426)
-
- 7,490,288
52,447
(48,511)
3,936
-
2,361
-
707
-
188
-
-
246
125
20
65
-
-
-
6,250
3,020
-
142
27
14
-
-
-
-
-
-
-
-
-
-
(20,111)
-
895
246
125
162
92
14
-
13,886
350
(20,111)
7,501,919
1
53,063 (7,501,919)
(53,064)
3,105,000
-
13,886
-
-
-
-
350
-
10,661,201 $
1 $
68,216
-
-
-
- $
-
-
-
- $
(68,622) $
(405)
Note: All share and per share data has been adjusted to reflect the 1-for-8 reverse stock split which became effective April 15, 2016, as
discussed in Note 2.
The accompanying notes are an integral part of these consolidated financial statements.
F-5
VIVEVE MEDICAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Restricted stock award granted to consultant
Fair value of warrants issued
Fair value of warrants issued to employees for bonuses
Non-cash interest expense
Changes in assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other noncurrent assets
Accounts payable
Accrued liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs
Proceeds from note payable
Repayments of note payable
Proceeds from exercise of warrants
Proceeds from exercise of stock options
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents - beginning of period
Cash and cash equivalents - end of period
Supplemental disclosure:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrant in connection with note payable
Restricted stock awards granted to employees for 2015 accrued bonuses
Net transfer of equipment from inventory to property and equipment
Year Ended
December 31,
2016
2015
$
(20,111) $
(12,426)
111
981
39
162
-
456
(1,498)
(1,237)
162
2
1,654
1,192
(18,087)
(256)
(256)
13,886
9,910
(4,833)
92
14
19,069
726
7,360
8,086 $
803 $
1 $
350 $
246 $
99 $
77
220
-
251
286
197
(587)
(1,438)
(879)
18
1,016
1,070
(12,195)
(109)
(109)
16,433
2,500
(167)
3
-
18,769
6,465
895
7,360
196
1
10
-
20
$
$
$
$
$
$
The accompanying notes are an integral part of these consolidated financial statements.
F-6
VIVEVE MEDICAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. The Company and Basis of Presentation
Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry by
marketing Geneveve™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity.
Public Offering
On June 17, 2016, in connection with the closing of a public offering (the “June 2016 Offering”), the Company issued an aggregate
of 3,105,000 shares of common stock, including the shares issued in connection with the exercise of the underwriters’ overallotment
option, at a public offering price of $5.00 per share for gross proceeds of approximately $15,525,000. The net proceeds to the
Company, after the deduction of underwriting discounts, commissions and other offering expenses, were approximately
$13,886,000.
Change of Corporate Domicile
On May 9, 2016, the Company filed the necessary Application for Authorization to Continue into Another Jurisdiction and
Statutory Declaration with the Yukon registrar. On May 10, 2016, the Company filed a Certificate of Incorporation with the
Secretary of State of the State of Delaware to move its domicile from the Yukon Territory to Delaware. In connection with the
incorporation in Delaware, the Company's stock now has a par value of $0.0001 per share.
Private Placements
On November 24, 2015, in connection with the closing of a private placement (the “November 2015 Offering”), Viveve Medical
issued an aggregate of 1,071,679 shares of common stock at $5.60 per share for gross proceeds of approximately $6,000,000 in
accordance with the terms and conditions of those certain Securities Purchase Agreements by and between the Company and certain
accredited investors. The net proceeds to the Company after the deduction of placement agent commissions and other expenses
were approximately $5,393,000.
On May 14, 2015, in connection with the closing of a private placement (the “May 2015 Offering”), Viveve Medical issued an
aggregate of 4,054,062 shares of common stock at $2.96 per share for gross proceeds of approximately $12,000,000 in accordance
with the terms and conditions of those certain Securities Purchase Agreements by and between the Company and certain accredited
investors. The net proceeds to the Company after the deduction of placement agent commissions and other expenses were
approximately $11,040,000.
Liquidity and Management Plans
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the
realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2016, the Company had
cash and cash equivalents of $8,086,000 and working capital of $6,791,000. The Company has incurred operating losses since
inception and has an accumulated deficit of $68,622,000 as of December 31, 2016. Management expects operating losses to
continue through the foreseeable future. The Company's ability to transition to attaining profitable operations is dependent upon
achieving a level of revenues adequate to support its cost structure. The Company has not generated significant revenues and has
funded its operating losses through the sales of its securities, loans from related parties and bank term loans. We expect that our cash
will be sufficient to fund our activities for the next six months, however, we will continue to require additional funds to fully
implement our plan of operation.
Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance
that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from
operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company’s
ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a
going concern. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.
F-7
2. Summary of Significant Accounting Policies
Basis of Presentation
The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and
Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassification of Prior Year Presentation
Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had
no effect on the reported results of operations. Accounting Standards Update (“ASU”) 2015-03 requires that debt issuance costs
related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt
liability, consistent with debt discounts. The Company adopted this guidance on January 1, 2016. Accordingly, the Company has
revised the classification in the consolidated balance sheet to report debt issuance costs as a contra debt liability as of December 31,
2015. This resulted in a decrease of $387,000 to the December 31, 2015 amounts reported as prepaid expenses and other current
assets, total assets, note payable, total liabilities, and total liabilities and stockholders’ equity.
Reverse Stock Split
On April 15, 2016, the Company effected a 1-for-8 reverse stock split of its common stock. On the effective date of the reverse
stock split, (i) each 8 shares of outstanding common stock were reduced to one share of common stock; (ii) the number of shares of
common stock into which each outstanding warrant or option to purchase common stock is exercisable were proportionately
reduced on an 8-to-1 basis; and (iii) the exercise price of each outstanding warrant or option to purchase common stock were
proportionately increased on a 1-to-8 basis. All of the share numbers, share prices, and exercise prices have been adjusted, on a
retroactive basis, to reflect this 1-for-8 reverse stock split.
Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America (“US GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience
and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect
on our operating results.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with an original maturity of three months or less, at the time of
purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand accounts primarily at one
financial institution. Deposits in this institution may, from time to time, exceed the federally insured amounts.
Concentration of Credit Risk and Other Risks and Uncertainties
To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no
assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance
characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the
Company’s financial results, financial position, and future cash flows.
F-8
The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory
agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these
required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse
effect on the Company’s financial results, financial position and future cash flows.
The Company is subject to risks common to companies in the medical device industry including, but not limited to, new
technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government
regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The
Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its
products.
The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal laxity that it
refers to as the Geneveve™, which includes the Viveve System™, single-use treatment tips and other ancillary consumables. The
Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other
components and materials that comprise the Geneveve are currently manufactured by a single supplier or a limited number of
suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third-party
suppliers would adversely impact the production of our products for a substantial period of time, which could have a material
adverse effect on our business, financial condition, operating results and cash flows.
During the year ended December 31, 2016, three customers accounted for 78% of the Company’s revenue. During the year ended
December 31, 2015, four customers accounted for 87% of the Company’s revenue. As of December 31, 2016, three customers
accounted for 81% of total accounts receivable. As of December 31, 2015, three customers accounted for 86% of total accounts
receivable.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount and are not interest bearing. Our typical payment terms vary by region and
type of customer (distributor or physician). Occasionally, payment terms of up to six motnhs may be granted to customers with an
established history of collections without concessions. Should we grant payment terms greater than six months or terms that are not
in accordance with established history for similar arrangements, revenue would be recognized as payments become due and payable
assuming all other criteria for revenue recognition have been met. The Company maintains an allowance for doubtful accounts for
estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions
relating to the collectibility of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the
amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit
evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future
and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of
December 31, 2016 and 2015, there was no allowance for doubtful accounts.
Inventory
Inventory is stated at the lower of cost or market. lnventory as of December 31, 2016 consisted of $181,000 of raw materials
and $2,506,000 of finished goods. All inventory as of December 31, 2015 was finished goods. Cost is determined on an actual cost
basis on a first-in, first-out method. Lower of cost or market is evaluated by considering obsolescence, excessive levels of inventory,
deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for
estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new lower-
cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or
increase in that newly established cost basis.
As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to
facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of
five years. The amortization of the demos is charged to selling, general and administrative expense and the demos are included in
the medical equipment line within the property and equipment, net balance on the consolidated balance sheets as of December 31,
2016 and 2015.
F-9
Property and Equipment, net
Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and
equipment is computed using the straight line method over their estimated useful lives of three to seven years. Leasehold
improvements are amortized on a straight-line basis over the lesser of their useful lives or the life of the lease. Upon sale or
retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the
resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Impairment of Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an
impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is
considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised
value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
Revenue Recognition
The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary
consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed
or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory
requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance,
in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe,
the Middle East and Asia Pacific.
The Company does not provide its customers with a right of return.
Customer Advance Payments
From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the
Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer
advance payment from accrued liabilities when revenue is recognized.
Product Warranty
The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework or replacement of
products (at the Company’s option) that fail to perform within stated specification. The Company has assessed the historical claims
and, to date, product warranty claims have not been significant. The Company will continue to assess the need to record a warranty
accrual at the time of sale going forward.
Shipping and Handling Costs
The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue.
Advertising Costs
Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded
in selling, general and administrative expenses, were immaterial for the years ended December 31, 2016 and 2015.
F-10
Research and Development
Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited
to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent,
equipment depreciation, and utilities.
Income Taxes
The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this
approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities
are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change
in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets
and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded
to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.
The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and
to the extent the Company believes that recovery is not likely, the Company establishes a valuation allowance. Management
judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities, and any valuation
allowance recorded against the net deferred tax assets. The Company recorded a full valuation allowance as of December 31, 2016
and 2015. Based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize its
deferred tax assets in the future. The Company intends to maintain valuation allowances until sufficient evidence exists to support
the reversal of such valuation allowances. The Company makes estimates and judgments about its future taxable income that are
based on assumptions that are consistent with its plans. Should the actual amounts differ from the Company’s estimates, the
carrying value of the Company’s deferred tax assets could be materially impacted.
The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not of being
sustained on audit, based on the technical merits of the position. The Company’s policy is to recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not believe there are any tax
positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or
decrease within 12 months of the reporting date.
Accounting for Stock-Based Compensation
Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over
the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service
period of the award.
We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value
for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which
determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock.
Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic
adjustment as the underlying equity instruments vest.
Comprehensive Loss
Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions.
Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended
December 31, 2016 and 2015, the Company’s comprehensive loss is the same as its net loss.
Net Loss per Share
The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common
stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock
equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock
and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net
losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been
issued if their effect is anti-dilutive.
F-11
The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive.
Stock options to purchase common stock
Warrants to purchase common stock
Restricted common stock awards
Recently Issued and Adopted Accounting Standards
December 31,
2016
2015
1,909,764
425,274
58,155
1,022,195
383,321
-
In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting
Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with
Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue
recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance
that have historically existed in US GAAP. The underlying principle of the new standard is that a business or other organization
will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in
exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for
transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial
adoption and is effective for annual and interim periods beginning after December 15, 2017. The FASB has issued several updates
to the standard which i) defer the original effective date from January 1, 2017 to January 1, 2018, while allowing for early adoption
as of January 1, 2017 (ASU 2015-14); ii) clarify the application of the principal versus agent guidance (ASU 2016-08); iii) clarify
the guidance on inconsequential and perfunctory promises and licensing (ASU 2016-10); and clarify the guidance on certain
sections of the guidance providing technical corrections and improvements (ASU 2016-10). In May 2016, the FASB issued ASU
2016-12, “Revenue from Contracts with Customers (Topic 606) Narrow-Scope Improvements and Practical Expedients”, to address
certain narrow aspects of the guidance including collectibility criterion, collection of sales taxes from customers, noncash
consideration, contract modifications and completed contracts. This issuance does not change the core principle of the guidance in
the initial topic issued in May 2014. We are currently evaluating the impact that this standard will have on our consolidated
financial statements.
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40):
Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This guidance is effective for the Company’s
annual reporting period ending December 31, 2016 and all annual and interim reporting periods thereafter. The Company adopted
this standard for the year ended December 31, 2016. This guidance requires management to evaluate whether there is substantial
doubt about the Company’s ability to continue as a going concern for at least 12 months from the issuance date of the consolidated
financial statements and to provide related footnote disclosures.
In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”). ASU 2015-11
requires that an entity should measure inventory within the scope of this pronouncement at the lower of cost and net realizable
value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of
completion, disposal, and transportation. The pronouncement does not apply to inventory that is being measured using the last-in,
first-out (“LIFO”) method or the retail inventory method. Subsequent measurement is unchanged for inventory measured using
LIFO or the retail inventory method. We plan to adopt this guidance as of January 1, 2017 and believe the adoption of the guidance
will not have a significant impact on the consolidated financial statements.
F-12
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize
right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance
offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to
disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess
the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods
beginning after December 15, 2018, including interim periods within the reporting period, and requires a modified retrospective
adoption, with early adoption permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated
financial statements.
In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting”. This guidance identifies areas for simplification involving several aspects of accounting for
share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an
option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain
classifications on the statement of cash flows. We plan to adopt this guidance as of January 1, 2017 and believe the adoption of the
guidance will not have a significant impact on the consolidated financial statements.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows, Classification of Certain Cash Receipts and Cash
Payments (Topic 230). This guidance addresses specific cash flow issues with the objective of reducing the diversity in practice for
the treatment of these issues. The areas identified include: debt prepayment or debt extinguishment costs; settlement of zero-
coupon debt instruments; contingent consideration payments made after a business combination; proceeds from the settlement of
insurance claims; proceeds from the settlement of corporate-owned life insurance policies; distributions received from equity
method investees; beneficial interests in securitization transactions and application of the predominance principle with respect to
separately identifiable cash flows. This guidance is effective for annual reporting periods beginning after December 15, 2017,
including interim periods within that reporting period, with early adoption permitted. We are currently evaluating the effect of the
adoption of this guidance on our consolidated financial statements.
In August 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, Restricted Cash (Topic 230). This guidance requires
that a statement of cash flows explain the total change during the period of cash, cash equivalents, and amounts generally described
as restricted cash or restricted cash equivalents. Amounts described as restricted cash and restricted cash equivalents should be
included with cash and cash equivalents when reconciling the beginning of period and end of period to total amounts shown on the
statement of cash flows. This guidance is effective for annual reporting periods beginning after December 15, 2017, including
interim periods within that reporting period, with early adoption permitted. We are currently evaluating the effect of the adoption of
this guidance on our consolidated financial statements.
3. Fair Value Measurements
The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to
valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon
unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of
subjectivity and difficulty involved in determining fair value.
Level 1
Level 2
Inputs used to measure fair value are unadjusted quoted prices that are available in
active markets for the identical assets or liabilities as of the reporting date. Therefore,
determining fair value for Level 1 investments generally does not require significant
judgment, and the estimation is not difficult.
Pricing is provided by third party sources of market information obtained through
investment advisors. The Company does not adjust for or apply any additional
assumptions or estimates to the pricing information received from its advisors.
F-13
Level 3
Inputs used to measure fair value are unobservable inputs that are supported by little or
no market activity and reflect the use of significant management judgment. These values
are generally determined using pricing models for which the assumptions utilize
management’s estimates of market participant assumptions. The determination of fair
value for Level 3 instruments involves the most management judgment and subjectivity.
Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the
fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its
entirety requires management to make judgments and consider factors specific to the asset or liability.
There were no financial instruments that were measured at fair value on a recurring basis as of December 31, 2016 and 2015.
The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable,
accounts payable, and accrued expenses as of December 31, 2016 and 2015 approximate fair value because of the short maturity of
these instruments. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of
the note payable approximates fair value.
There were no changes in valuation techniques from prior periods.
4. Property and Equipment, Net
Property and equipment, net, consisted of the following as of December 31, 2016 and 2015 (in thousands):
Medical equipment
Computer equipment
Furniture and fixtures
Less: Accumulated depreciation and amortization
Property and equipment, net
Life
(in years)
December 31,
2016
2015
5
3
7
$
$
657 $
83
57
797
(314)
483 $
454
56
24
534
(295)
239
Depreciation and amortization expense for the years ended December 31, 2016 and 2015 was $111,000 and $77,000, respectively.
5. Accrued Liabilities
Accrued liabilities consisted of the following as of December 31, 2016 and 2015 (in thousands):
Accrued bonuses
Accrued professional fees
Accrued payroll and other related expenses
Accrued interest
Other accruals
Total accrued liabilities
December 31,
December 31,
2016
2015
1,102 $
483
389
65
147
2,186 $
613
388
113
22
157
1,293
$
$
F-14
6. Note Payable
On September 30, 2014, we entered into a Loan and Security Agreement, as amended on February 19, 2015, May 14, 2015,
November 30, 2015 and March 18, 2016 (collectively, the “2014 Loan Agreement”), with Pacific Western Bank (as successor in
interest by merger to Square 1 Bank) (the “Lender”), pursuant to which we received a term loan in the amount of $5,000,000,
funded in three tranches. The first tranche of $2,500,000 was provided to us on October 1, 2014 and proceeds of $500,000 from the
second tranche were received on each of February 19, 2015, March 16, 2015 and April 6, 2015 for aggregate proceeds of
$1,500,000. The terms of the loan required that the Company meet certain financial covenants and milestones in connection with
the Company’s randomized, blinded and sham-controlled clinical trial in Europe and Canada (the “OUS Clinical Trial”), and on
July 15, 2015 we received the final $1,000,000 of the term loan with a drawdown of funds from the third tranche.
In connection with the 2014 Loan Agreement, we entered into an Intellectual Property Security Agreement, dated September 30,
2014, pursuant to which a first priority security interest was created in all of our intellectual property, and we issued a 10-year
warrant to the Lender for the purchase of 58,962 shares of the Company’s common stock at an exercise price $4.24 per share, and
pursuant to the first amendment to the 2014 Loan Agreement in February 2015, such number of shares to automatically increase in
the event the Company fails to meet certain covenants. In connection with the second amendment to the 2014 Loan Agreement in
May 2015, we issued a second 10-year warrant to the Lender to purchase a total of 3,125 shares of common stock at an exercise
price of $2.96 per share. These two warrants were exercised in July and August 2016 (See Note 8).
On June 20, 2016, we entered into a Loan and Security Agreement (the “2016 Loan Agreement”) with Western Alliance Bank
(“WAB”), pursuant to which WAB agreed to loan us up to an aggregate of $10,000,000 payable in two tranches of $7,500,000 and
$2,500,000. The funding conditions for both tranches were satisfied as of the closing date, and therefore, the aggregate principal
amount of $10,000,000 was provided to us on June 20, 2016. The proceeds received were used to repay the outstanding existing
indebtedness under the 2014 Loan Agreement and the remaining balance will be used for working capital purposes and to fund
general business requirements. The borrowings are repayable in interest only payments until July 1, 2017 and then 30 monthly
equal installments of principal and interest. The term loan bears interest on the outstanding obligations under the loan at a floating
per annum rate equal to the greater of (i) the Index Rate (i.e., the 30 day U.S. LIBOR rate reported in the Wall Street Journal) plus
6.96%, determined as of the last day of each month, and (ii) 7.40%. The interest rate for the note payable with WAB was 7.59% as
of December 31, 2016.
In connection with the 2016 Loan Agreement, we issued a 10-year warrant to WAB to purchase a total of 100,402 shares of the
Company’s common stock at an exercise price of $4.98 per share (See Note 8).
All borrowings under the 2016 Loan Agreement are collateralized by substantially all of the Company’s assets, including
intellectual property.
The Company is also required to meet certain financial and other covenants in connection with the 2016 Loan Agreement. These
covenants include actual performance to plan revenue of not less than 80% which is not required to be complied with if the
Company maintains a ratio of unrestricted cash with WAB to indebtedness of at least 1.25 to 1.00. As of December 31, 2016, the
Company was not in compliance with the covenants. The Company did not meet the performance to plan revenue covenant for the
measuring periods ended October 31, 2016 and November 30, 2016 and the ratio of unrestricted cash with WAB to indebtedness
ratio of 1.25 to 1.00. On January 13, 2017, the Company received a waiver from WAB which amended the covenant requirements
from the original 2016 Loan Agreement. As a result, the Company regained compliance with all covenants (See Note 13).
F-15
As of December 31, 2016, future minimum payments under the note payable are as follows (in thousands):
Year Ending December 31,
2017
2018
2019
Total payments
Less: Amount representing interest
Present value of obligations
Less: Unamortized debt discount
Less: Note payable, noncurrent portion
Note payable, current portion
7. Commitments and Contingencies
Operating Lease
$
$
2,719
4,463
4,512
11,694
(1,694)
10,000
(371)
9,629
7,762
1,867
In January 2012, the Company entered into a lease agreement for office and laboratory facilities. The lease agreement, as amended
in September 2016, commenced in March 2012 and will terminate in March 2018. Rent expense for the years ended December
31, 2016 and 2015 was $236,000 and $210,000, respectively.
As of December 31, 2016, future minimum payments under the lease are as follows (in thousands):
Year Ending December 31,
2017
2018
Total minimum lease payments
Indemnification Agreements
$
$
303
82
385
The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these
arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or
incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the
agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party
has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The
term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum
potential amount of future payments the Company could be required to make under these arrangements is not determinable. The
Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the
Company believes the estimated fair value of these agreements is minimal.
Loss Contingencies
The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The
Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from
any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the
estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For
potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a
loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an
estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential
liability related to pending claims and litigation and may revise its estimates, which could materially impact the consolidated
financial statements. Management does not believe that the outcome of any outstanding legal matters will have a material adverse
effect on the Company's consolidated financial position, results of operations and cash flows.
F-16
8. Common Stock
On June 17, 2016, in connection with the closing of the June 2016 Offering, we issued an aggregate of 3,105,000 shares of common
stock, including the exercise of the underwriters’ overallotment option, at a public offering price of $5.00 per share for gross
proceeds of approximately $15,525,000. The net proceeds to the Company, after the deduction of underwriting discounts,
commissions and other offering expenses, were approximately $13,886,000.
On November 24, 2015, in connection with the closing of the November 2015 Offering, we issued an aggregate of 1,071,679 shares
of common stock at $5.60 per share for gross proceeds of approximately $6,000,000 in accordance with the terms and conditions of
those certain Securities Purchase Agreements by and between the Company and certain accredited investors. The net proceeds to
the Company after the deduction of placement agent commissions and other expenses were approximately $5,393,000.
On May 14, 2015, in connection with the closing of the May 2015 Offering, we issued an aggregate of 4,054,062 shares of common
stock at $2.96 per share for gross proceeds of approximately $12,000,000 in accordance with the terms and conditions of those
certain Securities Purchase Agreements by and between the Company and certain accredited investors. The net proceeds to the
Company after the deduction of placement agent commissions and other expenses were approximately $11,040,000.
Warrants for Common Stock
As of December 31, 2016, outstanding warrants to purchase shares of common stock were as follows:
Issuance Date
September 2014
October 2014
November 2014
February 2015
March 2015
May 2015
May 2015
December 2015
April 2016
May 2016
June 2016
Exercisable
for
Expiration
Date
Exercise
Price
Number of
Shares
Outstanding
Under
Warrants
Common Shares September 23, 2019 $
$
Common Shares October 13, 2019
Common Shares November 12, 2019 $
$
Common Shares February 17, 2025
$
Common Shares March 26, 2025
Common Shares May 12, 2025
$
$
Common Shares May 17, 2020
Common Shares December 16, 2025 $
$
Common Shares April 1, 2026
$
Common Shares May 11, 2021
$
Common Shares June 20, 2026
4.24
4.24
4.24
4.00
2.72
4.24
4.24
5.60
6.08
7.74
4.98
91,532
29,000
12,500
75,697
1,454
36,229
21,585
26,875
25,000
5,000
100,402
425,274
In connection with the September 2014 Offering, the Company issued warrants to purchase a total of 117,535 shares of common
stock at an exercise price of $4.24 per share. The warrants have a contractual life of five years and are exercisable immediately in
whole or in part, on or before five years from the issuance date. In 2016, warrants to purchase a total of 25,268 shares were
exercised (including a warrant that was exercised on a cashless basis) and 23,560 net shares of common stock were issued. In 2015,
a warrant was exercised and 735 shares of common stock were issued.
In connection with the 2014 Loan Agreement entered into on September 30, 2014, the Company issued a warrant to the Lender to
purchase a total of 58,962 shares of common stock at an exercise price of $4.24 per share. The warrant had a contractual life of ten
years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined
the fair value of the warrant on the date of issuance to be $622,000 using the Black-Scholes option pricing model. Assumptions
used were dividend yield of 0%, volatility of 77%, risk free interest rate of 2.5% and a contractual life of ten years. The warrant had
a contractual life of 10 years. The fair value of the warrant was recorded as debt issuance costs, presented in the consolidated
balance sheets as a deduction from the carrying amount of the note payable, and was being amortized to interest expense over the
loan term. The outstanding indebtedness was repaid in June 2016 from the proceeds of the new term loan in connection with the
2016 Loan Agreement and the remaining unamortized balance of debt issuance costs was recorded to interest expense. During the
years ended December 31, 2016 and 2015, the Company recorded $387,000 and $187,000, respectively, of interest expense relating
to the debt issuance costs. This warrant was exercised on a cashless basis in August 2016 and 17,295 net shares of common stock
were issued.
F-17
In October and November of 2014, the Company issued common stock warrants to various vendors and nonemployee contractors to
purchase a total of 47,751 shares of common stock at an exercise price of $4.24 per share. The warrants have a contractual life of
five years and are exercisable in whole or in part, either immediately upon grant or in some cases upon achieving certain milestones
or vesting terms. The Company determined the fair value of the warrants using the Black-Scholes option pricing model.
Assumptions used were dividend yield of 0%, volatility of 61.3%, risk free interest rate of 1.55% to 1.65% and a contractual life of
five years. The fair values of the warrants were recorded as professional consulting fees or clinical costs, which are included in
selling, general and administrative and research and development expenses in the consolidated statements of operations for the year
ended December 31, 2015, depending on the nature of the services provided. A total of 1,094 and 5,157 shares issuable pursuant to
the warrants were cancelled in 2016 and 2015, respectively, as the milestones related to these shares were not achieved.
In February 2015, the Company issued common stock warrants to employees for performance bonuses to purchase a total of 75,697
shares of common stock at an exercise price of $4.00 per share. The warrants have a contractual life of ten years and are exercisable
immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the
warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 77.6%, risk free
interest rate of 2.14% and a contractual life of ten years. The fair values of the warrants were recorded in selling, general and
administrative and research and development expenses in the consolidated statements of operations, depending on the department
classification of the employee.
In March 2015, the Company issued a common stock warrant to a nonemployee contractor to purchase a total of 1,454 shares of
common stock at an exercise price of $2.72 per share. The warrant has a contractual life of ten years and is exercisable immediately
in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrant using the
Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 78.9%, risk free interest rate of
1.94% and a contractual life of ten years. The fair value of the warrant was recorded as professional consulting fees, which are
included in selling, general and administrative expenses in the consolidated statements of operations.
In May 2015, the Company issued common stock warrants to nonemployee contractors to purchase a total of 36,229 shares of
common stock at an exercise price of $4.24 per share. The warrants have a contractual life of ten years and are exercisable
immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the
warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 80.1%, risk free
interest rate of 2.28% and a contractual life of ten years. The fair values of the warrants were recorded as professional consulting
fees, which are included in selling, general and administrative expenses in the consolidated statements of operations.
In conjunction with the second amendment to the 2014 Loan Agreement in May 2015, the Company issued a warrant to the Lender
to purchase a total of 3,125 shares of common stock at an exercise price of $2.96 per share. During the year ended December 31,
2015, the Company recorded $10,000 of interest expense relating to the debt issuance costs for this warrant. The debt issuance
costs for this warrant were fully amortized as of September 30, 2015. This warrant was exercised on a cashless basis in July 2016
and 885 net shares of common stock were issued.
In May 2015, the Company issued a common stock warrant to a nonemployee contractor to purchase a total of 21,585 shares of
common stock at an exercise price of $4.24 per share. The warrant has a contractual life of five years and is exercisable immediately
in whole or in part, on or before five years from the issuance date. The Company determined the fair value of the warrant using the
Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 64.4%, risk free interest rate of
1.54% and a contractual life of five years. The fair value of the warrant was recorded as professional consulting fees, which are
included in selling, general and administrative expenses in the consolidated statements of operations.
F-18
In December 2015, the Company issued common stock warrants to employees and nonemployee contractors for performance
bonuses to purchase a total of 26,875 shares of common stock at an exercise price of $5.60 per share. The warrants have a
contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The
Company determined the fair value of the warrants using the Black-Scholes option pricing model. Assumptions used were dividend
yield of 0%, volatility of 76.8%, risk free interest rate of 2.27% and a contractual life of ten years. The fair values of the warrants
were recorded in selling, general and administrative and research and development expenses in the consolidated statements of
operations, depending on the department classification of the employee or nonemployee contractor.
In April 2016, the Company issued a common stock warrant to a distributor to purchase a total of 25,000 shares of common stock at
an exercise price of $6.08 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in
part, on or before ten years from the issuance date. The Company determined the fair value of the warrant using the Black-Scholes
option pricing model. Assumptions used were dividend yield of 0%, volatility of 72.1%, risk free interest rate of 1.78% and a
contractual life of ten years. The fair value of the warrant was recorded as sales costs, which are included in selling, general and
administrative expenses in the consolidated statements of operations.
In May 2016, the Company issued common stock warrants to nonemployee contractors to purchase a total of 5,000 shares of
common stock at an exercise price of $7.74 per share. The warrants have a contractual life of five years and are exercisable
immediately in whole or in part, on or before five years from the issuance date. The Company determined the fair value of the
warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 61.6%, risk free
interest rate of 1.20% and a contractual life of five years. The fair value of the warrants was recorded as clinical consulting costs,
which are included in research and development expenses in the consolidated statements of operations.
In connection with the 2016 Loan Agreement, the Company issued a warrant to purchase a total of 100,402 shares of common stock
at an exercise price of $4.98 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in
part, on or before ten years from the issuance date. The Company determined the fair value of the warrant on the date of issuance to
be $350,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 63.0%, risk
free interest rate of 1.67% and a contractual life of ten years. The fair value of the warrant, along with other legal fees totaling
$90,000, were recorded as debt issuance costs, presented in the consolidated balance sheet as a deduction from the carrying amount
of the note payable, and are being amortized to interest expense over the loan term. During the year ended December 31, 2016, the
Company recorded $69,000 of interest expense relating to the debt issuance costs. As of December 31, 2016, the unamortized debt
issuance cost was $371,000.
The total stock-based compensation expense related to warrants issued was $162,000 and $537,000 for the years ended December
31, 2016 and 2015, respectively.
9. Summary of Stock Options
Stock Option Plans
The Company has issued equity awards in the form of stock options and restricted stock awards from three employee benefit plans.
The plans include the Company’s 2005 Stock Incentive Plan (the “2005 Plan”), the Viveve Amended and Restated 2006 Stock Plan
(the “2006 Plan”) and the Company’s Amended and Restated 2013 Stock Option and Incentive Plan (the “2013 Plan”).
The 2005 Plan was adopted by the Company’s board of directors and approved by its stockholders. As of December 31, 2016, 1,892
shares of common stock remain reserved for issuance under the 2005 Plan. The Company does not intend to grant further awards
from the 2005 Plan, however, it will continue to administer the 2005 Plan until all outstanding awards are exercised, expire,
terminate or are forfeited. There are currently outstanding stock option awards issued from the 2005 Plan covering a total of 1,892
shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $116.29 per share
and the weighted average remaining contractual term is 0.73 years.
F-19
The 2006 Plan was adopted by the board of directors of Viveve, Inc. and was terminated in conjunction with the merger that took
place on September 23, 2014 between PLC Systems Inc., Viveve, Inc. and PLC Systems Acquisition Corp. (the “Merger”). Prior to
the Merger, the board of directors voted to accelerate the vesting of all unvested options that were outstanding as of the date of the
Merger such that all options would be immediately vested and exercisable by the holders. In conjunction with the Merger, the
Company agreed to assume and administer the 2006 Plan and all outstanding options to purchase shares of Viveve, Inc. common
stock issued from the 2006 Plan were converted into options to purchase shares of the Company’s common stock (rounded down to
the nearest whole share). The number of shares of the Company’s common stock into which the 2006 Plan options were converted
was determined by multiplying the number of shares covered by each 2006 Plan option by the exchange ratio of 0.0080497 (or
0.0010062 on a post- reverse stock split basis). The exercise price of each 2006 Plan option was determined by dividing the exercise
price of each 2006 Plan option immediately prior to the Merger by the exchange ratio of 0.0080497 (or 0.0010062 on a post- reverse
stock split basis) (rounded up to the nearest cent). There are currently outstanding stock option awards issued from the 2006 Plan
covering a total of 38,378 shares of the Company’s common stock and no shares are available for future awards. The weighted
average exercise price of the outstanding stock options is $10.49 per share and the weighted average remaining contractual term is
5.88 years.
The 2013 Plan was also adopted by the Company’s board of directors and approved by its stockholders. The 2013 Plan is
administered by the Compensation Committee of the Company’s board of directors (the “Administrator”). Under the 2013 Plan, the
Company may grant equity awards to eligible participants which may take the form of stock options (both incentive stock options
and non-qualified stock options), stock appreciation rights, restricted, deferred or unrestricted stock awards, performance based
awards or dividend equivalent rights. Awards may be granted to officers, employees, nonemployee directors (as defined in the 2013
Plan) and other key persons (including consultants and prospective employees). The term of any stock option award may not exceed
10 years and may be subject to vesting conditions, as determined by the Administrator. Options granted generally vest over four
years. Incentive stock options may be granted only to employees of the Company or any subsidiary that is a “subsidiary
corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award
cannot be less than the fair market value of the Company’s common stock, provided, however, that an incentive stock option
granted to an employee who owns more than 10% of the Company’s outstanding voting power must have an exercise price of no
less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years.
On August 22, 2016, the Company’s stockholders approved an amendment to the 2013 Plan increasing the maximum number of
shares of common stock reserved and available for awards under the 2013 Plan (the “Stock Issuable”) by 737,500 shares
from 1,262,500 shares to a total of 2,000,000 shares and to add an “evergreen” provision to the 2013 Plan which will automatically
increase annually, on the first day of each January, the Stock Issuable by an amount equal to the lesser of (i) the number of shares
that will increase the Stock Issuable by 4% of the total number of shares of common stock outstanding (on a fully diluted basis) or
(ii) an amount determined by the board of directors. On December 23, 2016, the board of directors approved the 2017 evergreen
increase equal to 4% of the total number of fully diluted common shares or 523,209 shares, which is effective January 1, 2017.
As of December 31, 2016, there are outstanding stock option awards issued from the 2013 Plan covering a total of 1,869,494 shares
of the Company’s common stock and there remain reserved for future awards 10,236 shares of the Company’s common stock. The
weighted average exercise price of the outstanding stock options is $5.99 per share, and the remaining contractual term is 9.19 years.
F-20
Activity under the 2005 Plan, the 2006 Plan and the 2013 Plan is as follows:
Year Ended December 31, 2016
Number
of
Weighted
Average
Exercise
Weighted
Average
Remaining
Contractual
Aggregate
Intrinsic
Value
(in
thousands)
Shares
Price
Term (years)
Options outstanding, beginning of period
Options granted
Options exercised
Options canceled
Options outstanding, end of period
1,022,195 $
978,966 $
(3,020) $
(88,377) $
1,909,764 $
6.47
6.00
4.80
7.41
6.19
9.37 $
1,194,180
9.12 $
211,396
Vested and exercisable and expected to vest, end of
period
1,761,430 $
6.22
9.09 $
204,619
Vested and exercisable, end of period
368,681 $
7.51
8.04 $
102,306
The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s
closing share price as of December 31, 2016.
The options outstanding and exercisable as of December 31, 2016 are as follows:
Options Outstanding
Options Exercisable
Weighted
Average
Exercise
Number
Outstanding
as of
December 31,
2016
Price
Term (Years)
Weighted
Average
Remaining
Contractual
Number
Exercisable
as of
December 31,
2016
Weighted
Average
Exercise
Price
12,500 $
79,376 $
197,969 $
595,034 $
565,628 $
129,267 $
284,075 $
38,135 $
7,780 $
1,909,764 $
2.64
3.75
4.80
5.22
6.00
6.35
7.71
9.92
83.66
6.19
8.37
8.10
7.80
9.98
8.96
9.15
9.49
5.89
0.83
9.12
5,209 $
36,382 $
109,150 $
7,250 $
141,412 $
- $
23,363 $
38,135 $
7,780 $
368,681 $
2.64
3.75
4.80
5.22
6.00
-
7.72
9.92
83.66
7.51
Range of
Exercise Prices
$2.64
$3.68 - $3.76
$4.80 - $4.92
$5.22
$6.00
$6.24 - $6.40
$7.00 - $7.92
$9.92
$56.00 - $296.00
Restricted Stock Awards
In January 2016, the Company granted restricted stock awards (“RSAs”) for 39,494 shares of common stock under the 2013 Plan to
employees for 2015 accrued bonuses with a weighted average grant date fair value of $6.24 per share, based on the market price of
the Company’s common stock on the award date. The RSAs vest on the one-year anniversary of the award date. As of December
31, 2016, none of these RSAs were vested.
In August 2016, the Company granted RSAs for 5,998 shares of common stock under the 2013 Plan to board members as director
compensation with a weighted average grant date fair value of $7.89 per share, based on the market price of the Company’s
common stock on the award date. The RSAs were fully vested on the date of grant.
F-21
In September 2016, the Company granted 25,000 shares to a consultant with a weighted average grant date fair value of $7.58 per
share, based on the market price of the Company’s common stock on the award date. The RSA vests over one year at a rate of 1/4th
per quarter beginning as of the award date. As of December 31, 2016, 6,250 shares were vested.
In November 2016, the Company granted RSAs for 6,544 shares of common stock under the 2013 Plan to board members as
director compensation with a weighted average grant date fair value of $5.91 per share, based on the market price of the Company’s
common stock on the award date. The RSAs were fully vested on the date of grant.
A total of 89 shares pursuant to a RSA granted in January 2016 were cancelled in September 2016.
The total number of shares pursuant to outstanding RSAs as of December 31, 2016 were 58,155 shares of common stock.
Stock-Based Compensation
During the years ended December 31, 2016 and 2015, the Company granted stock options to employees to purchase 919,841 and
753,880 shares of common stock with a weighted average grant date fair value of $2.63 and $3.13 per share, respectively. The
aggregate intrinsic value of options exercised during the year ended December 31, 2016 was $5,000. There were no options
exercised during the year ended December 31, 2015.
The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee
stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee
stock options granted was estimated using the following weighted average assumptions:
Expected term (in years)
Average volatility
Risk-free interest rate
Dividend yield
Year Ended
December 31,
2016
2015
5
49%
1.78%
0%
5
63%
1.70%
0%
During the year ended December 31, 2016, the Company granted stock options to nonemployees to purchase 59,125 shares of
common stock with a weighted average grant date fair value of $4.60 per share. There were no options granted to nonemployees
during the year ended December 31, 2015. There were no options exercised by nonemployees during the years ended December 31,
2016 and 2015.
The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions:
Expected term (in years)
Average volatility
Risk-free interest rate
Dividend yield
F-22
Year Ended
December 31,
2016
10
51%
2.43%
0%
Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price
volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over
a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back
volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options
represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises
and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected
remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is
consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends
and does not anticipate issuing any dividends in the future.
The following table shows stock-based compensation expense included in the consolidated statements of operations for the years
ended December 31, 2016 and 2015 (in thousands):
Research and development
Selling, general and administrative
Total
Year Ended
December 31,
2016
2015
$
$
114 $
867
981 $
18
202
220
As of December 31, 2016, the total unrecognized compensation cost in connection with unvested stock options was approximately
$3,757,000. These costs are expected to be recognized over a period of approximately 3.27 years.
10. Income Taxes
No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no
benefit has been recorded.
A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows:
Income tax provision (benefit) at statutory rate
State income taxes, net of federal benefit
Change in valuation allowance
Other
Effective tax rate
Year Ended
December 31,
2016
2015
(34)%
(2)%
33%
3%
-%
(34)%
(6)%
39%
1%
-%
F-23
The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands):
December 31,
2016
2015
Deferred tax assets:
Net operating loss carryforwards
Capitalized start up costs
Research and development credits
Accruals and reserves
Total deferred tax assets
Deferred tax liabilities:
Fixed assets and depreciation
Valuation allowance
$
16,888 $
5,944
518
1,095
24,445
(7)
(24,438)
Net deferred tax assets
$
- $
10,726
7,225
248
497
18,696
(8)
(18,688)
-
The Company has recorded a full valuation allowance for its deferred tax assets based on it past losses and the uncertainty
regarding the ability to project future taxable income. The valuation allowance increased by approximately $5,750,000 and
$4,822,000 during the years ended December 31, 2016 and 2015, respectively.
As of December 31, 2016, the Company has net operating loss (“NOL”) carryforwards for federal and state income tax purposes of
approximately $45,468,000 and $24,498,000, respectively, which expire beginning in the year 2017.
The Company also has federal and California research and development tax credits of approximately $440,000 and $454,000,
respectively. The federal research credits will begin to expire in 2027 and the California research and development credits have no
expiration date.
Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to
ownership changes that have occurred previously or that could occur in the future, as provided by Section 382 of the Internal
Revenue Code of 1986, as well as similar state provisions. Ownership changes may limit the amount of NOL and tax credit
carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined
by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a
corporation by more than 50 percentage points over a three-year period. If the Company has experienced a change of control,
utilization of its NOL or tax credits carryforwards would be subject to an annual limitation under Section 382. Any limitation may
result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Subsequent
ownership changes could further impact the limitation in future years. Until a Section 382 study is completed and any limitation
known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the
Company’s NOL carryforwards and research and development credit carryforwards and, if an adjustment is required, this
adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no net impact to the balance sheet or
statement of operations if an adjustment were required.
As of December 31, 2016, the Company had not accrued any interest or penalties related to uncertain tax positions.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
Year Ended
December 31,
2016
2015
Balance at the beginning of the year
Additions based upon tax positions related to the current year
Balance at the end of the year
$
$
128 $
140
268 $
97
31
128
If the ending balance of $268,000 of unrecognized tax benefits as of December 31, 2016 were recognized, none of the recognition
would affect the income tax rate. The Company does not anticipate any material change in its unrecognized tax benefits over the
next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of
business.
F-24
The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception
remain open to examination due to the carryover of unused net operating losses and tax credits.
11. Related Party Transactions
In June 2006, the Company entered into a Development and Manufacturing Agreement (the “Agreement”) with Stellartech
Research Corporation (“Stellartech”). The Agreement was amended on October 4, 2007. Under the Agreement, the Company
agreed to purchase 300 generators manufactured by Stellartech. As of December 31, 2016, the Company has purchased 345 units.
The price per unit is variable and dependent on the volume and timing of units ordered. In conjunction with the Agreement,
Stellartech purchased 37,500 shares of Viveve, Inc.’s common stock. Under the Agreement, the Company paid Stellartech
$6,485,000 and $3,446,000 for goods and services during the years ended December 31, 2016 and 2015, respectively.
12. Segments and Geographic Information
The Company has determined that it operates as a single operating and reportable segment. Revenue from unaffiliated customers by
geographic area was as follows (in thousands):
Asia
Europe and Middle East
Latin America
United States
Canada
Other
Total
Year Ended
December 31,
2016
2015
$
$
4,946
1,489
382
315
9
-
7,141 $
889
551
-
-
5
2
1,447
The Company determines geographic location of its revenue based upon the destination of shipments of its products.
The Company’s long-lived assets by geographic area were as follows (in thousands):
United States
Europe
Asia
Canada
Total
Year Ended
December 31,
2016
2015
$
$
370 $
72
39
2
483 $
100
99
32
8
239
Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.
13. Subsequent Events
Amendment to Loan Agreement
On January 13, 2017, we entered into a waiver and amendment (the “First Amendment”) to the 2016 Loan Agreement with WAB.
Pursuant to the First Amendment, WAB agreed to waive the default resulting from the failure to comply with the performance to
plan revenue covenants described in the 2016 Loan Agreement for the measuring periods ending October 31, 2016 and November
30, 2016. In addition, the First Amendment added a financial covenant that until the Company maintains a ratio of minimum
unrestricted cash in accounts with WAB to indebtedness of at least 1.25 to 1.00, the Company must at all times maintain
unrestricted cash in accounts with WAB in an amount equal to or greater than $2,000,000, which financial covenant shall no longer
apply at such time that the Company achieves a ratio of minimum unrestricted cash in accounts with WAB to indebtedness of at
least 1.25 to 1.00.
F-25
Sublease Agreement and Relocation of Corporate Headquarters to Englewood, Colorado
On February 1, 2017, the Company entered into a sublease agreement (the “Sublease”) for approximately 12,400 square feet of
building space for the relocation of the Company’s corporate headquarters to Englewood, Colorado (the “Sublease Premises”),
which was effective as of January 26, 2017. Physical relocation is planned toward the end of the first quarter of 2017 pending
completion of the build-out of all office and warehouse facilities.
The term of the Sublease will commence on the later of (i) 120 days after the date sublandlord delivers possession of the Sublease
Premises to the Company or (iii) upon substantial completion of the tenant improvements pursuant to the Sublease (the
“Commencement Date”), and will expire 36 months after the Commencement Date, or such earlier date as the Master Lease may be
terminated pursuant to the terms thereof.
The monthly base rent under the Sublease will be equal to $20.50 per rentable square foot of the Sublease Premises during the first
year. The monthly base rent will be equal to $21.12 and 21.75 per rentable square foot during the second and third years,
respectively. In connection with the execution of the Sublease, the Company also agreed to pay a security deposit of approximately
$22,000. The Company is entitled to an allowance of approximately $88,000 for certain tenant improvements relating to the
engineering, design and construction of the Sublease Premises.
F-26
NAME
Viveve, Inc.
Viveve B.V.
JURISDICTION OF
INCORPORATION
Delaware
Netherlands
SUBSIDIARIES
PERCENTAGE OWNERSHIP
100%
100%
EXHIBIT 21
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Exhibit 23.1
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-213682) and Form S-8 (Nos.
333-213363, 333-206041, 333-201551, 333-153535 and 333-127770) of Viveve Medical, Inc. of our report (which contains an
explanatory paragraph relating to the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial
statements) dated February 16, 2017 relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.
/s/ BPM LLP
San Jose, California
February 16, 2017
Exhibit 31.1
Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
I, Patricia Scheller, certify that:
1. I have reviewed this Annual Report on Form 10-K for Viveve Medical, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal
control over financial reporting.
Date: February 16, 2017
/s/ Patricia Scheller
Patricia Scheller
Chief Executive Officer
(Principal Executive Officer)
Exhibit 31.2
Certification of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
I, Scott Durbin, certify that:
1. I have reviewed this Annual Report on Form 10-K for Viveve Medical, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal
control over financial reporting.
Date: February 16, 2017
/s/ Scott Durbin
Scott Durbin
Chief Financial Officer
(Principal Financial and Accounting Officer)
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (A) and (B) of Section 1350, Chapter 63 of Title 18,
United States Code)
Exhibit 32.1
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States
Code), the undersigned officer of Viveve Medical, Inc. (the “Company”), does hereby certify with respect to the Annual Report of the
Company on Form 10-K for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof
(the “Report”), that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Date: February 16, 2017
/s/ Patricia Scheller
Patricia Scheller
Chief Executive Officer
(Principal Executive Officer)
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (A) and (B) of Section 1350, Chapter 63 of Title 18,
United States Code)
Exhibit 32.2
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States
Code), the undersigned officer of Viveve Medical, Inc. (the “Company”), does hereby certify with respect to the Annual Report of the
Company on Form 10-K for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof
(the “Report”), that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Date: February 16, 2017
/s/ Scott Durbin
Scott Durbin
Chief Financial Officer
(Principal Financial and Accounting Officer)